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Abstract 
Unlike the peripheral nervous system, the spinal cord which forms part of the 
central nervous system (CNS) is unable to regenerate. Intrinsic and extrinsic 
environment changes following spinal cord injury are the main factors contributed 
to inhibit neuronal survival and axonal growth. However, manipulating the growth-
relative genes in the CNS after injury can induce limited axon regeneration. In this 
study we demonstrate by manipulating expression of three protein molecules 
AMIGO3 (an amphoterin-induced gene open reading frame), RTN3 (Reticulon 3) 
and astrocyte elevated gene-1 (AEG-1/ also known as MTDH/LYRIC1)), where 
axon regeneration in the CNS is possible. Data from a microarray screen in 
regenerating and non-regenerating spinal cord injury models showed that low 
levels of AMIGO3 expression correlated with regenerating sciatic nerve (SN) and 
preconditioning SN+DC lesion models. Conversely, high levels of RTN3 and AEG-
1 were found to be correlated with regeneration injury models. In vitro knockdown 
of AMIGO3 combined with neurotrophin 3 (NT3) has been shown to promote 
dorsal root ganglion neuron (DRGN) neurite outgrowth, and in vivo delivery of non-
viral mediated shRNA/AMIGO3 plasmid to suppress AMIGO3 expression 
demonstrated significant DC axon regeneration. In addition, in vitro knockdown of 
both RTN3 and AEG-1 suppressed DRGN neurite outgrowth, demonstrating that 
they are required for axonal growth. The mechanisms by which AMIGO3, RTN3 
and AEG-1 suppress or promote axonal regeneration is not yet known but we 
conclude that they play a major role in axonal regeneration and could be 
harnessed to promote regeneration of the CNS.  
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CHAPTER 1: General Introduction 
 
 
 
 
 
 
1 
 
1.1 The complex system of the CNS 
The CNS comprises the brain and the spinal cord. The brain receives and 
processes sensory inputs from both the spinal cord and its own nerves whilst the 
spinal cord conducts sensory information to the brain and motor information from 
the brain to skeletal, cardiac and smooth muscle, and glands among other 
functions. These actions enable the CNS to control motor movement, regulate 
respiration, maintain homeostasis, and provide logical coordination of all bodily 
activity (Shoichet et al., 2008). Any injury to the CNS will thus result in the inability 
of the CNS to perform these actions leading to morbidity, and ultimately mortality. 
Accidents, stroke, trauma, and tumours among others can cause injuries to the 
CNS system.  
 
1.2 Spinal cord anatomy 
The spinal cord caudally extends below the brainstem, which is an essential part 
of the central nervous system. The spinal cord plays important roles in transmitting 
and integrating the sensory, motor and autonomic signals between the brain and 
the body. It is protected and supported by the bony structure of the vertebral 
column and like the brain, is encapsulated by three membranes of the CNS known 
as meninges, i.e, pia, arachnoid and dura mater. The pia mater, the innermost 
layer is extremely delicate and adheres to the surface of the spinal cord whereas 
the arachnoid mater is a web-like membrane that lies between pia and the tough 
outermost layer, the dura mater (Figure  0.1) (Nógrádi and Vrbová, 2006).  
 
2 
 
The cord contains regions of long myelinated fibers of inter-neurons that run in 
bundles refered to as tracts. These regions are refered to as white mattter (WM) 
as a result of their colouration due to the heavy degree of myelination. The WM is 
divided into three regions known as ventral (anterior), lateral and dorsal (posterior) 
culumns. The dorsal tracts bring messages from the periphary to the brain, hence 
termed ascending, with the ventral tract being predominantly concerned with 
relaying information from the brain to the periphery. The inner cord, is termed gray 
matter (GM), and is composed of nerve-cell bodies. Each spinal nerve emerging 
from the spinal cord is connected to it by short branches, one from the ventral 
region, and one from the dorsal region, called the dorsal and ventral roots. These 
roots join in the spinal nerve before the nerve leaves the vertabral column (Miele 
et al., 2012, Oke, 1844). 
 
The vertebraes in the human spinal cord are comprised of 31 segments, which are 
divided into five groups; 8 cervical, 12 thoracic, 5 lumbar, 5 sacral and 1 
coccygeal. In each vertebral level, there are entry and exit nerves of the spinal 
cord, motor and sensory nerve roots where they are named according to their 
emergence site. Cervical nerves mainly control neck, head and upper part of the 
human body, whilst thoracic spinal nerves provide control for abdominal muscles. 
Lumbar and sacral nerve levels mainly control lower organs and extremities.    
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Figure  0.1: Anatomy of the spinal cord.  
Illustrates the white and gray matter of the spinal cord together with the meninges 
(pia, arachnoid and dura maters) and surrounding vertebral column. Also presents 
dorsal (posterior) and ventral (anterior) roots that carry the sensory and motor 
signals. (Adapted from (Mohamad and Anuar, 2014)). 
 
1.2.1 Dorsal root ganglion neurons (DRGN) 
DRGN are sensory neurons that relay sensory inputs from the periphery of the 
body to the spinal cord and the brain with their cell bodies lying in the dorsal root 
ganglia lateral to the spinal cord (Saijilafu and Zhou, 2012). The axons of DRGN 
grow from the cell body and branch into two; one innervating the peripheral targets 
such as motor muscles and other body organs, and the other innervating the CNS 
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through the spinal cord. Since the cell bodies of DRGN lie outside the CNS, they 
are considered part of the peripheral nervous system (PNS) (Figure  0.2). While 
successful regeneration of adult neurons in the CNS is limited, the peripheral 
DRGN projections are known to readily regenerate after injury (Wall, 1992). 
However, it has been shown that if damage to the peripheral DRGN projection 
occur prior to the CNS damage (pre-conditioning lesion), there is hastened 
recovery of the CNS neuron (Wall, 1992). This has led many researchers to 
hypothesize that DRGN have a role to play in the regeneration of the CNS 
neurons and understanding the environmental factors influencing the two neural 
systems and their interaction with each other may help improve the regenerative 
strategies of the CNS. For example, the central axons of the DRGN share the 
same environment as the axons of the CNS neurons in the spinal cord since the 
two form synapses (Wall, 1992). The molecular factors that influence the growth of 
the DRGN should therefore be the same as those that influence the growth of the 
CNS neurons in the spinal cord. Therefore, controlling and understanding the 
regeneration of DRGN can derive better methods of enhancing the growth of CNS 
neurons. 
Peripheral conditioning lesions are one of the major tools being used to 
understand regenerative capacity of CNS neurons (Hollis and Zou, 2012). Many 
researchers tend to agree that injury to the peripheral DRGN projection regulates 
gene expression to increase the intrinsic growth capacity of the neurons to 
regenerate (Richardson and Issa, 1984). By providing permissive growth 
substrates, peripheral nerves can be stimulated to regenerate but the regeneration 
of the CNS through this method is still moderate. Also, by controlling the 
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environment, DRGN can be manipulated to create models of CNS neurons 
making regenerative studies possible.   
For example, Chong et al (1999) found that the central axons of the DRGN 
regenerated after injury but only up to the dorsal root entry zone (DREZ) and were 
prevented from re-growing back into the spinal cord. By sectioning L4 and L5 
dorsal roots in adult rats, they demonstrated that central axons of the DRGN were 
able to grow back into the spinal cord (Chong et al., 1999). Another study by Irina 
et al (2010) suggests that the response to growth factors responsible for the 
regeneration of the DRGN into the spinal cord is also dependent on the spinal 
level. Different regenerative responses may be observed in the DRGN compared 
to the CNS neurons under the same conditions, however, DRGN still provide good 
models for understanding axonal regeneration in the CNS (Vetter et al., 2010). 
 
Figure  0.2: Diagram of spinal cord cross section showing dorsal root 
ganglion neurons (DRGNs).  
DRGN are located in dorsal root ganglia and give rise to both peripherally and 
centrally directed axons. (Adapted from, www.socratic.org, 2016).  
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1.2.2 Ascending pathways in the dorsal column  
The ascending pathway of the spinal cord mainly conducts the signals and 
information from receptors in the limbs and trunk to the brain. Two main groups 
found essential in the spinal cord ascending fibres, direct and postsynaptic dorsal 
column pathways. The ascending pathway in the direct dorsal column comprised 
of two branches from primary afferents of the sensory neurons. One innervates 
receptors in the muscle, skin while the other branches connected to the brain via 
the dorsal roots of the spinal cord (Waile et al., 1995, Willis Jr and Coggeshall, 
2004). 
The ascending branches from primary afferents mainly end in the gray matter of 
the spinal cord while a fraction of these branches project to the dorsal nuclei. A 
large number of DRGN that are based in the cervical region project directly to the 
dorsal nuclei compared with lumbar DRGN. Axons travelling within the dorsal 
column normally terminate in different areas of gray matter such as the ventral 
horn, dorsal horn and intermediate region (Smith and Bennett, 1987, Giuffrida and 
Rustioni, 1992, Willis Jr and Coggeshall, 2004). In the rat spinal cord, 25% of the 
dorsal column axons are unmyelinated, which suggests that these unmyelinated 
projections might carry information from visceral or nociceptors to the dorsal 
column nuclei (Chung et al., 1987, McNeill et al., 1988, Tamatani et al., 1989, 
Patterson et al., 1990). On the other hand, the postsynaptic dorsal column 
pathway is different from the direct pathway; here the pathway is formed by the 
axons of spinal neurons that travel to the dorsal column nuclei. These neurons are 
in the nucleus proprius, which reside ventral to the substantia gelatinosa and the 
postsynaptic pathway axons terminate at all rostrocaudal levels of the cuneate and 
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gracile nuclei (Giesler and Cliffer, 1985, Giesler et al., 1984, de Pommery et al., 
1984).  
 
1.3 Epidemiology of spinal cord injury (SCI) 
SCI is one of the major types of CNS injuries that cause loss of autonomic, motor 
and sensory function, which lead to long-term personal difficulty to the patient. 
Patients with SCI normally have a permanent loss of function due to lack of 
effective treatments to repair and regeneration of the damaged axons or to 
prevent the secondary injury that normally results after SCI (Di Giovanni, 2006, 
Luo et al., 2009). It is estimated that each year there are 130,000 new cases of 
SCI around the world and approximately 40 new cases of SCI per million of the 
worldwide population (Illes et al., 2011, Forostyak et al., 2013). There are 
approximately 1000 new cases of SCI in UK alone and estimates of 12,000 new 
cases per year in the Unites States (Devivo, 2012).  
The major causes of SCI include vehicular accidents, traumatic falls, violence and 
sports. The consequences of SCI are psychological, physical, and economical. 
Statistics show that only about 12% of people with SCI are able to maintain their 
employment after one year of injury. This employment rate increases to about 
30% over a 20-year period but generally over 60% of these injured individuals are 
unable to work again during their lifetime. Loss of employment, together with 
lengthy periods of admissions in hospitals, the economic burden of SCI is 
estimated to average $70,000 per injured person per year. This translates to over 
$840 million every year (The National Spinal Cord Injury Statistics Centre 
(NSCISC)).  
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1.4 The pathological response to SCI  
1.4.1 Phases of SCI 
There are three generalised phases of responses after SCI, which extend from 
acute, secondary and chronic phases that respond to the primary injury event  
(Hulsebosch, 2002). 
 
1.4.1.1 Acute phase  
The acute phase begins from the moment of the injury and extends for few days, 
where different pathophysiological processes are activated. There is immediate 
mechanical disruption to the neurons among other soft tissue including endothelial 
cells of the surrounding vasculature. The mechanical damage in the immediate 
hours after SCI leads to cell loss including neurons and oligodendrocytes and 
necrosis (Hulsebosch, 2002, Di Giovanni, 2006). In the next few minutes of the 
insult, the injured neuron responds back by injury-induced barrage of action 
potentials accompanied with electrolyte shifts that contribute to spinal shock and 
functional neural failure, which is a generalized failure of circuitry in the spinal 
neural network, lasting for about 24 hours (Hulsebosch, 2002).  
 
Furthermore, loss of micro-circulation by thrombosis, haemorrhage which is 
accompanied by oedema, loss of auto-regulation and vasospasm and mechanical 
damage further aggravate the neural injury. The acute phase usually persists for 
hours up to days before being subsequently resolved into the sub-acute phase 
(Mohamad and Anuar, 2014).  
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1.4.1.2 Secondary phase  
The pathology of the secondary injury phase is an outcome of the molecular and 
cellular responses after mechanical trauma to the spinal cord. In the secondary 
phase, several pathologies processing continued from the acute phase, including 
oedema, cell death and electrolyte shifts (Lu et al., 2000). The cell death or 
necrosis is characterised by energy loss, swelling and intense damage of 
mitochondria which lead to cell lysis. The release of intracellular constituents due 
to cell rupture results in the induction of the inflammation processes, where the 
extracellular concentrations including excitatory amino acids (EAA) and glutamate 
reach toxic levels (Hulsebosch, 2002, Mohamad and Anuar, 2014).  
 
Later on, apoptosis or programmed cell death occurs that is associated with 
increased expression levels of glial fibrillary acidic protein (GFAP), astrocyte 
proliferation that plays a role in oligodendrocytes death thus, axonal 
demyelination. Increasing the concentration of local chemokine and cytokines and 
invading inflammatory cells such as; lymphocytes and neutrophils leads to further 
necrosis and apoptosis. (Liu et al., 1997, Hulsebosch, 2002). The inhibitory 
molecules to axonal regeneration begin to be expressed surrounding the lesion 
area and subsequently enlargement of the lesion cavity/size results in further cell 
death and damage to the axonal architecture.  
 
1.4.1.3  Chronic phase  
The chronic phase of SCI lasts from weeks to years; apoptosis is continued in 
both orthograde and retrograde direction of the lesion site. Ion channels and other 
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different types of receptors become altered in their activation status and 
expression levels. These events lead to scar formation in the cord and conduction 
deficits due to demyelination as well as syringomyelia (a fluid-filled cyst formed 
and continue to enlarge). However, chronic pain syndrome occurs in most SCI 
patients due to neural circuit disruption in inhibitory and excitatory inputs 
(Christensen et al., 1996, Christensen and Hulsebosch, 1997, Hulsebosch, 2002, 
Bertram and Heil, 2017). 
 
1.4.2 Inflammatory response 
As with all forms of physical injury, spinal cord damage is followed by a significant 
inflammatory response. However, due to the highlighted specialised and sensitive 
nature of neural tissues, the nature and outcome of this secondary inflammation 
within the spine is highly pertinent to the overall outcome of the injury, and much 
research has been focused on elucidating the nature of the response and in 
finding ways to manipulate this response towards a less deleterious outcome (Ju 
et al., 2014). When a physical insult to the spinal cord occurs, the tissue, including 
the neural axons that travel longitudinally through the vertebral column are 
damaged, as are the glial cells, including the oligodendrocytes, astrocytes and 
microglia that sub-serve the neurons and maintain homeostasis within the tissue.  
 
On a timescale of hours to days subsequent to the initial insult, secondary 
pathological processes occur including changes to the regional vasculature that 
affects blood flow to the wound environment. This includes obstruction of the 
vessels serving the wound site itself; changes in the availability of local 
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electrolytes, the generation of excess free radicals within the affected tissues, the 
generation of action potentials by excitotoxicity, and the cascades of molecules 
and cells that accompany a generic innate immune response (Cao and He, 2013, 
Ankeny and Popovich, 2009). During this second phase of damage to the spinal 
cord, the site of injury becomes a fluid filled cavity enclosed by a glial scar, which 
acts as an impediment for neuron growth and axonal regeneration (Ankeny and 
Popovich, 2009, Fawcett and Asher, 1999). Among the many processes which 
take place in the time immediately after SCI, the inflammatory cascades are 
perhaps the most damaging in terms of perturbing the repair processes that 
attempts to regenerate competent, preserved tissues (Hammond et al., 2014).  
 
The initial disruption to the blood-spinal cord barrier (BSCB) which occurs during a 
SCI results in the migration of immune cells from the peripheral circulation into the 
site of inflammation as a result of chemotactic proteins generated from the 
complement cascade which is triggered at the time of the physical damage to the 
tissue (Hawthorne and Popovich, 2011). Following the initial influx of neutrophils, 
inflammatory cells secrete extracellular matrix (ECM) digesting elastases and 
matrix metalloproteinases (MMP), the site is then populated by macrophages and 
their precursors, monocytes, around 2 - 4 days after injury (Hawthorne and 
Popovich, 2011). These cells continues to migrate into the wound for a number of 
weeks after injury and following these, around 4 weeks post injury, adaptive 
immune cells such as T and B cells begin to migrate into the lesioned area.  
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1.4.3 Glial scar and cavity formation 
The formation of scar tissue surrounding the lesion site is one of the many reactive 
changes that has received attention after SCI. This pathological response is also 
referred to ‘glial scar’ due to reactive astrocytes playing a prominent role in this 
process, however other studies have suggested that cells of pericyte origin are 
also involved in the scar formation (Goritz et al., 2011, Faulkner et al., 2004). The 
term reactive astrogliosis (will be discussed below in section 1.4.4.1 in more 
details) is a result of local astrocytes undergoing proliferation, hypertrophy and 
increased secretion of GFAP that respond to the injury (Pekny and Nilsson, 2005, 
Pekny et al., 2014). The formation of the glia scar has both advantages and 
disadvantages. The heavy glial scar that is formed surrounding the dying and 
damaged tissues at the lesion site have several advantages, including re-
establishment of the BSCB, restrict the cytotoxic inflammatory response within this 
lesion, release anti-oxidants that help defend against oxidative stress and protects 
against glutamate excitotoxicity via glutamate uptake. On the other hand, the 
damaged area which is sealed by the scar continues to undergo apoptosis and 
necrosis. These processes produce a large quantity of tissue debris resulting in a 
fluid-filled cavity surrounded by a dense glial scar (Figure  0.3) (Fitch et al., 1999, 
Sofroniew, 2009, Karimi-Abdolrezaee and Billakanti, 2012, Fitch and Silver, 2008). 
The early formation of a physical barrier of glia scar by reactive astrocytes appear 
to be vital in limiting secondary damage after SCI. Once local homeostasis is re-
established, the detrimental role of reactive astrogliosis becomes more apparent 
providing a physical barrier to axonal regeneration and secretion of several factors 
that inhibit cell replacement and axon growth (James, 2013). 
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Figure  0.3: Illustration of glial scar processes at the lesion site.  
Fibroblasts and reactive astrocytes start sealing off the lesion site, which form a 
glial fibrotic scar. Fibroblasts can be recruited either from perivascular scours e.g. 
contusion injury or from the meninges (if the meninges is damaged). The levels of 
Inhibitory chondroitin sulphate proteoglycans (CSPG) that are secreted from 
reactive astrocytes increase surrounding the injury area. Circulating lymphocytes, 
macrophages and microglia are also recruited to the injury site. Adapted from 
(James, 2013).  
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1.4.4 Glial cell responses after SCI  
1.4.4.1 Astrocytes and reactive astrocytosis 
The activation of astrocytes in the process of gliosis results in astrocytes with 
increased size, displaying a hypertrophic morphology, increased synthetic 
capacity, resulting from the transcription and secretion of proteins, and positive 
immunostaining for GFAP (Ridet et al., 1997, Sofroniew, 2009). These cells result 
from the activation of quiescent or resting astrocytes, which are perennially 
present with in the spinal cord tissue. Recently, these cells have been shown to 
express nestin and other markers of neural progenitor cells suggesting that the 
reactive process may involve dedifferentiation from astrocytes into neural stem 
cells (Lang et al., 2004, Robel et al., 2011). Reactive astrocytes have also been 
shown to express and secrete cytokines which contribute an inflammatory 
phenotype, such as tumour necrosis factor alpha (TNFα), and interleukins-1 and -
6 (IL-1/-6). Reactive astrocytes have been demonstrated to produce CSPG and 
neurotropic factors and other factors that regulate axon growth, such as leukaemia 
inhibitory factor (LIF), ciliary neurotrophic factor and insulin-like growth factor 
(Ridet et al., 1997, Robel et al., 2011). It is thought however, that the diversity in 
the production of these factors produced during astrogliosis may result from 
heterogeneity in the population of astrocytes in the tissue, which become 
activated, resulting in a heterogeneous reactive response.  
 
The mechanisms of astrocyte activation are complex and have not yet been 
comprehensively elucidated. Research to understand how these cellular 
responses are initiated and subsequently maintained, including the regulation of 
migration of reactive astrocytes is still on-going. However, numerous studies have 
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pointed at transforming growth factor beta (TGFβ/Smad) signalling for a key role in 
the process. Similarly, IL-1 and interferon gamma (IFNγ) have been shown 
experimentally to activate astrocytes (Ridet et al., 1997, Schachtrup et al., 2010, 
Sofroniew, 2009). Further work has demonstrated the mTOR signalling pathway is 
vital in the regulation of the gene expression profile associated with reactive 
astrocytes. Furthermore, the bone morphogenic protein (BMP) - microRNA-21 
signalling axis has also been implicated in regulating gliosis, though the 
mechanisms remain elusive (Codeluppi et al., 2009, Sahni and Kessler, 2010, 
Sahni et al., 2010). However, experimental interference with these signalling 
networks was shown to significantly impede gliosis and glial scar formation after 
SCI.  
 
In addition to the cytokines and transcription factors required to activate and 
maintain reactive astrocyte phenotype, cytoskeletal proteins such as vimentin and 
GFAP are required for the altered morphology of reactive astrocytes (Menet et al., 
2003). In addition, the expression of matrix metalloproteinase-9 (MMP9) is thought 
to be important. MMP9 is capable of potently degrading ECM and is crucially 
important in the migration and invasion of cancer cells, as well as in wound 
healing. As such, expression of MMP9 in reactive astrocytes was shown to 
facilitate the migration of reactive astrocytes (Hsu et al., 2008). 
 
While the process of astrogliosis is represents an evolutionarily derived and 
physiologically important process, it does present something of a double edged 
sword in the case of SCI. One particularly deleterious element of the reactive 
astrocyte response which has been shown to impede repair of axonal pathways is 
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the production of CSPG and keratin sulphate proteoglycans (KSPG) during gliosis. 
Both of these sulphated glycosaminoglycans are signalling and structural 
components of tissues throughout the body, but they are understood to act in an 
inhibitory fashion in the context of neural growth (Silver and Miller, 2004). 
Similarly, reactive astrocytes have been shown to produce Ephrin-B2 and 
Semaphorin 3A, both of which act as repellents to neuronal growth, preventing the 
regenerating neural axons from developing through and in the lesion, and newly 
formed scar tissue (Silver and Miller, 2004). Furthermore, astrocytes have been 
shown to secrete endothelin-1, which can directly inhibit myelination (Hammond et 
al., 2014).  
 
On the other hand, however, reactive astrogliosis prevents further increases to the 
size of the cavity produced by the physical insult to the cord, and has been shown 
to modulate the extent and type of inflammation, inducing the migration and 
activity of innate cells within the tissue environment. In addition, astrocytes 
increase the uptake of glutamate from the extracellular compartment, induce 
angiogenic processes which aid healing and reduce ischemia, and perhaps most 
importantly rebuild the physical BSCB and the physical matrix which supports 
neurons within the tissue (Rolls et al., 2009). Indeed, experimental depletion of 
astrocytes in animal models has demonstrated that these cells required re-
establishment of this barrier, and their absence from the lesion increases the 
migration of innate cells such as neutrophils and results in increased death of 
neurons and increases in demyelination of neurons. Animals which lack astrocytes 
have significantly reduced recovery of locomotion (Rolls et al., 2009).  
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1.4.4.2 Oligodendrocytes 
As with other glial cell types located within the spinal cord, oligodendrocytes are 
susceptible to damage from primary and secondary injury after SCI. Numerous 
studies have shown that oligodendrocytes die as a result of necrosis and 
apoptosis after tissue injury, and given their role in providing the myelin sheath to 
nearby neurons, the death of these cells leads to demyelination of axons and 
impeded neuronal signalling (Casha et al., 2001, Kim et al., 2003). Indeed, this 
demyelination as a result of oligodendrogial death is a significant contributor to the 
secondary pathology of injury to the spinal cord (Casha et al., 2001). 
Experiments conducted in rodents and cats have demonstrated that significant 
demyelination does indeed take place after experimentally induced spinal cord 
contusions, especially within the first 2 weeks following the insult (Gledhill et al., 
1973, Blight, 1985). Furthermore, evidence from samples of human tissue have 
demonstrated that the damage to the myelination of axons after spinal injury can 
persist for up to 22 years. However, the extent of demyelination that takes place 
varies highly and depends on the extent of the lesion present (Guest et al., 2005). 
 
It should also be noted that the failure of studies to observe extensive chronic 
demyelination post-SCI in humans is due to spontaneous remyelination by 
surviving oligodendrocytes (Guest et al., 2005). The ability of neurons to become 
remyelinated after injury was first observed in the sixties, demonstrating promise 
for experimental manipulation to increase healing potential and restore locomotion 
to victims of SCI (Bunge, 1960, Bunge and Bradbury, 1961). In humans, 
remyelination by oligodendrocytes is initiated by about two weeks after the initial 
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insult (Gledhill et al., 1973), however, it has been noted that remyelination 
frequently results in thinner sheaths and shorter internodes when compared to the 
myelin that preceded it (Gledhill et al., 1973). This is usually termed 
dysmyelination, or abnormal myelination. Interestingly, dysmyelination may prove 
to be worse than no myelination at all, as it leads to the production of incorrect 
signals being sent through the system (McDonald and Belegu, 2006). 
 
On the other hand, Schwan cells (responsible glia for myelinated damaged axons 
in PNS) has been implicated in the myelinating central axons after SCI particularly 
DC that associated with peripheral myelin. The presence of Schwan cells in spinal 
cord could be concluded into two mechanisms; (1) might have access to SC due 
to injury to transition zone between CNS/PNS; (2) could be derived from CNS 
resident oligodendrocytes precursors by differentiation (Bartus et al., 2016). 
 
While it has been understood that remyelination occurs after injury, the cells which 
were responsible for performing this task were unknown. Indeed, it was revealed 
in 1999 that oligodendrocytes are not actually the cells responsible for 
remyelination, but rather oligodendrocyte precursor cells (OPC) (Keirstead and 
Blakemore, 1999, Blakemore and Keirstead, 1999). Unlike oligodendrocytes, OPC 
maintain a proliferative state, whereas oligodendrocytes are post-mitotic 
(Keirstead and Blakemore, 1999). It is now been understood that after injury and 
during gliosis, these OPC which are present throughout the spinal cord, in both 
white and gray matter, become activated in response to demyelination and begin 
to proliferate and migrate into the zone of injury to replace the oligodendrocytes 
which have died in response to the secondary injury (Watanabe et al., 2002). OPC 
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are identified by their expression of nerve-glial antigen 2 (NGA2), are however 
thought to be a relatively heterogeneous population of cells and only a fraction of 
these respond to injury and are capable of remyelination (Nishiyama et al., 2009, 
Suzuki and Nishiyama, 2009). However, the understanding that this subset of 
OPC is responsible for myelination produces opportunities for therapeutic 
intervention to aid this process. Several molecules, have been identified which 
induce differentiation of NGA2+ cells into OPC including epidermal growth factor 
receptor (EGFR), neurogenic transcription factor (Ngn2) and several other growth 
factors (Ohori et al., 2006, Aguirre and Gallo, 2007).  
 
A number of relevant studies have addressed the role and therapeutic use of OPC 
post injury to the spinal cord. One rat model of spinal cord damage at the level of 
T9 has generated a number of interesting results. In a systematic analysis of 
collected data it was discovered that transplanted OPC introduced to the post 
injury scar were able to migrate throughout the injury site and ultimately 
differentiate into fully mature post-mitotic oligodendrocytes as opposed to other 
nervous tissue, such as neurons or astrocytes (Lee et al., 2005b). These 
transplants were also able to reduce functional recovery over time and resulted in 
a far higher number of new neuronal connections within treated tissue, indicating a 
positive effect on neuronal axon generation (Keirstead et al., 2005). In other work, 
embryonic stem cells (ESC) were differentiated into OPC ex vivo and 
subsequently transplanted into rat SCI sites at both 1 week and 10 week after 
injury. The transferred OPC demonstrated good overall survival and were shown 
to migrate into the scar where they differentiated into mature oligodendrocytes. 
Interestingly, similar results were obtained at both time-points after injury 
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(Faulkner and Keirstead, 2005, Nistor et al., 2005). Further work using this model 
of SCI has combined the transplant of OPC with treatment with neural growth 
factors. These experiments demonstrated both further increases in the formation 
of mature oligodendrocytes within the scar tissue but also increased numbers of 
ascending and descending axons and increased signalling, showing significant 
potential for interventions in humans (Sharp et al., 2010). 
Progress has also been made in the implementation of such neuro-regenerative 
methodologies into the clinic, using the work performed in numerous animal 
models as the template. The American Spinal Injury Association (ASIA) approved 
a national phase-one trial, which was funded by the Geron Corporation. This trial 
was implemented to assess the tolerability and safety of human ESC-derived 
OPC-based therapies in patients with spinal injuries manifesting sub-acute 
thoracic damage, in which this trial have been reported to efficiently contribute to the 
functional improvement (Sypecka, 2011). Another trail is in progress by Asterias 
Biotherapeutic where they occupied the same stem cells that been used by 
Geron’s trail and employs many of the same people (Willyard, 2013).  
 
1.4.4.3 Microglia 
Microglia are cells considered to be specialised components of the innate immune 
arm of the immune system. Like oligodendrocytes, these cells possess many 
branching processes and are phenotypically distinct (Cao and He, 2013). It is 
estimated that microglial cells make-up around 10% to 20% of all the cell types in 
the CNS (Hammond et al., 2014). Microglia are distinct from other cell types of the 
nervous system, in that they are derived from macrophages which emerge from 
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early haematopoiesis during development in the yolk sac, these then migrate to 
and undergo further differentiation within the developing neural tube to form 
microglia. This is distinct from other nervous system components which develop 
from neural stem cells. Interestingly, microglia revert back into macrophages 
during inflammation (Ransohoff and Cardona, 2010). Microglial cell populations 
within the spinal cord persist and are replenished from a local population of 
progenitor cells and distinct from this is a population, which is derived from bone 
marrow-derived monocytes, which consistently migrate into the CNS and 
differentiate into mature microglia, both homeostatically, and in response to injury 
(Ransohoff and Cardona, 2010, Aguzzi et al., 2013). Microglia are generally 
considered the first myeloid-derived cell to respond to SCI and quickly differentiate 
into activation of macrophages in response to early inflammatory signals. These 
early responding microglial-derived macrophages then cannot be differentiated in 
terms of morphology from peripherally recruited macrophages (Hawthorne and 
Popovich, 2011).  
 
Within the cellular milieu which characterises the early inflammatory response 
after tissue damage at the spinal column, these resident microglial macrophages 
are key components, serving to determine changes to the immediate micro-
environment in ways which are both beneficial and detrimental in terms of axon 
regeneration (David and Kroner, 2011).  As with other types of macrophages in 
other tissues, microglial macrophages demonstrate significant plasticity in terms of 
their activation states. The traditionally accepted phenotypic characteristic of 
activated macrophages are termed M1 and M2, though it should be noted that 
these represent phenotypic extremes and it is now generally accepted that a full 
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scale of intermediate phenotypes between these two are produced depending on 
the specific signalling resulting from the stimulation by molecules in the immediate 
inflammatory milieu (Kigerl et al., 2009). M1 macrophages are generally known as 
classically activated, and are pro-inflammatory. These respond to toll-like receptor 
(TLR) signalling in response to lipopolysaccharide and other microbial pathogenic 
signals by activation and secretion of cytokines such as IFNγ, IL-1β, TNFα, all of 
which cause a further cascade of innate immune activation and increase 
inflammation within the area. Microglial macrophage M1 activation results from 
stimulation by pro-inflammatory cytokines, such as IL-12, IL-1β, TNFα and other 
small molecules known to induce M1 phenotypes (e.g. reactive oxygen species 
and reactive nitrogen species are frequently present in inflammation after spinal 
cord damage) (Kigerl et al., 2009, Ju et al., 2014). M1 activation not only leads to 
an increase in the secretion of further inflammatory molecules, but also leads to an 
increase in antigen presentation and phagocytic capabilities of the macrophages, 
which enables them to clear the surrounding tissue of cellular debris resulting from 
tissue damage, remove pathogens, and subsequently induce an adaptive 
response to any dangers present within the area. Alternatively, microglial 
macrophages can undergo an M2 type activation. This is usually in response to 
the stimulation by the cytokines, IL-4 and IL-13. In contrast to M1, M2 activated 
cells are generally anti-inflammatory and secrete the immune suppressive 
cytokines TGFβ and IL-10 which have been shown to lead to the resolution of 
inflammation (Lawrence and Natoli, 2011).  
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1.5 Limited regenerative capacity of CNS axons 
Damage to the CNS causes permanent disabilities due to limited capacity of repair 
and functional recovery after CNS injury, in which the CNS enables a significant 
regenerative response to restore lesioned areas compared to PNS that launches a 
robust regenerative in response to injury (Huebner and Strittmatter, 2009, Giger et 
al., 2010, Kempf et al., 2013). Several factors contributed to the limited 
regenerative capacity of CNS neurons, which fall into two main categories; 
intrinsic growth limiting factors and extrinsic inhibitory factors present after SCI.  
 
1.5.1 Intrinsic growth limiting factors 
Many studies have attempted to regenerate CNS neurons after injury by providing 
growth permissive environments such as cell transplants and peripheral nerve 
grafts but, these attempts have shown feeble regeneration whist others showed no 
regenerative response (Richardson et al., 1980, David and Aguayo, 1981, Li et al., 
1997, Houle et al., 2006, Grill et al., 1997, James, 2013). The key mechanism 
responsible for this failure is a pattern of proteins synthesis and gene regulation in 
axotomised neurons. The pattern of these factors becomes clear when 
comparisons are made with axotomised neurons in the PNS, where regeneration 
associated genes (RAGs) are elevated far early after PNS injury compared to the 
CNS (Huebner and Strittmatter, 2009). The upregulation of RAGs including genes 
that transcribe cytoskeletal proteins such as actin, tubulin, growth associated 
proteins-43 (GAP43) and cytoskeleton associated protein-23 (CAP23) were shown 
to play important roles in mediating growth cone elongation (Bulsara et al., 2002, 
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James, 2013). Moreover, PTEN is one of the RAGs that promoting axon 
regeneration and functional repair after adult spinal cord injury through 
PTEN/mTOR pathway (Liu et al., 2010). One of the other RAGs is Krüppel-like 
Transcription Factor 7 (KLF7), in which overexpression of KLF7 in adult rat RGCs, 
found to increase RGC survival and induce axon regeneration after optic nerve 
injury (Wang et al., 2013). Epothilone B (that reactivated neuronal polarization by 
inducing concerted microtubule polymerization into the axon tip) (Ruschel et al., 
2015), pregabalin (Warner et al., 2017) and c-Jun (Fagoe et al., 2015) are other 
RAGs found recently that implicated in CNS axon regeneration. 
 
In the development stage of the nervous system, most RAGs are found highly 
expressed and then decrease in the adult, while in the PNS RAGs are robustly re-
expressed (Fernandes et al., 1999, Bulsara et al., 2002). The presence of RAGs 
and local protein synthesis in the CNS is necessary for rapid formation of growth 
cones, along with their guidance and elongation. In contrast, low levels of these 
factors and components would definitely contribute to the limited intrinsic growth 
capacity of CNS axons (James, 2013).  
 
 
Another intrinsic mechanism that limits the growth in injured CNS axons is the 
response of microtubules to axotomy. After CNS injury, microtubules are unable to 
propel axon growth because they become depolymerised at the axon stump, 
resulting in formation of retraction bulbs (disorganised microtubules network) 
(Erturk et al., 2007). Retraction bulbs are not present in PNS injury since 
microtubules in the PNS are effective and quickly restore the organisation at the 
axon stump, leading to axon extension and a rapid growth cone formation 
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therefore, stabilisation and organisation of microtubules in CNS axons result in 
stimulation of axon extension and successful growth cone formation (Erturk et al., 
2007, Hellal et al., 2011). 
 
Furthermore, another key mechanism that may be responsible for regeneration 
failure of CNS axons is the activation and expression of different receptors e.g. 
high affinity neurotrophin receptors (tropomyosin receptor kinases (Trk)). Trk 
receptors have three forms including TrkA, TrkB and TrkC, which bind with 
specific neurotrophins. This binding promotes neurite outgrowth, enhances cell 
survival and regulates the advance of the growth cones (James, 2013). All forms 
of Trk receptors expression is lost after either contusion injury or spinal 
hemisection, therefore the reduced expression of these receptors after SCI leads 
to sequestration of neurotrophins, which clearly have negative outcomes on 
axonal growth and survival (King et al., 2000, Liebl et al., 2001, Widenfalk et al., 
2001). Moreover, another receptor appears to negatively affect injured CNS axon 
is the integrins, these types of receptors bind with ECM molecules e.g. fibronectin, 
collagen and laminin and allow axonal elongation over ECM components. The 
levels of integrin receptors decrease in CNS axons after injury, which leaves the 
axons without the important adhesion molecules to grow back through the injury 
sites resulting in dramatic elevation of ECM components (Jones, 1996, Wallquist 
et al., 2004, Eva et al., 2012). The lack of these receptors after SCI leads to the 
accumulation of dense ECM at the lesion site, adding further difficulty of axons re-
growing through the lesion area (Tan et al., 2011).  
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All of the above intrinsic mechanisms are found to contribute to limit the growth 
capacity of CNS neurons after injury. There are also large numbers of extrinsic 
inhibitory molecules available along with lack of trophic support present in the 
adult CNS which contributes to further lack of axonal repair after injury.  
 
1.5.2 Extrinsic inhibitory factors 
Damaged CNS axons are incapable of re-growing after injury with different 
degrees of success once provided with growth permissive substrates. 
Unfortunately, many CNS neurons have lower intrinsic capacity and are 
surrounded by extrinsic inhibitory factors after the injury, compared to their 
peripheral counterparts, but still they are able to grow if the regenerative growth 
environment is replaced with a PNS environment (Richardson et al., 1980, David 
and Aguayo, 1981, Houle et al., 2006). A wide range of research has been carried 
out to investigate the non-growth permissive environment correlated with CNS 
damage and why it is inhibiting axon regeneration especially after injury. 
 
1.5.2.1 Myelin-associated inhibition 
In 1982, Berry was the first person who suggested that CNS myelin may inhibit 
axonal growth after CNS injury, and indicated that non-myelinated CNS axons 
have the ability to regenerate after injury if surrounding myelin remains intact, but 
unable to regenerate if the myelin was disrupted, therefore speculating that myelin 
products were involved in axonal growth inhibition (Berry, 1982, James, 2013). 
Since then, the myelin-associated inhibitory molecules were identified; NogoA, 
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myelin associated glycoprotein (MAG) and oligodendrocyte-derived myelin 
glycoprotein (OMGp), which are considered to be the major CNS axon growth 
inhibitory factors (Hunt et al., 2002, Filbin, 2003, Sandvig et al., 2004). Each of 
these inhibitory molecules will be discussed below in more details. 
 
The first myelin-associated inhibitors is Nogo, this protein belongs to the Reticulon 
protein family (RTN1, 2, 3 and 4), since Nogo has a similar gene structure to 
RTN4, which was characterised by its physiological role in maintaining the shape 
of the endoplasmic reticulum (ER) (Oertle and Schwab, 2003). Expression of 
Nogo is found on both inner and outer surfaces of myelin sheaths, as well as 
reduces axonal growth following CNS injury (Voeltz et al., 2006). Two main 
regions of Nogo are potentially responsible for inhibiting neurite outgrowth; the 66-
amino acid loop region located at C-terminal and the region including two 
stretches at the N-terminal. These regions are found to induce neuronal growth 
cone collapse following CNS injury (Oertle and Schwab, 2003). Targeting Nogo 
also underwent clinical trial (see section 7.4). 
 
The second myelin-derived inhibitor is MAG, which is a transmembrane 
glycoprotein expressed in oligodendrocytes at the axonal membrane between 
axons and the innermost myelin sheath. It acts to maintain the myelination of 
axons in the nervous system. However, MAG has been shown to inhibit neurite 
growth (Schnaar, 2010, McKerracher et al., 1994). In the context of axon 
regeneration, MAG can act as an inhibitor of axon remyelination and growth 
(Filbin, 2003, Gao et al., 2003). MAG has a dual role in axon growth, it is growth 
promoting on younger neurons while growth inhibitory on older neurons, with this 
transition in function occurring at or soon after birth (McKerracher et al., 1994). 
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MAG also signals through binding to ganglioside receptors, which has been shown 
to mediate MAG's role in inhibition of myelination (Quarles, 2002). It has been 
postulated that integrin receptors may also mediate the inhibitory functions shown 
by MAG (Hu and Strittmatter, 2008). However, its role in regeneration is likely far 
more complex and not fully understood, having multiple roles in axonal responses 
after injury in the adult CNS (Nguyen et al., 2009). 
  
The glycoprotein, OMGp is the third myelin-derived inhibitor, which was originally 
discovered as a peanut agglutinin-binding protein found in CNS myelin 
preparations (Mikol et al., 1988). It is now known that OMGp is also expressed 
prominently in neurons (Habib et al., 1998). Studies are only now beginning to 
garner useful insights into the physiological role of OMGp. In the OMGp knockout 
mouse, axons exhibit significant overgrowth causing a deleterious phenotype, and 
suggesting that OMGp serves as an inhibitor to axon growth (Gil et al., 2010). The 
OMGp gene is found in an intron of the neurofibromatosis type 1 gene (NF1) 
(Viskochil et al., 1991) so it was initially postulated to play a role in the induction of 
neurofibromatosis. OMGp was reported to inhibit aberrant collateral sprouting from 
the nodes of Ranvier, by its expression in oligodendroglia-like cells which 
ensheathe the nodes during development (Voeltz et al., 2006, Schnaar, 2010). 
 
All of these three myelin molecules are able to bind with the same GPI-linked 
protein (Nogo receptor 1 (NgR1)) (Domeniconi et al., 2002, Fournier et al., 2001). 
NgR1 forms a complex signalling receptor with p75 or TROY and LINGO-1 to 
mediate the inhibitory signals generated by these ligands (Mi et al., 2004, Park et 
al., 2005, Wong et al., 2002). Furthermore, PirB paired-immunoglobulin-like 
29 
 
receptor-B (LILRB) was discovered to bind and act as receptor for Nogo, MAG 
and OMgp, and when binding takes place in conjunction with NgR1, it was shown 
to mediate potent myelin-associated axon growth inhibition (Atwal et al., 2008). 
More recently, AMIGO3 has been identified to substitute LINGO-1 in the acute 
phase of SCI acting as a co-receptor for p75 and NgR1, since LINGO-1 was 
raised 2 weeks after SCI (Ahmed et al., 2013).  
 
However, the activation of the complex receptors leads to downstream signalling 
via the activation of RhoA (Figure  0.4) (Ahmed et al., 2013). Since RhoA exists in 
equilibrium between active GTP complexed (Rho-GTP) and inactive GDP 
complexed (Rho-GDP), a guanine-nucleotide exchange factor (Rho-GEFs) 
activates Rho-A by converting Rho-GDP to Rho-GTP (Overbeck et al., 1995, 
Schmidt and Hall, 2002). Rho-GTP active form leads to activate a number of 
signalling pathways contributed in growth cone collapse via Rho-associated 
kinase (ROCK). ROCK has two subtypes but they are considered as together, and 
has two major functions: formation of stress fibres and inhibition of actin 
depolymerisation (Schmandke et al., 2007). Many pathways can regulate actin 
polymerisation but the most important pathways are LIM-domain containing 
protein kinases 1 and 2 (LIMK) and cofilin, in which activation of ROCK leads to 
phosphorylation of LIMK result in deactivation of cofilin by phosphorylation 
(Maekawa et al., 1999, Zhao and Manser, 2005, Schmandke et al., 2007). 
Although actin cytoskeleton plays an important role in neuronal morphology and 
growth cone extension, actin can be affected due to deactivation of cofilin causing 
neuronal growth cone collapse and axon degeneration (Mizuno, 2013). 
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Figure  0.4: The signalling pathway activated by myelin molecules when 
bound with NgR1/LINGO-1/p75 complex receptors.  
This binding complex leads to displacement of Rho-GDI (Rho GDP-dissociation 
inhibitor) from Rho-GDP leading to activation of Rho-GTP by GEF. This activates 
ROCK leading to inhibition of actin depolymerisation by phosphorylation of LIM 
Kinase and cofilin result in occurrence of growth cone collapse and inhibition of its 
motility. Figure provided by Dr Zubair Ahmed. 
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1.5.2.2 Inhibitory guidance molecules 
There are a number of axon guidance molecules which play a role in restricting 
axonal growth after CNS injury; in contrast, they also play a vital role in correct 
wiring of the CNS during development. An example of these guidance molecules 
is the Semaphorin family, which contribute in developing CNS shape by deflecting 
axons from inappropriate areas and potent repellents of axon growth during 
development (Messersmith et al., 1995, Behar et al., 1996). Semaphorin-3A is 
expressed in the glial scar by meningeal fibroblasts and inhibition of Semaphorin-
3A after CNS injury was found to promote axon regeneration (Pasterkamp and 
Verhaagen, 2001, Kikuchi et al., 2003). 
There are other important inhibitory guidance molecules such as; eph receptor 
tyrosine kinases and their ligands. Eph receptors are upregulated after SCI and 
some ephrins are expressed by astrocytes at the lesion site (Willson et al., 2002, 
Bundesen et al., 2003). Genetic knockout studies of the ephrin and EPHA4 and 
application of a blocking peptide of these proteins showed enhanced regeneration 
of CNS axons after injury (Goldshmit et al., 2004, Fabes et al., 2007). Moreover, a 
genetic knockout of EPHB3 enhanced regenerative response after spinal 
hemisection and optic nerve crush (Duffy et al., 2012). Therefore blocking these 
molecules lead to provide better growth permissive for injured CNS axons.    
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1.5.2.3 Proteoglycans 
As previously mentioned, glial cells form a physical barrier to axonal regeneration 
in response to SCI, however these cells (particularly reactive astrocyte) also 
create a chemical barrier to regeneration by producing a number of inhibitory ECM 
molecules (Fitch and Silver, 2008, Sharma et al., 2012). In the context of SCI, the 
most widely studied of these upregulated ECM inhibitory molecules are 
proteoglycans (Jones and Tuszynski, 2002). Proteoglycans can be chondroitin 
sulphate, keratin sulphate, heparan sulphate or dermatan sulphate, in which 
chondroitin sulphate proteoglycans (CSPGs), heparan sulphate proteoglycans 
(HSPGs) and keratin sulphate proteoglycans (KSPGs) are all induced after CNS 
injury (Jones et al., 2003, Ramer et al., 2005).  
 
CSPG and its family molecules (neurocan, aggrecan, brevican and versican) are 
the most abundant proteoglycans in the CNS and are secreted by glia scar cells 
creating CSPG rich ECM surrounding lesion site (Jones et al., 2003), NG2 is other 
CSPGs are expressed in glial cell membranes and react rapidly to CNS injury 
(Fidler et al., 1999, Tang et al., 2003).  CSPGs have been observed to have a role 
in axon growth inhibition, for example: in vitro evidence demonstrates that a 
normal growth permissive substrate containing CSPGs prevent sensory neurons 
extending neurites (Snow et al., 1990) as well as, disrupt growth cone dynamics of 
adult CNS neurons and prevent their neurite extension in the presence of 
explanted glial scars (James, 2013).  
 
Furthermore, in vivo studies show axons of transplanted adult sensory neurons 
will extend in the CNS, however these axons will form dystrophic end bulbs and 
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halt abruptly upon reaching the reactive gliosis site correlating with areas of 
induced CSPG expression (James, 2013). Disruption and degradation of CSPG 
and its inhibitory interaction either by antibody neutralisation, targeting 
downstream effector molecules or by enzymatic degradation enhanced axonal 
growth both in vitro and in vivo (Grimpe and Silver, 2004, Shen et al., 2009, Fisher 
et al., 2011, Bradbury et al., 2002). The sustained and dramatic elevation of 
CSPGs along with multi-faceted inhibitory actions of these molecules following 
injury remain a key target for the development of potential therapeutic 
interventions for use in SCI (James, 2013). In vivo study, a mammalian-compatible 
engineered chondroitinase ABC (ChABC) has been delivered using lentiviral 
vector (LV-ChABC) to explore the consequences of large-scale CSPG digestion 
for SC repair. The results demonstrate significantly reduced secondary injury 
pathology in adult rats injected LV-ChABC with after spinal contusion injury, with 
reduction of the cavitation and enhanced preservation of spinal neurons and 
axons at twelve weeks post-injury (Bartus et al., 2014). Manipulating these 
molecules along with inhibitory factors listed earlier lead to the promotion of 
regeneration of injured CNS axons. 
 
1.6 CNS repair and axon regeneration 
Due to long-term disabilities resulting from damage to the CNS, it was initially 
thought that the adult CNS has no ability to repair itself. However, in 1928 Ramon 
Y Cajal (Ramón y Cajal et al., 1991) observed that the CNS may actually have the 
ability to repair itself given the right environmental conditions. Regeneration of the 
CNS is first of all dependent on whether the neural cell itself survives the injury. 
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The other factors are the availability of molecules involved in axon growth and 
guidance, and the local permissive and inhibitory signalling cascades. Aguayo et 
al (Richardson et al., 1980) later replicated Ramon Y Cajal’s findings and further 
established that the inability of the CNS to regenerate was the result of a local 
environment that was always altered in response to the injury. Aguayo’s group 
was able to observe elongation of regenerative axonal “sprouts” in both the CNS 
and PNS after injury (Richardson et al., 1980). They determined that neuronal 
responses to injury were possibly influenced by glial cells, growth factors and 
target tissues such as smooth muscle cells. 
This has since led to a number of investigations into axonal regeneration of the 
CNS with the aim of developing regenerative strategies that could be adopted for 
therapeutic applications. Because of the fact that neuronal regeneration requires 
the neural cell to be alive in the first place, any successful regenerative strategy 
are likely to benefit SCI rather than brain injuries.  
Any regenerative strategy employed must take into consideration the viability of 
the neuronal cells, the availability of target tissues, the elongation of the cut axon 
and dendrites, re-myelination and the formation of new synapses for total recovery 
of function that may have been lost after injury. Regeneration in the adult CNS is 
therefore a step wise process that involves factors which affect the parameters 
listed above.  Therefore, most of the strategies currently being employed are 
aimed at stimulating “cellular replacement, neurotrophic factor delivery, axon 
guidance and removal of growth inhibition, manipulation of intracellular signalling, 
bridging and artificial substrates, and modulation of the immune response (Horner 
and Gage, 2000)”. 
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To replace neuronal and glial cells lost during CNS injury, researchers have 
considered the use of fetal tissue grafts (Richfield, 2000) and neural stem cells 
(Gage, 2000). Stem cells have the ability to differentiate into glial and neural cells 
once transplanted into the brain and given the right neurotropic factors. However, 
ethical, physical and mechanical difficulties still limit the use of fetal tissue grafts 
and restoration of function after cell replacement using neural stem cells still has 
to be proved (Horner and Gage, 2000).  These hurdles still put to question 
whether cellular replacement is viable in CNS axon regeneration. This takes us 
back to the first requirement that for any viable regeneration of the CNS to occur, 
the neuronal cell has to have survived the initial injury. Once the cell is alive, 
neurotrophic factors are believed to be able to signal axonal regrowth. 
Neurotrophins however, are said to induce axonal growth only when the 
permissive factors provided by for example Schwann cells are present (Xu et al., 
1995). Despite the ability of neurotrophins to generally induce axonal growth, the 
need to direct regenerating axons into the injured CNS begs the question of 
axonal guidance factors and removal of any inhibitory signals. Growth promoting 
molecules including ECM molecules, immunoglobulin, inflammatory cytokines and 
tyrosine kinase receptors among others are some of the molecules that are 
responsible for axonal growth and guidance (Horner and Gage, 2000).  All these 
factors explained above are extracellular. However, there are intracellular factors 
that are vital in cellular survival and axonal growth, and their roles have to be 
understood as well if regeneration of the CNS is to be understood. Some of these 
factors can influence apoptotic cell death in response to injury thus minimizing any 
chances of regeneration.  Manipulation of these factors is important in stimulating 
the cells to start regenerating. Immune responses activated by the body to remove 
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necrotic tissues, may in turn lead to progressive damage to the CNS thus 
preventing neuronal repair (Bredesen, 1995). 
In general, the CNS is a complex system whose regeneration is possible but 
dependent on a number of factors both extrinsic and intrinsic to the damaged cell. 
Research has shown that these regenerative factors can be induced both in-vivo 
and in-vitro. Restoration of damaged cells however cannot be taken as restoration 
of function and functional deficiencies may still exist even after CNS repair.  
 
1.7 SCI models  
Over the past century, SCI models have evolved since Allen in 1911 developed 
the first SCI model by weight-drop contusion model. Complete and incomplete SCI 
models been developed in animals, which aimed to understand the biological and 
anatomical consequences of SCI and resemble human SCI as closely as possible. 
Rat models are most commonly used in preliminary studies of SCI since they are 
readily available, inexpensive, easily housed and can be studied in large numbers. 
Mice are useful for genetic studies and are also implemented in SCI research. 
Large animals such as dogs and pigs can be used for SCI models but it is rare 
because they require expensive housekeeping, care and stringent ethical 
considerations. The only use for large mammals is for further validation required of 
some experimental conditions.  Currently, researchers are using a range of SCI 
models that includes contusion, compression and complete spinal cord transection 
models among others. The reason behind the variety of these models is that they 
never truly express the human condition (Allen, 1911, Metz et al., 2000, Jakeman 
37 
 
et al., 2000, Talac et al., 2004, Davoody et al., 2011, Kundi et al., 2013, Cheriyan 
et al., 2014).    
 
 
1.7.1 Limitations of SCI models 
In the contusion models, it may be hard to assess pain behaviour, since pain 
sometimes is not appear from weight that released from short distance to precise 
area (Nakae et al., 2011). Although, contusion models mainly performed in 
thoracic level of the spinal cord, as a contusion to cervical level affects 
cardiovascular and respiratory functions, which can be a life threating of the 
animal (Yisheng et al., 2007). However, a contusion controlled by a computer is 
useful model that obtain a reliable SCI and reduces experiment variability but it is 
expensive method to use and requires sophisticated equipment (Jakeman et al., 
2000, Ma et al., 2001). Other limit of using computer-controlled method in axon 
regeneration study is that distinguish between spared and regenerating axons is 
difficult at produced lesions (Talac et al., 2004).  
In addition, complete transection model is usually used to study regeneration in 
present of scaffolds, biomaterials and stem cells, but it causes a large scar at the 
lesion surface therefore produces a sever model that dedicated an intensive care 
after surgery (De Winter et al., 2002, Talac et al., 2004, Lee and Lee, 2013). Other 
than evaluation of axon regeneration and devices implantation, this models is 
rarely reported in human thus, has no clinical relevance (Talac et al., 2004). On 
the other hand, injury induced by photochemical model is extent and difficult to be 
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controlled, since this method producing large area that may affected by the 
ischemic environment created by this model (Surey, 2015).  
Furthermore, anaesthesia and laminectomy are two factors limiting the models 
that rely on these factors, which they play crucial role in SCI experiments, since 
they not mimicking the clinical injury of humans. For example, CNS pathology and 
recovery after the injury can be affected following anaesthesia that includes 
respiratory rate, blood pressure metabolism. Each of these symptoms affected 
differently either directly or indirectly depends on different concentrations of the 
same anaesthetic procedure (Akhtar et al., 2008). The other factor is laminectomy 
when it has performed in humans it can cause spinal instability, beside that local 
trauma can be increased. Instability of the spine can occur when the bone, 
ligaments and muscles are removed surrounding the injury during operation, in 
which removal of these components can alter the physiological responses 
following SCI (Akhtar et al., 2008, Surey, 2015).  
There are variations between clinical and experimental models in behavioural 
assessments and functional outcomes of SCI, since it is easy for human to 
express the symptoms and pain correlates with injury compare to animal models 
where it is difficult. Therefore, specific tests and analysis methods been created 
and applied after injury to carry out behavioural patterns correlated with SCI 
(Blight, 2000). The Basso, Beattie, Bresnahan (BBB) rating scale method is a 
locomotor activity evaluation that used to assess the functional outcomes of 
animals. This analysis was originally developed in Ohio State University and aims 
to evaluate the hind limb and forelimb movements of the animal following injury to 
express recovery. While this method is reproducible and reliable, it has been 
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tested in mild severity condition but whenever the condition become more severs, 
the reproducibility is decrease. Although it is, only assess hind limb function it 
does not consider other symptoms that require coordinated spinal cord activity 
such as bladder, bowel and pain function (Basso et al., 1995, Basso et al., 1996, 
Barros Filho and Molina, 2008, Akhtar et al., 2008).    
 
1.7.2 Non-regeneration (DC) and regeneration (SN, pSN+DC) injury models. 
1.7.2.1 Dorsal column injury model (DC) 
Dorsal column (DC) including the Gracile and Cuneate Fasciculi are part of the 
spinal cord white matter. In this PhD, we used our well-established DC injury 
model to investigate genes related to axon growth inhibition/promotion and to 
observe axon regeneration at the lesion site following manipulation of some of 
these genes in DRGN. This method was used by us to study axon regeneration 
and to document cellular responses after SCI injury (Lagord et al., 2002, Ahmed et 
al., 2011a, Ahmed et al., 2013). However, the model is limited since there are no 
behavioural deficits in terms of responses to thermal or mechanical allodynia but 
does serve as a useful model to study long tract DRGN axon regeneration (Surey 
et al., 2014). The injury was performed by identifying the 13th rib of rats externally, 
using this as a landmark to count to the T8 vertebrae. After sterilising the surgery 
site, a 4-5 cm skin incision was made and the erector spinae muscles removed as 
much as possible to be able to reach the T8 vertebra. By using rongeurs, the T8 
vertebra was gently removed along with lamina (partial laminectomy) and the 
spinal cord was exposed, and crushed bilaterally with a calibrated watchmaker’s 
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forceps (for 10s), inserted through the spinal cord meninges to a depth of 1mm 
(Figure  0.5). The erector spinae muscles were closed with absorbable sutures 
and skin overlaid using staples.  
 
 
1.7.2.2 Sciatic nerve injury (SN) 
Much investigation on neuronal response after peripheral nerve injury includes 
sciatic nerve, aimed at studying the mechanism of neuropathic pain rather than 
the mechanisms of regeneration. Studies that aimed to examined the change in 
gene expression of DRGN that associate with neuropathic pain caused by SCI, 
have subsequently able to identify novel regeneration-associated gene following 
sciatic nerve injury (Blain, 2009). This model was also used by us in this study and 
others (Ahmed et al., 2011a, Ahmed et al., 2013) to investigate the genes 
associated with SN axon regeneration. The SN injury was performed at the left 
posterior thigh to greater trochanter in the level of sacrotuberous ligament 
(Figure  0.6). After sterilising the operating area, approximately 2cm skin incision 
was made and gluteal muscles were split using retractors. The SN was then 
exposed unilaterally and crushed using calibrated forceps for 10s (Figure  0.7). 
After crush, gluteal muscles and the skin were closed by absorbable sutures; 
animals were monitored until recovery from anaesthesia and allowed to survive for 
7 days then L4/5 DRGN collected for further analysis. 
41 
 
  
 
 
 
 
Figure  0.5: Dorsal column crush at T8 vertebrae in female Sprague-Dawley 
rats.  
(A) Diagram of cross-section of rat spinal cord at T8 with width and depth of 1mm 
used to perform the injury in dorsal funiculus, (Adapted from (Surey, 2015).  (B) 
Spinal cord exposed after 4-5 cm skin incision and removal of erector spinae 
muscles followed by insert of calibrated watchmaker forceps (white arrow marks 
the crush site).  
A 
B 
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Figure  0.6: Diagram of cross section of the spinal cord showing the site of 
SN injury and relevant anatomical features of the injury.  
Adapted and modified from (Blain, 2009). 
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Figure  0.7: Operation images for left SN crush in adult Sprague-Dawley rat.  
(A) About 2cm of skin incision at the left posterior thigh to greater trochanter 
followed by gluteal muscles cut then sciatic nerve was exposed after gently 
removal of the muscles. (B) Crush step using calibrated forceps for 10s.   
 
 
A B 
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1.7.2.3 Preconditioning sciatic nerve injury (pSN+DC) 
Since DRGN branched two projections one to periphery and other to central 
nervous system, injured peripheral branch found capable to regenerate whereas 
central not. However, if PNS injured before CNS (precondition) those cells found 
primed to sprout some central fibres demonstrate that central branches are 
capable to regenerate (Case and Tessier-Lavigne, 2005). As stated above this 
injury model was used to study gene relative to axon regeneration and to model a 
preconditioning injury, the SN was crushed 7 days prior to DC injury as described 
above. 
 
1.8 Main hypothesis 
In a microarray screen in regenerating and non-regenerating models of SCI 
(described above), approximately 350 genes were observed to correlate with axon 
regeneration. Therefore, understanding the contribution of these genes and 
manipulation of these genes either by knockdown or overexpression may lead to 
the promotion of axon regeneration and enhanced regenerative responses after 
SCI. This led to hypothesis that manipulating some of the most highly regulated 
genes (i.e. AMIGO3, RTN3 and AEG-1) will promote enhanced DRGN axon 
regeneration after DC injury.  
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1.9 Main aims  
• To determine protein and messenger RNA (mRNA) levels of these genes in 
both regenerating and non-regenerating SCI models after 7 days post 
injury. 
•  To knock down these genes using siRNA in an in vitro model of SCI using 
cultured primary DRGN in the presence of an axon growth inhibitory CNS 
myelin extract (CME) and observe how they regulate neurite outgrowth. 
• Supress or overexpress these gene in vivo depending on how they regulate 
disinhibited DRGN neurite outgrowth and determine their effects on 
promoting DC axon regeneration in vivo. 
• To assess the inflammatory responses including glial activity, macrophages 
and T cells after injection of plasmids encoding shAMIGO3.   
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2.1 In vivo methods 
2.1.1 Animal surgery 
All animal procedures were licensed and approved by the University of 
Birmingham’s Ethical Review Committee and by the UK Home Office. Adult 
female Sprague-Dawley rats were used in these experiments weighing between 
180-250g (Charles River, Margate, UK). Prior to surgery animals were injected 
with 0.05ml of Buprenorphine for analgesia and then placed in a chamber for 
anaesthesia using 5% of Isoflurane, 1.8/mg of O2 and monitoring body 
temperature and heart rate during surgery.  
 
2.1.2 Injury models 
The T8 DC model, SN and pSN+DC models have been described in the 
introduction (see section 1.7.2). (all injuries were performed by Dr Zubair Ahmed)  
 
2.1.3 Intra-DRG injection 
While the animal was under deep anaesthesia we preformed intra-DRG injection 
to lumbar (L)4/5 DRG ganglia after DC injury. At the level of midline lumbar region 
about 4-5 cm skin incision was made and erector spinae muscles were removed 
and split using retractor to visualise the contralateral side at lumbar level. The L4 
vertebra was marked and approximately 2cm paramedian incision was made from 
left of the spinous processes down to the articulating surfaces of the facet joints. 
Ligaments attached to the articular surfaces were removed by using rongeurs and 
further dissection was made to reach the lateral vertebra which was then removed 
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to reveal the ventral L4/5 rami. By further gentle dissection, the L4/5 DRG was 
exposed in the intervertebral foramina and 2µl of plasmids or PBS solution, 
depending on the experiment was injected using microglass needle attached to a 
20ml syringe. It is sign of successful process if the DRG ganglia was observed to 
swell during the injection (Figure  2.1), finally retractor was removed and muscle 
was closed using absorbable suture followed by skin closure using staples. (Intra-
DRG injections were performed by Dr Zubair Ahmed).   
 
 
 
 
 
 
 
 
 
 
Figure  2.1: Injection paradigm showing anatomic level of intra-DRG injection 
preformed in this study. 
S1 
L4 
L6 
L3 
L2 
L1 
T8 
L5 
L5 DRG bundle 
Microglass needle 
Spinal cord columns 
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2.1.4 Experimental design for in vivo experiments 
Different surgical procedures have been carried out in this thesis that includes 
injury models, microarrays, injection of different plasmids. In injury models three 
different crushes were performed (DC, SN and pSN+DC) and DRG ganglia were 
collected at day 7, in which pSN+DC model preformed 7 days prior to DC injury 
(Figure 2.2A) to preform microarray screening and validate the highlighted genes 
using immunohistochemistry, western blot and RT-PCR. However, down-regulate 
and overexpression using plasmid injection was carried out in two chapters in this 
thesis; (1) down-regulate AMIGO3 after DC injury for 29 days (2) overexpress 
RTN3 after pSN+DC for 21 days (Figure 2.2B, C). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2:Timelines for in vivo surgical procedure. (A) Timeline for microarray 
and genes validation, (B) timeline used in chapter 3,(C) timeline used in chapter 5. 
pSN+DC 
-7 days Day 0 Day 7 
DC and SN  Sacrifice and tissue        
harvested 
Day 0 
DC+ PBS and in vivo-jetPEI injection/plasmids 
Day 29 
Sacrifice and tissue        
harvested 
Day 0 Day 21 -7 days 
pSN+DC DC+ in vivo-jetPEI injection/plasmids 
Sacrifice and tissue        
harvested 
A 
B 
C 
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2.2 In vitro methods 
2.2.1 Tissue processing and sectioning 
For microarrays, RT-PCR and western blot, animals were killed at 7 days after 
injury by rising CO2 levels and fresh DRG tissue were collected and immediately 
frozen in liquid N2. Samples were stored at -80oC until required. 
 
2.2.2 Intracardic perfusion  
For immunohistochemistry, animals were intracardially washed with phosphate 
buffer saline (PBS) and then perfused using 4% formaldehyde (PFA: TAAB 
Laboratories, Berkshire, UK). Once animals were perfused DRG and injury sites 
were dissected out and postfixed for 2 hours at room temperature (RT). Tissues 
were washed in 3 changes of PBS for 30mins each, and cryoprotected in 10%, 
20% and 30% sucrose solutions diluted in PBS. Tissues were then embedded in 
OCT and cut at 15µm thick using a cryostat (Bright Instrument, Cambridgeshire, 
UK), adhered onto Superfrost plus slides (Fisher Science, Loughborough, UK) and 
stored at -20oC until required.  
 
2.2.3 Immunohistochemistry  
Sections were thawed for 30 mins at RT then washed twice in PBS for 5 mins 
each. Sections were permeabilized in 0.1 Triton X-100 (Sigma, Pool, UK) in PBS 
for 10 mins at RT, washed twice for 5 mins in PBS and then blocked for 30 mins at 
RT using PBS containing 0.5% bovine serum albumin (BSA; Sigma, Pool, UK) and 
0.05% Tween 20. Appropriate primary antibodies, diluted in PBS containing 0.5% 
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BSA and 0.05% Tween 20 were incubated overnight at 4oC in a humidified 
chamber (Table  2.1). Sections were then washed three times in PBS for 5 mins 
each, and relevant secondary antibodies were applied to the sections and 
incubated at RT for 1 hr (Table  2.1). Sections were then washed 3 x 5 mins in 
PBS and mounted in Vectashield with DAPI (Vector Laboratories, Peterborough, 
UK). 
 
2.2.4 Protein extraction and western blot analysis 
2.2.4.1 Homogenisation of spinal cords 
To extract total protein, DRG were cut and placed in ice for at least half an hour, 
200µl of ice-cold lysis buffer (1M Tris HCL pH7.4, 5M NaCL, 0.5M EDTA, .025M 
EGTA, 1%NP-40, 5µl/ml protease inhibitor) was added to each sample and 
homogenised for 1 min at 4000g. Samples were left on ice for a furhter 30 mins 
and then transferred to eppendorf tubes and clarified by centrifugation at 17680g 
for 30 mins at 4oC. The supernatant was removed and 5µl/ml of protease inhibitor 
cocktail (Sigma, Pool, UK) was added to inhibit protein degradation, aliquoted and 
stored at -20oC until required. 
 
2.2.4.2 Protein concentration assay 
Using a 96 well plate microassay, 5μl of tissue lysates or protein standards were 
added, followed by 20µl reagents A, B and S (BioRad, Hertfordshire, UK) were 
added to the rest of the well as following (20µl of A and S (20µl of reagent S per 
1ml of reagent A) and 160µl of reagent B). The plate was kept in the dark for 15 
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mins for colour to develop and the absorbance at 750nm was read using a plate 
reader within 1 hr (Bio-Rad, Hertfordshire, UK). 
 
2.2.4.3 Gel casting  
A 12% polyacrylamide gel was cast in 1mm disposal cassettes (Fisher Scientific, 
Loughborough, UK). Each gel was composed of resolving and stacking gel. The 
resolving gel comprised 2.75ml Protogel (Geneflow, Fradley, UK), 1.65ml of 1.5M 
Tris-HCL pH  8.8, 2.2ml MilliQ water, 66µl 10% sodium dodecyl sulphate (SDS) 
(Fisher Scientific, Loughborough, UK), 23.1µl 10% ammonium persulphate (APS) 
and 9.9μl Tetramethylethylenediamine (TEMED, VWR International, Lutterworth, 
UK), all these components mixed and approximately 2/3 of resolving gel was 
loaded onto the cassette. Seventy present ethanol was layered onto resolving gel 
in order to exclude air bubbles during polymerisation. While resolving gel was 
polymerising, a stacking gel was prepared as following; 0.4ml Protogel, 1.85ml 
0.5M Tris-HCL pH 6.8, 0.75ml MilliQ water, 30μl 10% SDS, 15μl 10% APS, 7.5μl 
TEMED, then layered ethanol was removed followed by loading of stacking gel. 
Then a 1mm 10 well comb was inserted and the gel was allowed to polymerise at 
RT.  
 
2.2.4.4 Western blot 
Western blot gels were made at least 20 mins before running the procedure. 
Protein samples were prepared by adjusting the protein concentration by dilution 
with 2X sample Lamelli loading buffer (4% SDS, 20% glycerol, 10% 2-
mercaptoethanol, 0.004% bromphenol blue and 0.125 M Tris HCl, pH about 6.8 
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(Sigma, Pool, UK)) and denatured at 90oC for 4 mins. Five microlitre of molecular 
weight standard markers (Rainbow markers, Invitrogen) and 20µl of protein 
samples were loaded onto gels and proteins separated for 2 hr at 125V, 18mA, 
2.1W under running buffer containing of 25mM Tris-base, 192mM glycine and 
0.01% SDS.  
 
Proteins were then transferred from gels onto immobilon polyvinylidene fluoride 
membranes (PVDF), which were activated by soaking in 100% methanol for 1min 
followed by a 1min wash in MilliQ water then 5min in transfer buffer containing 
25mM Tris-base, 192mM glycine, 20% methanol and 0.02% SDS, at 25V for 2hr. 
Membranes were then washed with Tween-Tris buffered saline (TTBS (0.12% 
Tris-base, 0.88% NaCl, pH 7.4, 0.05% Tween 20)) for 5 mins, incubated in a 5% 
non-fat milk blocking solution (Marvel, Lincolnshire, UK) for 1 hour at RT, and then 
incubated overnight at 4oC with relevant primary antibodies (Table  2.2: . 
Membranes were then washed with TTBS 3 times and incubated with relevant 
secondary antibodies conjugated to HRP (1:1000, GE Healthcare, 
Buckinghamshire, UK) for 1hr at RT (Table  2.2: .  
 
Membranes were then incubated for 1min in 2ml of enhanced chemiluminescence 
(ECL) solution (GE Healthcare, Buckinghamshire, UK) at RT. The membranes 
were then placed in a transparent bag and exposed onto Kodak Biomax film 
(Kodak) to visualise the protein bands.  
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2.2.4.5 Stripping blots 
Membranes may be stripped of primary and secondary antibodies using a low pH 
stripping solution (25Mm Glycine-HCL, pH2, 1% SDS) for 1hr at RT. Blots were 
then washed with TTBS for 5 mins and blocked in 5% non-fat milk solution for 1 
hour at RT and then incubated with relevant primary and secondary antibodies as 
described above (Table  2.2). 
 
2.2.5 Antibodies specificity 
AMIGO3: same antibody has been used from (Ahmed et al., 2013) were the 
author used blocking peptide in rat DRG sections for antibody specificity. 
RTN3: according to the manufacturer RTN3 antibody has been tested using 
western blot analysis of human brain tissue extract. 
AEG-1: the manufacturer reported specificity for AEG-1 using 
immunohistochemistry of tissue section of human skin cancer that fixed with 
formalin and embedded with paraffin. 
CRELD1: a 45kDa was specific binding in mouse heart tissue lysate of CRELD1 
using western blot according to the manufacturer. 
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2.2.6 Antibodies used  
2.2.6.1 Immunohistochemistry antibodies 
Antibody (Cat No)       Dilution Factor   Species                 supplier  
Primary Antibody 
AMIGO3 (sc-49881)  1:200            Goat                 Santa Cruz, USA 
NT3 (ab6203)   1:100     Rabbit               AbCam, Cambridge, UK 
NF200 (N4142)     1:400  Mouse              Sigma-Aldrich, Poole, UK 
AEG-1 (ab45338)   1:200    Rabbit               AbCam, Cambridge, UK 
RTN3 (sc-33599)  1:200   Rabbit    Insight Biotech, UK 
CRELD1 (ab131286)  1:200  Rabbit               AbCam, Cambridge, UK 
β-III-tubulin (T2200)  1:400  Mouse              Sigma-Aldrich, Poole, UK 
GAP43 (SAB1405847)  1:200  Goat                 Sigma-Aldrich, Poole, UK 
CD68/ED1 (MCA341R) 1:100  Goat                 Serotec, UK 
CD8 (MCA1226)  1:100  Goat                  Serotec, UK 
CD4 (MCA1267)  1:100  Goat                  Serotec, UK 
GFAP (AB5804)   1:200  Mouse               Sigma-Aldrich, Poole, UK 
Secondary antibody 
Alexa Fluor 488  1:400        Goat, Rabbit Invitrogen Ltd, Paisley, UK 
Alexa Fluor 594  1:400  Mouse  Invitrogen Ltd, Paisley, UK 
Texas Red   1:400       Mouse, Rabbit Molecular Probes, UK 
 
Table  2.1: Primary and secondary antibodies used for staining and detecting 
proteins in immunohistochemistry (IHC). 
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2.2.6.2 Western blot antibodies 
 
Antibody (Cat No)        Dilution Factor   Species                supplier  
Primary Antibody 
AMIGO3 (sc-49881)  1:1000  Goat  Santa Cruz, USA 
NT3 (ab6203)   1:1000  Rabbit  AbCam, Cambridge, UK 
AEG-1 (ab45338)  1:1000  Rabbit  AbCam, Cambridge, UK 
RTN3 (sc-33599)  1:1000  Rabbit  Insight Biotech, UK 
MBP (ab40390)   1:1000  Rabbit  AbCam, Cambridge, UK 
OMGp (ab78595)   1:1000  Mouse  AbCam, Cambridge, UK 
CSPGs (C8035)  1:1000  Mouse  Sigma-Aldrich, Poole, UK 
CRELD1 (ab131286)  1:1000  Rabbit  AbCam, Cambridge, UK 
Actin β (A5441)  1:1000  Mouse  Sigma-Aldrich, Poole, UK 
Secondary antibody 
HRP- anti mouse 1:1000  Mouse  WB    GE Healthcare, Buckinghamshire, UK 
HRP- anti-rabbit 1:1000  Rabbit             WB     GE Healthcare, Buckinghamshire, UK 
HRP- anti-goat 1:1000  Goat               WB     GE Healthcare, Buckinghamshire, UK  
 
Table  2.2: Primary and secondary antibodies used for detecting proteins in 
Western blot (WB). 
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2.2.7 Dorsal Root Ganglion Neuron (DRGN) culture 
2.2.7.1 Dissection and well preparation  
Animals were killed in a chamber by a rising concentrations of CO2 and T13-L5 
dorsal root ganglia (DRG) were dissected out from the spinal cord. DRG ganglia 
were washed in Neurobasal-A (NBA; Invitrogen Ltd, Paisley, UK), then digested in 
1.8ml of NBA media and 200µl of collagenase (1.125% concentration) for 2 hrs at 
37oC. DRG were then moved into a screw capped tube containing 10ml of 
Neurobasal-A to wash out the collagenase enzyme, the media was then removed 
and 2 ml of supplemented NBA (24.2mls NBA, 500ul B27 supplement, 62.5ul L-
Glutamine (200mM), 125ul Gentamicin) was added and DRG and dissociated into 
single cells by trituration. The DRGN suspension was then layered onto a BSA 
gradient (1ml 30% BSA, 1ml NBA) and centrifuged at 120 x g for 10 min. The 
supernatant was removed and 100µl of Trypsin Inhibitor/DNase (TID) (0.01ml 
HBSS, 0.89ml MilliQ water, 0.46µl sodium bicarbonate, 0.3mg BSA, 0.25mg 
Trypsin inhibitor, 0.05mg Deoxyribonuclease and 10µl 3.8% MgSO4) was added to 
prevent cell adhesion and thus clumping and then DRGN were resuspended with 
NBA for cell counting (as described below).     
 
2.2.7.2 Chamber slide preparation and Cell counting 
Chamber slides were pre-coated with 150µl of poly-D-lysine PDL (100ug/ml) for 1 
hour at RT. Wells were then washed with PBS 3 x and 150µl of Laminin was 
added to each well and left at RT in readiness for cell seeding. For DRGN 
counting 10µl of cell suspension was added to an eppendorf tube and mixed with 
10µl of Trypan blue, and a Haemocytometer was used to count the number of live 
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cells. 300 DRGN/well were plated in a total of 500µl of supplemented NBA for the 
neurite outgrowth experiments. Cells were grown in the presence or absence of 
100µg/ml CME (described below). 
The same protocol was used to prepare DRGN after pSN+DC lesions. For these 
experiments, the SN was preconditioned for 7 days and DRG were collected 7 
days after DC lesion to mimic the in vivo scenario.   
 
2.2.7.3 siRNA transfection 
DRGN were removed from the incubator after 1 day of seeding and left for 20 min 
at RT to settle. Short interferon RNA (siRNA) (Table  2.3) was prepared in 
Lipofectamine 2000 reagent (Invitrogen Ltd, Paisley, UK). The concentration of 
siRNA required to cause maximal knockdown was pre-optimised using different 
concentrations ranging from 10 – 150nM in Lipofectamine 2000, and optimal 
concentration of siRNA was determined as 50-100nM/well. 
The siRNA was prepared in 100μl of NBA while 6μl of Lipofectamine 2000 
(Invitrogen Ltd, Paisley, UK) was mixed with 100μl NBA. These were allowed to 
settle for 5 min prior to mixing the two tubes and incubating at RT for 20min to 
allow siRNA to enter within the liposome formed by Lipofectamine 2000 reagent. 
The medium from cells was removed and 200μl of NBA containing the siRNA/ 
Lipofectamine 2000 reagent were used to transfect the cells for 5 hours at 37oC 
and 5% CO2. Each well was then supplemented with 300µl of supplemented NBA 
and incubated for a further 3 days at 37oC and 5% CO2.  
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 Table  2.3: Small/Short interferon RNA (siRNA) used in this study. 
2.2.7.4 Immunocytochemistry 
DRGN were fixed in 4% paraformaldehyde (PFA) for 10 min, washed in three 
changes of PBS. Non-specific staining was then blocked in 3% BSA and 0.1% of 
Triton X-100 for 10 min at RT, followed by incubation in primary antibody (diluted 
1:200) for 1 hour at RT (Table  2.1). After 3 washes in PBS for 10 min each, DRGN 
were incubated with secondary antibody, diluted 1:400 (Table  2.1). After 3 further 
washes in PBS, coverslips were mounted in Vectamount with DAPI (Vector 
Laboratories). 
siRNA (Cat 
No) 
sequence Isoform 
accession 
No 
Stock 
concentration  
supplier 
siAMIGO3 
isoform 1   
(sc-60166) 
GGCTGCTCGATCTATCATCTA NM_198722 10µM Santa Cruz, 
USA 
siRTN3 
isoform 3 
(orb298058) 
GGTTTCTCTTGCAGCTGACAT NM_080909.3 5nmol/µl Biorbyt, 
USA 
siAEG-1 
isoform 1 
(sc-77797) 
GAGCGAGGAACAGAAGAAGAA NM_178812 10µM Santa Cruz, 
USA 
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2.2.7.5 Measurement of neurite outgrowth 
Each chamber slide was divided into 9 fields and 9 images were randomly 
captured from each quadrant using an Axioplan 200 fluorescent microscope, 
equipped with an Axiocam HRc and Axiovision software (all from Carl Zeiss, 
Hertfordshire, UK). The longest neurite from 30 DRGN/well were measured using 
the built-in facilities in Axiovision and recorded (Figure 2.3). The number of DRGN 
with neurites and DRGN survival were also counted. Each experiment was 
performed in duplicate and repeated on 3 independent occasions.   
  
 
Figure  2.3: neurite outgrowth measured using built-in facilities in Axiovision 
Image presented shows an example of a primary cultured DRGN followed by 
immunostaining with βIII-tubulin. The longest neurite outgrowth of each neuron 
was measured and recorded. Scale bar = 50µm.  
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2.2.8 Image capture for analysis of in vivo GFP expression 
Images of whole DRG ganglia at x10 magnification from each animal group 
(n=6/group) were captured using an Axioplan 200 fluorescent microscope, 
equipped with an Axiocam HRc and Axiovision Software (all from Carl Zeiss, 
Hertfordshire, UK). Images were combined in Adobe Photoshop (Adobe Systems 
Incorporated) using the automated Photomerge feature. Composite images of the 
whole DRG ganglia were then used for analysis, including the number of gfp+ 
DRGN, total number of DRGN and quantification of DRGN diameter. 
 
2.2.9 Measurement of DRGN diameters 
DRGN have high heterogenic size distribution since most of the literature 
classified DRGN as small and large (Schmalbruch, 1987). DRGN were divided by 
size into small, medium and large according to the following measurements: small 
(0-29 μm), medium (30-59 μm), large (> 60 μm) (Jacques et al., 2012a). DAPI 
channel images of the whole DRGN ganglia were converted to grayscale and 
DRGN were identified as a large round empty cell body surrounded by satellite 
cells (Figure  2.). Images were then examined using ImagePro image analysis 
software (Media Cybernetics Inc., Maryland, USA) to obtain diameter 
measurements. 
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Figure  2.4: Method to measure DRGN diameter.  
(A) DAPI channel for DRGN converted to grayscale and shown visible as empty 
areas with different diameter (1-3) large, medium and small. (B) Confirmation of 
DRGN nucleus not glia cells (arrow), Scale bar = 50μm. 
 
 
 
 
 
1 2 
3 
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2.2.10 Quantification of axons 
Axon regeneration in the spinal cord was quantified according to the methods of 
Hata et al., (2006) (Hata et al., 2006). Serial parasagittal sections were completely 
reconstructed by collecting all serial 50-μm-thick sections (∼20–30 sections per 
animal; n = 6 animals/treatment). On each section, the number of intersections of 
GAP43+ fibers with a dorsoventral line was counted from 4 mm above to 4 mm 
below the lesion site (Figure  2.) . Axon number was calculated as a percentage of 
the fibers seen 4 mm above the lesion, where the DC was intact. The distance 
beyond the epicenter of the lesion was scored as positive and otherwise as 
negative distance. 
 
 
 
Figure  2.5: Paradigm of axon quantification in injured spinal cord. 
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2.2.11 Preparation of CNS myelin extracts (CME) 
Myelin is a white insoluble precipitate and includes Nogo-A, myelin associated 
glycoprotein (MAG), and oligodendrocyte-derived myelin glycoprotein (OMgp). In 
this project, we extracted myelin from approximately 5 adult Sprague-Dawley rat 
brains as described previously (Ahmed et al., 2005). Brains were chopped into 
small pieces and homogenated in 10% (0.32M Sucrose, 1mM EDTA, pH 7.0) at 
4oC, then centrifuged at 800g (586 rpm) (< 10oC) for 10 min.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
The resultant supernatant was collected and the pellet was re-suspended in the 
original volume before centrifugation at 800g (586 rpm) (< 10oC) for 10 min. The 
supernatant was again collected and combined with the first supernatant and 
centrifuged at 13,000g (9533 rpm) for 20 min. The supernatant was removed and 
the pellet was re-suspended in 0.9M Sucrose to the original volume (10x tissue 
weight) and overlaid with 1-2ml of 0.32M Sucrose and centrifuged at 20,000g 
(14,666 rpm) for 60 min using ultra-centrifuge (Beckman centrifuge, UK). The 
white material at the interface was carefully collected in the minimum volume 
possible and dispensed in 20 volume of 0.32M Sucrose then centrifuged at 
13,000g (9533 rpm) for 25 mins. Again, the white material was collected and 
diluted in 25 volumes of pure water and left on ice for 30 min before being 
centrifuged at 20,000g (14,666 rpm) for 25 min. The final white pellet, containing 
the CME was re-suspended in a small volume of pure water and kept in -80oC 
freezer until required. 
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2.2.11.1 Procedure for using myelin on cells 
Aliquoted CME were defrosted at 4oC overnight and then triturated as follows to 
ensure a homogenous preparation: 200µl pipette tip (7-10 times), 19G needle (2-3 
times), 23G needle (2-3 times). Myelin was then exposed to UV irradiation for 1 
minute for sterilization and was then ready to be added onto cultured cells. At the 
required concentration, myelin can be either added directly to adhered DRGN or 
mixed with culture medium when medium replaced. Since myelin is an insoluble 
precipitate, the mixture of DRGN and CME was swirled every 24 hours to ensure 
equal distribution across the well.  
 
2.2.12 Reverse Transcriptase-polymerase chain reaction (RT-PCR) 
2.2.12.1 RNA extraction 
All RNA samples were extracted from either L4/5 DRG ganglia or cultured DRGN. 
Two methods described below have been used in the project to obtain best RNA 
quality and quantity.  
 
2.2.12.1.1 TRIAZOL method 
DRG ganglia were thawed for 30mins (for DRG culture, media was aspirated out 
and cells were ready to be used for extraction methods). 1ml of TRIAZOL 
(Invitrogen Ltd, Paisley, UK)  was added to the cells and incubated for 5mins at 
RT. Samples were then transferred to a new eppendorf tube and 200µl/1ml of 
chloroform were added in a fume hood and then vortexed for 15 seconds. Tubes 
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were then incubated at RT for 2-3 mins then centrifuged at 16200g for 20 mins at 
RT.  
The overlying solution was carefully collected and transferred to a sterile 
Eppendorf tube. 500µl of isopropanol was added and mixed well, then kept for 30 
mins at RT before storing at -20oC overnight. The next day, tubes were 
centrifuged at 16200g for 20 mins at 4oC and supernatant was removed and pellet 
was re-suspended for washing in 75% ethanol, mixed well and then centrifuged at 
10800g for 20 mins at 4oC.  
Ethanol was removed and the pellet was left to dry for 15-30 mins at RT before 
30-50µl of RNase free water added to dissolve the pellet. Water was passed well 
through the pellet and incubated for 10-20 mins at RT then the RNA concentration 
was determined by loading about 2µl of RNA solution into Nanodrop 
spectrophotometer (NanoDrop Lite; Thermo Scientific, USA) to measure the 
absorbance at 260nm. Sample purity was also performed using Nanodrop 
machine by measuring the 260/280nm absorbance ratio, RNA with a purity value 
of >1.8 was used in all experiments  
 
2.2.12.1.2 Qiagen RNeasy kit  
Approximately 350µl of RTL buffer was added to the samples (buffer was added 
directly to the cell samples and vortexed at high speed, while buffer was added 
and disrupted using homogenizer on tissue samples). One volume of 70% ethanol 
was added to the lysate and mixed well by pipetting. Total volume of 700µl of the 
samples were transferred including any precipitate to an RNeasy mini spin column 
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and placed in a 2ml Eppendorf tube then centrifuged at 10800g for 15 seconds. 
The supernatant was discarded and 700µl of RW1 buffer was added before 
centrifugation at 10800g for 15 seconds. Pellet was kept and 500µl of RPE buffer 
was added then centrifuged at 10800g for 15 seconds, which was repeated but 
centrifuged for 2 mins. RNeasy spin columns were removed and placed in a new 
1.5ml Eppendorf tube and 30-50µl RNase-free water was added directly then 
centrifuged at 10800g for 1 min. Then RNA concentration and purity was 
measured using Nanodrop spectrophotometer (NanoDrop Lite; Thermo Scientific, 
USA) as described above. 
 
2.2.12.2 cDNA synthesis 
After extraction of total RNA from DRG using the methods described above, 
complimentary DNA (cDNA) single strand was synthesised by reverse 
transcription using the SuperScript First-Strand Reverse Transcription System for 
RT-PCR (Invitrogen Ltd, Paisley, UK). The reaction master mix mixture was 
prepared as shown in (Table  2.4), mixed briefly, and then combined with 12µl of 
RNA (1µg/12µl RNase free water) in a PCR tubes then placed at room 
temperature for 2 min. The PCR tubes were then transferred to PCR thermal 
cycler machine for preforming reverse transcription as shown in (Table  2.5). The 
reverse-transcribed first strand cDNA was stored at -20°C until use for RT-PCR. 
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 Components Volume (µl) per reaction 
Reverse Transcription Buffer 
10mM dNTPs 
Random Primers  
DTT 
Superscript Reverse Transcriptase  
4 
1 
1 
1 
1 
Total per reaction 20 include 12µl of RNA  
 
Table  2.4: RT master mix used for cDNA synthesis. 
 
 
Steps 1 2 3 4 
Temperature °C 25 37 85 4 
Time/min 10 120 5 ∞ 
 
Table  2.5: Thermal cycler setting used for the reaction. 
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2.2.12.3 Semi-quantitative RT-PCR 
Primer concentrations were normalised by mixing 5 pmol/µl of forward and reverse 
primers (Table  2.8), where all primers design to detect all isoforms. An ABI Prism 
SDS 7000 PCR machine was used to set up the PCR program shown in 
(Table  2.6). The reaction master mix mixture was prepared in sterilised PCR tubes 
as shown in (Table  2.7). PCR reaction product was then analysed on 1% agarose 
gels (Bioline Ltd, London, UK) at either 3 or 5 cycle intervals to ensure exponential 
PCR product amplification, in which this step done by Dr Zubair Ahmed. 
Steps 1 2 (35-40 cycles) 3 4 
Temperature °C 96 96      58      72 72 4 
Time 2min 30s    30s    45s 5min ∞ 
 
Table  2.6: PCR thermal cycles settings used for PCR. 
Reagent Volume (µl) 
Buffer + MgCl 1.5mM 
dNTPs 
cDNA 
Forward primer 
Reverse primer 
Taq polymers 
H2O  
5 
3 
3 
1 
1 
0.2 
11.8 
Total per reaction 25 
 
Table  2.7: PCR master mix reagents volumes. 
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Primer name Sequence (5’-3’)  Accession No 
 
AMIGO3 
Forward: GAATCGGCTCTACTTGCACA NM_178144.1 
Reverse: AAGTCGTGCAGAGCACTTAG 
 
AEG-1 
Forward: 
GGCGGATCCGCTGGGCCGCGGCTTGC 
NM_133398.1 
Reverse: 
GGCGTCGACTCACGTTTCTCGTCTGGC 
 
RTN3 
Forward: TCAGTCTTCCGAACAGGCTA NM_001009953.3 
Reverse: AATCAGATCATGCACCGCAC 
 
CRELD1 
Forward: CTAAAACAATGGGCTGACGC NM_001024783.1 
Reverse: CTGGAAAAGCCAGCCGTAG 
 
GAPDH 
Forward: CTCTGCTCCTCCCTGTTCTA NM_017008.4 
Reverse: CGTTGATGGCAACAATGTCC 
 
NT3 
Forward: CGCAGTGAGGATTACGGAAA NM_031767.1 
Reverse: CCAAGATCAGCTTTGCAGGA 
 
Table  2.8: Forward and reverse primers used in PCR reactions 
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2.2.13 Densitometry 
Bands detected by western blot and RT-PCR  were both scanned using Adobe 
Photoshop (Adobe Systems Inc, San Jose, CA, USA) keeping all scanning 
parameters constant. ImageJ (NIH, USA, http://imagej.nih.gov/ij) was used to 
quantify the bands using the built-in-gel plotting macros (Figure  2.). Each 
densitometric value was derived from 3 independent experiments and normalised 
to loading controls either to β-actin in western bolts or glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) in RT-PCR. The densitometric values were 
also normalised to the densities of the relevant intact controls for each experiment 
and presented as mean ± SEM. 
 
 
Figure  2.6: Illustration of how densitometry obtained using built-in macro 
function of ImageJ program.  
Peaks of interest were enclosed by drawing a line then peaks area were 
measured using Wand tool to define the integrity.   
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2.2.14  Enzyme linked immunosorbent assay (ELISA)  
A sandwich ELISA was used to measure neurotrophin 3 (NT3) level in NBA media 
following transection of CMV-shAMIGO3/nt3-gfp plasmid to DRGN cultures. All the 
reagents with kit provided from (R&D Systems, Abingdon, UK). Coated sterile 96-
well plats (Nunc, Loughborough, UK) with polyclonal antibody against NT-3 was 
sealed with Parafilm (Pechiney Plastic Packaging Company, Chicago, IL, USA) 
and incubated at 4°C overnight, then washed 3 times with wash buffer. 300µl of 
block reagent was added in each well and incubated for 1hr at RT, followed by 
washing step. 100µl of NT-3 standards and samples were added to each well 
followed by incubation period 2-4hrs on a shaker at RT. After this, around of wash 
was performed and 100µl of detection monoclonal antibody at a dilution of 1:4000 
was added to each well then incubated at 4°C overnight. The plate was washed 
then a 100µl of HRP-conjugated mouse IgG was added to each well at dilution of 
1:100 and the plate was placed on shaker for 2hrs at RT followed by three times 
washing. After this, each well received a 100µl of substrate solution and incubated 
on a shaker for 20mins at RT, and then 100µl of stop solution was added and 
mixed gently on a shaker. The absorbance of the plate was then measured within 
30mins in microplate reader set to 450 nm (Victor3, Perkin Elmer). The standard 
curve of NT-3 concentration vs absorbance was the plotted using Excel, the curve 
was used to determine the concentration of NT-3 in each sample.  
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2.2.15 Microarray analysis 
The rat genome AROS V3.0 set has 26962 long-mer probes containing 27044 
gene transcripts were purchased form Operon Biotechnology (Operon 
Biotechnology GmbH, Cologne, Germany). The microarray reaction was 
performed and prepared by the Functional Genomic Lab (University of 
Birmingham, UK). By using Pronto Universal slide spotting solution (Fisher 
Science, Loughborough, UK) oligonucleotides were resuspended and 
subsequently spotted onto UltraGAPS coated slides with Bar code (Fisher 
Science) using BioRobotic microgrid II spotter (Genomic Solution Ltd, Huntington, 
UK). The amount of 0.5-1 ug of the total extracted RNA form each animal (n=6) 
was amplified and then labelled with either Cy3 orCy5 dye (GE Healthcare, Little 
Chalfont, UK) following the protocol. By using the dye incorporation calculator 
(www.ambio.com/tools/dye) the frequency was calculated with frequencies of 30-
60 dye molecules per 1000 nucleotides. The probes were resuspended in 
hybridization buffer (Corning BV, Koolhovenlaan, UK) and microarray was 
performed using Pronto Kit following the manufacturer’s protocol. Slides were then 
scanned and images were analysed using GenePix software. The microarray was 
performed by Dr Martin Read using previous BBSRC funding obtained by Prof 
Ann Logan. 
Data from the microarray were analysed using GenSpring GX7 (Agilent) and 
normalised to intact controls (Sohaib Mir PhD Thesis, 2009). Excel spread sheets 
were then created with fold changes of gene expression listed from the highest to 
the lowest. These spread sheets were interrogated for regeneration-related genes 
in this project.  
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2.2.16 Statistical analysis 
All experiments were repeated on 3 independent occasions and no efforts were 
made to avoid bias. Statistical analyses were performed using IBM SPSS software 
(version 15). These analyses were applied to confirm whether the needed 
statistical significant differences observed between untreated controls and treated 
groups were real. The data from multiple treatment groups were analysed using 
one-way Analysis of Variance (ANOVA) combined with Games Howell post-hoc 
test, whereas t-test was applied to compare data from 2 experimental treatment 
groups. Data was then considered to be statically significant if the probability (p) 
was less than the specified significance levels (where *p ≤ 0.05, **p ≤ 0.001, ***p ≤ 
0.0001). 
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 CHAPTER 3: Suppression of AMIGO3 promotes 
dorsal column axon regeneration after spinal 
cord injury 
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Sections of this chapter are included in the following paper: 
Almutiri S., Berry M., Logan A., Ahmed .,Z (2017). Non-viral-mediated 
suppression of AMIGO3 promotes disinhibited NT3-mediated regeneration of 
spinal cord dorsal column axons. Submitted to ELife. 
 
3.1 Introduction  
3.1.1 Leucine-rich repeat (LRR) family of proteins 
 
The leucine-rich repeat (LRR) containing motif is found in a family of proteins 
classified as synaptic proteins that play a role in “axonal guidance, target 
selection, synapse formation and stabilization of connections” (de Wit et al., 2011, 
de Wit and Ghosh, 2014). There is also some evidence that LRR may be involved 
in neurodegenerative disorders (Seeger et al., 1993). Therefore LRR plays a role 
in neural development, function and disorders.  The LRR proteins are 20-30 amino 
acids in length and their concave/convex nature allows them to interact with a vast 
number of ligands making them a very efficient and versatile protein interaction 
motif. 
Because of the rather elaborate role of LRR, understanding the mechanisms that 
enable these molecules to perform these functions may help provide information 
about axonal regeneration in the CNS. Proteins with LRR domains are found to be 
suited for communication between cells and cell adhesion and their diverse 
cellular interactions and ligand-binding specificity has been cited in directing 
neural connectivity, which is a major aspect in formation of neural circuitry. The 
role played by Slits and Robo receptors in axonal guidance are not disputed (Luo 
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and Flanagan, 2007). Slits contain four LRR proteins and Robo proteins have a 
high binding affinity to the Slit proteins. These therefore form a Slit-Robo pair, 
which is responsible for axonal guidance and dendritic arborisation (Cho et al., 
2007). Trk receptors, another family of LRR proteins are also found to be involved 
in axonal guidance and targeting (de Wit and Ghosh, 2014, de Wit et al., 2011).  
Target selection is another role played by LRR proteins in neuronal development 
involving a global targeting role played by molecular gradients and a specific 
targeting role played by discrete molecular cues. Slit has been cited as a 
molecular cue involved in global targeting while Capricious (Caps) has been found 
to act as a discrete cue in studies carried out in drosophila olfactory and visual 
systems (Luo and Flanagan, 2007). Slit and Caps are both LRR proteins, yet 
again entrenching the role of LRR proteins in axonal target selection. 
 
3.1.2 leucine-rich repeat and immunoglobulin domain-containing Nogo 
receptor-interacting protein-1 (LINGO-1) 
LINGO-1 was identified based on its symmetry to the guidance molecule Slit. 
LINGO-1 is located in 15q24 chromosome and belongs to the LRR protein family, 
consisting of twelve LRRs and a type 1 transmembrane with one immunoglobulin 
(Ig) right after the transmembrane segment (Mi et al., 2004, Carim-Todd et al., 
2003). There are three human homologs of LINGO-1; LINGO-2, LINGO-3 and 
LINGO-4. LINGO-1 is predominantly expressed in the CNS including brain and 
spinal cord: no expression of LINGO-1 is detectable in non-neuronal tissues. Not 
much is known about LINGO-2, LINGO-3 and LINGO-4 expression, but studies 
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revealed that they expressed in far lower levels compared to LINGO-1 in the CNS 
(Haines and Rigby, 2008, Llorens et al., 2008). Human LINGO-1 consists of 614 
amino acids and is a co-receptor of the NgR1 receptor (Nogo-66 receptor). The 
extracellular LRR domain of LINGO-1 interacts with NgR1 LRR domain and 
activates the signalling pathway of NgR1 in the CNS (Zhou et al., 2012).  
The LRR domain of this protein is implicated in protein-protein interactions and in 
cell adhesion/signaling in specific areas of the brain. Most studies have revealed 
that the role of LINGO-1 is in axon growth inhibition, distribution of oligodendrocyte 
myelination and differentiation (Meabon et al., 2016, Mi et al., 2005, Zhang et al., 
2015). 
LINGO-1 is a signaling co-receptor with NgR1 and p75NTR or TROY/TAJ after 
spinal cord injury (Mi et al., 2004). However,  the low intrinsic capacity of the spinal 
cord to regenerate is combined with a non-permissive environment which contain 
myelin inhibitors Nogo-A (Voeltz et al., 2006), MAG (Schnaar, 2010), and OMgps 
(Gil et al., 2010). All of these inhibitory ligands bind to the NgR1/p75NTR/LINGO-1 
tripartite receptor complex (McKerracher and Winton, 2002) and activate axon 
growth cone collapse through the RhoGTPase pathway (Ahmed et al., 2013). 
Rho-A binding to its Rho domain leads to activation of Rho kinase (ROCK-1) 
which activates LIM-kinase-1 (LIMK-1) thus results in phosphorylation by 
inactivation of cofilin (Yang et al., 1998). Inactivation of cofilin leads to 
polymerization of actin filaments, which inhibit the growth of axons (Lingor et al., 
2007).  
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Although, LINGO-1 is implicated in axon degeneration after CNS injury, studies 
revealed that LINGO-1 also contributed in myelination and differentiation of 
oligodendrocytes. Since LINGO-1 is detected in neurons and oligodendrocytes, 
inhibition of LINGO-1 enhances the development of myelinated axons by 
promoting outgrowth of oligodendrocytes processes (differentiation) (Mi et al., 
2008, Mi et al., 2007). The full mechanism of how LINGO-1 promotes 
oligodendrocyte differentiation and myelination remains to be elucidated. 
However, a recent study showed that LINGO-1 blocked the β1-integrin signalling 
pathway which negatively regulated oligodendrocytes differentiation (Mi et al., 
2016). The integrin pathway is known to play an important role in oligodendrocytes 
differentiation and survival and β1-integrin is required for oligodendrocyte 
precursor cell (OPC) differentiation. LINGO-1 was found to interact and reduce β1-
integrin expression whereas anti-LINGO-1 antibodies induced β1-integrin levels 
and enhanced both differentiation and myelination of oligodendrocyte (Mi et al., 
2016). 
 
3.1.3 Amphoterin-induced gene and open reading frame (AMIGO) 
Amphoterin is a heparin binding protein known as high-mobility group box-1 
(HMGB1) proteins, first isolated in 1987 as a neurite outgrowth-promoting factor 
from perinatal rat brain (Rauvala and Pihlaskari, 1987, Merenmies et al., 1991, 
Kuja-Panula et al., 2003). Amphoterin-induced gene and open reading frame 
(AMIGO) was first identified by Juha et al, the author binds Amphoterin to RAGE 
(receptor for advance glycation end products) in E18 rat hippocampal neurons, 
then was able to identify AMIGO using order differential display (ODD) screening 
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technique. By cloning AMIGO, Juha et al were subsequently able to find two other 
proteins, AMIGO2 and AMIGO3, all transmembrane proteins containing six LRRs 
and a type 1 transmembrane domain with one immunoglobulin Ig domain right 
after the transmembrane segment and implicated in axonal growth (Figure  3.1) 
(Kuja-Panula et al., 2003, Chen et al., 2006, Kajander et al., 2011). AMIGOs refer 
to LRRs protein family and immunoglobulin (Ig) superfamily due to multi LRR and 
immunoglobulin (Ig) found in their domain structure. While AMIGO is said to 
promote axonal growth, AMIGO3 on the other hand has been found to inhibit 
axonal growth after CNS injury (Kuja-Panula et al., 2003, Ahmed et al., 2013). 
 
3.1.3.1 AMIGO1 
AMIGO1 is involved in cell adhesion that manage axon fasciculation and 
extension via promoting neurite outgrowth through its extracellular region by 
homophilic binding. The ectodomain part of AMIGO1 was also shown to enhance 
attachment and neurite outgrowth of hippocampal neurons in culture (Kuja-Panula 
et al., 2003). Moreover, in cultured DRGN AMIGO1 showed to co-expressed with 
other LRRIG protein TrkA where the binding or co-expression was nearly all in 
TrkA+ neurons including a subset of medium and large diameter TrkA- DRGN. The 
interaction or binding with TrkA may contribute to the development of sensory and 
motor neurons via modulating the functions of Trks and Ret receptor tyrosine 
kinases through distinct phases of axonal guidance, extension and target 
innervation (Mandai et al., 2009, Zhao, 2016). 
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Figure  3.1: Schematic represents AMIGOs containing six LRRs and type1 
transmembrane with one immunoglobulin (Ig) right after transmembrane 
segment. 
(Adapted from (Kuja-Panula et al., 2003). 
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However, recently AMIGO1 was found to co-localise with Kv2.1 potassium 
channel in hippocampal neurons indicating that AMIGO1 takes part in neuronal 
channel function. Both AMIGO1 and Kv2.1 was found to be co-expressed in axon 
initial segment and dendrites where they may modulated action potential 
frequency, where Kv2.1 known as susceptibility gene for schizophrenia spectrum 
disorders. Therefore, Kv2.1 and AMIGO1 may provide a new therapeutic drug for 
neuronal excitability (i.e. psychiatric disorders and epilepsy) (Peltola et al., 2011, 
Peltola et al., 2016) 
 
3.1.3.2 AMIGO2 
Three different research groups have independently identified AMIGO2, otherwise 
known as Alivin1 and DEGA (differentially expressed in gastric adenocarcinomas) 
(Kuja-Panula et al., 2003, Ono et al., 2003, Rabenau et al., 2004). As mentioned 
above Kuja-Panula et al (2003) used ODD screening on hippocampal neurons in 
the presence of Amphoterin where they were able to identify AMIGO1, AMIGO2 
and AMIGO3.  Ono et al (2003) was able to identified Alivin1 gene that played a 
role in depolarization-dependent survival of cerebellar granule neurons and then 
two other similar genes were also isolated namely Alivin2 and Alivin3. Rabenau et 
al (2004) found Alivin1 to be differentially expressed in about 45% of human 
gastric adenocarcinomas (termed DEGA from differentially expressed in gastric 
adenocarcinomas). DEGA and Alivin1 were found to be identical to AMIGO2 
(Laeremans et al., 2013). 
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During adulthood, AMIGO2 mRNA is expressed in neurons, astrocytes and 
oligodendrocytes whislt no expression of AMIGO2 was detectable in the spinal 
cord (Homma et al., 2009, Chen et al., 2012).  
 
3.1.3.3 AMIGO3 
 
Little is known about the function and implication of AMIGO3, which forms a 
complex  with NgR1-p75/TROY after spinal cord injury, and inhibiting axon 
regeneration (Ahmed et al., 2013). The levels of LINGO-1 expression in the spinal 
cord after a spinal cord injury do not increase until 14 days (Mi et al., 2004), this is 
because it is likely that during the critical stages after CNS injury other NgR1 co-
receptors that mediate the inhibition of axon growth are expressed and able to 
function. In the acute stage of spinal injury, LINGO-1 was reported to substitute by 
AMIGO3 in centrally axotomized DRGN and retinal ganglion cells (RGC). 
Immediate responses to inhibition of axon growth to CNS myelin are mediated by 
the NgR1-p75/TROY-AMIGO3 receptor complex. As much as LINGO-1 is an 
agreed upon as co-receptor in the NgR1-p75/TROY receptor complex which 
signals inhibition of the CNS axon growth, its patterns of expression after an injury 
in the spinal cord are not in line with its proposed function. This is because 
LINGO-1 levels do not increase in an appreciable rate in the DRGN until after 14 
days, therefore other molecules may contribute in signaling the axon growth 
inhibition in the acute stage of spinal injury (Ahmed et al., 2013). Disinhibition on 
its own is not enough to propel the outgrowth of the neurites in the presence of 
CNS myelin but addition of relevant neurotrophic factors is necessary to drive the 
growth (Berry et al., 1996). When combined, disinhibition and neurotrophic factors 
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propel regeneration of the CNS axon. Therefore, AMIGO3 is a receptor complex 
that in a big way signals the inhibition of ligands derived from CNS myelin.  
Suppression of the function of AMIGO3 rather than LINGO-1, when it is combined 
with NTF may be an effective acute therapeutic method in the promotion of CNS 
axon regeneration after injury. 
 
3.1.4 Hypothesis  
We hypothesise that AMIGO3 substitutes for LINGO-1 in acute phase of spinal 
cord injury by forming complex receptors with NgR1/p75-TROY, and that 
suppression of AMIGO3 together with driving regeneration by NTF will promote 
CNS axon regeneration.  
 
3.1.5 Aims 
• To confirm the levels of AMIGO3 increased in non-regenerating (DC) injury 
models. 
• To promotes DRGN neurite outgrowth by knocking down AMIGO3 in 
presence of CME and Fibroblast growth factor-2 (FGF-2).  
• To determine the optimal does of DNA plasmids in DRGN transfection by in 
vivo-jetPEI delivery vector. 
• Validate the efficiency of non-viral delivery of CMV-shAMIGO3-nt3 plasmids 
to promote DRGN neurite outgrowth in presence of CME. 
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• Validate the efficiency of non-viral CMV-nt3/gfp plasmids to overexpress 
NT3 levels in DRGN culture and in vivo. 
• Validate the efficiency of non-viral delivery of CMV-shAMIGO3/gfp to 
supress AMIGO3 levels in vivo. 
•  To assess which of DRGN diameters (small, medium and large) are GFP+ 
after injection with plasmids (mentioned below in methods section). 
• To promote dorsal column axon regeneration after DC lesion by in vivo-
jetPEI-shAMIGO3/nt3 plasmid delivery.  
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3.2 Materials and Methods 
Please refer to the main materials and methods chapter for standard and detailed 
protocols. 
3.2.1 Experimental design  
The experiment in this chapter comprised 6 groups each contain n = 6 rats/group, 
as follows: 
• Group 1 = intact control (IC) to detect baseline levels.  
• Group 2 = DC transected controls (DC) to detect injury-mediated changes.  
• Group 3 = DC+intra-DRG injection of in vivo-jetPEI-gfp (DC+PEI-gfp) to 
detect if transfection of gfp caused adverse effects and monitor DRGN 
transduction efficiencies. This experimental groups in which the DC was 
transected and DRG were injected with plasmid-containing in vivo-jetPEI 
complexes, comprised: DC+intra-DRG injection of in vivo-jetPEI-gfp  
• Group 4 DC+in vivo-jetPEI -nt3/gfp to monitor DRGN transduction and NT3 
over-expression 
•  Group 5 DC+in vivo-jetPEI-shAMIGO3/gfp (DC+PEI-shAMIGO3/gfp) to 
monitor AMIGO3 knockdown in DRGN and to establish if AMIGO3 
knockdown without concomitant stimulation with NT3 promotes DRGN axon 
regeneration. 
• Group 6 DC+intra-DRG injection of in vivo-jetPEI-shAMIGO3/nt3 (DC+PEI-
shAMIGO3/nt3) to determine if AMIGO3 knockdown and simultaneous 
stimulation with NT3 is required for DRGN axon regeneration). 
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3.2.2 Plasmids construction  
Several plasmids were created expressing control gfp, shgfp, shAMIGO3/gfp, 
nt3/gfp, shAMIGO3/nt3, in different combinations based on their experimental use. 
This is because we are currently restricted to the delivery/expression of two 
transgenes in target tissues. Plasmids were produced as described previously 
(Feng et al., 2009). To construct bicistronic plasmids (pH1-shAMIGO3-CMV-gfp 
(shAMIGO3/gfp) and pH1-shAMIGO3-CMV-nt3 (shAMIGO3/nt3): shAMIGO3 
encoding complementary DNA sequences were designed using the online Ambion 
software and shAMIGO3 oligonucleotides were cloned into pRNAT-H1.1/shuttle 
along with cDNA for either nt3 or gfp (Addgene, Cambridge, MA, USA). To create 
pCMV-nt3-gfp (nt3/gfp), the coding sequence of rat NT3 and the nerve growth 
factor signal sequence (Zhou et al., 2003) were cloned into pIRES-EGFP 
(Clonetech, Mountain View, CA, USA).  
 
3.2.3 Preparation of in vivo-jetPEI vector 
In vivo-jetPEI (Polyplus Transfection, New York, USA) was prepared according to 
the manufacturer’s instructions. For example, for intra-DRG injection, 2μg/μl of 
DNA plasmid was added to 4μl of 5% glucose solution and 0.24μl 100mM of in 
vivo-jetPEI was added to 4μl of 5% glucose in separate tubes then vortexed well. 
Tubes were mixed and incubated for 15mins at RT before injection (5µl total 
volume). 
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3.2.4 Optimal concentration of plasmid  
DRGN were transfected with 0.5, 1, 2, 3 and 4μg of plasmid DNA containing either 
a control shgfp (PEI-shgfp) or shAMIGO3/nt3 (PEI-shAMIGO3/nt3). Additional 
controls included untreated DRGN (Untreated), DRGN transfected with in vivo-
jetPEI only (Sham), and in vivo-jetPEI-shAMIGO3/gfp (PEI-shAMIGO3/gfp). 
DRGN were allowed to incubate for 3 days prior to harvesting of cells and 
extraction of total RNA for validation of shAMIGO3 knockdown using RT-PCR 
(refer to section 2.2.11 for more details).  
 
To monitor NT3 production and disinhibited DRGN neurite outgrowth after 
shAMIGO3 knockdown and NT3 stimulation in cultures, DRGN were transfected 
with the optimal dose of plasmid DNA (2 μg) and incubated for 3 days in the 
presence of 100 μg/ml CME (Ahmed et al., 2005), prior to harvesting culture 
supernatant to detect NT3 production by ELISA (see section 2.2.13) and neurite 
outgrowth by immunocytochemistry (more details in section 2.2.6.4). 
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3.3 Results 
3.3.1 AMIGO3 levels increased in non-regeneration models after 7 days 
post injury 
We used double immunohistochemistry for AMIGO3 and neurofilament-200 in 
DRGN sections in regenerating (SN and pSN+DC) and non-regenerating (DC) 
models after 7 days post injury to detect AMIGO3 levels. No changes of AMIGO3 
levels in intact DRGN were present, but higher levels of AMIGO3 were found in 
non-regenerating DRGN (DC injury alone) (Figure  3.2). By contrast, lower levels 
of AMIGO3 were seen in regenerating SN paradigm compared to those seen in 
non-regenerating DRGN. However, regenerating DRGN after preconditioning 
lesions (pSN+DC) showed absence of AMIGO3 levels (Figure  3.2), suggesting 
depressed AMIGO3 levels correlate with enhanced axon regeneration. 
 
3.3.2 Knockdown of AMIGO3 enhances disinhibited DRGN neurite 
outgrowth only in the presence of FGF-2 
In primary DRGN, AMIGO3 protein was localised in approximately 90% of βIII-
tubulin+ DRGN (Figure  3.3). In addition, transfected DRGN with Lipofectamine 
2000, siGFP, and siAMIGO3 did not show enhanced neurite outgrowth in the 
presence of CME. However, disinhibited DRGN neurite outgrowth from around 
45% of  DRGN were observed when transfected with shAMIGO3 only in the 
presence of FGF-2 compare to DRGN treated with FGF-2 alone, demonstrating 
that knockdown of AMIGO3 in presence of CME and driven by FGF-2 enhanced 
disinhibited DRGN neurite outgrowth. The results in (Figure  3.2, Figure  3.3 and 
Figure  3.4)  have been repeated from (Ahmed et al., 2013) to confirm that 
suppression of AMIGO3 is required to enhance CNS axon regeneration before 
establishing the in vivo study. 
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Figure  3.2: AMIGO3 levels in intact, non-regeneration and regeneration 
DRGN models at 7 days after injury.  
Double immunohistochemistry for AMIGO3 and neurofilament-200 in DRGN 
sections showed high level of AMIGO3 protein in non-regeneration (DC) compare 
to intact and regeneration (SN and pSN+DC). Scale bar = 500 µm. (n=3) 
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Figure  3.3: localisation of AMIGO3 in DRGN primary cultured for 3 days.  
(A) Double immunohistochemistry showed that AMIGO3 was co-localised in βIII-
tubulin+ DRGN (B) the proportion of AMIGO3 with βIII-tubulin co-localised DRGN 
was 88%. Estimate scale bar = 500µm. (n=3)  
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Figure  3.4: Knockdown of AMIGO3 promotes neurite outgrowth in presence 
of CME and stimulated by FGF-2.  
(A) Representative photomicrograph of βIII-tubulin+ DRGN neurite outgrowth in 
transfected with Lipofectamine-2000, siGFP, CME, FGF-2, siAMIGO3 and 
siAMIGO3+CME+FGF-2. (B) Quantification of the mean DRGN neurite length and 
(C) mean the number of surviving DRGN (D) mean the proportion of DRGN with 
neurites. . **P<0.001, Analysis of Variance, scale bar = 50µm. (n=3) 
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3.3.3 In vivo-JetPEI delivered plasmids into primary culture DRGN knocked 
down AMIGO3 mRNA and increased NT3 secretion in media 
 
Adult primary DRGN cultured used to test the efficacy of shAMIGO3 plasmid to 
supress mRNA levels of AMIGO3 following transfection with in vivo-jetPEI vector. 
In untreated, sham and non-specific shgfp 1µg control-treated DRGN, there were 
no change in mRNA for AMIGO3 suggesting that none of these treatments had 
any non-specific effects on AMIIGO3 mRNA (Figure 3.5). Treatment with 
increasing amounts of shAMIGO3 plasmid caused a dose-dependent decrease in 
AMIIGO3 mRNA to a maximum observed with 2µg of plasmid DNA, correlating 
with 80% knockdown compared to untreated, sham or shgpf controls (Figure 
3.5A). Increasing the amount of plasmid DNA above the optimal amount did not 
decrease AMIIGO3 mRNA level, suggesting that 2µg of plasmid DNA was optimal. 
 
On the other hand, overexpression of NT3 in untreated, non-specific PEI-shgfp 
1µg and PEI-shAMIGO3/gfp-treated DRGN cultured was observed, little or no NT3 
was detected by ELISA in culture supernatant. However, in culture media from 
DRGN treated with 2µg of PEI-shAMIGO3/nt3 plasmid DNA the production and 
release of significant amounts of NT3 were detected, where 164 ± 24 ng/ml of NT3 
was detected by ELISA. These results suggest that 2µg of plasmid DNA is optimal 
for AMIGO3 mRNA knockdown and NT3 production (Figure 3.5B). 
 
 
95 
 
                 
Figure  3.5: Knockdown of AMIGO3 and NT3 overexpression by in vivo 
jetPEI-delivered plasmid DNA. 
 (A) Increasing concentrations of plasmid DNA encoding shAMIGO3/nt3 efficiently 
suppress AMIGO3 mRNA in cultured DRGN. (B) Plasmids encoding nt3 induce 
the production of significant titre of NT3 in DRGN culture media. ***P<0.0001, 
Analysis of Variance. (n=3). 
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3.3.4 Knockdown of AMIGO3 and concomitant stimulation with NT3 
promotes disinhibited DRGN neurite outgrowth 
In PEI-shgfp- or PEI-shAMIGO3/gfp-treated DRGN cultures, little or no disinhibited 
DRGN neurite outgrowth was observed (Figure  3.6A-C). However, treatment of 
cultures with PEI-shAMIGO3/nt3 caused significant disinhibited DRGN neurite 
outgrowth in terms of both neurite length, increasing significantly to 448 ± 31µm 
compared to PEI-shAMIGO3/gfp, and the proportion of DRGN with neurites, 
increasing significantly to 82 ± 8% compared to PEI-shAMIGO3/gfp; (Figure 3.6A-
C). These results suggest that delivery of shAMIGO3/nt3 plasmids in primary 
DRGN culture by in vivo-jetPEI significantly enhances disinhibited DRGN neurite 
outgrowth.  
 
3.3.5 In vivo-jetPEI/plasmids targeted large diameter DRGN 
Sections of DRG from intact controls showed an absence of gfp+ localisation in 
DRGN (Figure 3.7A) whilst DRG injected with DC+PEI-gfp containing plasmids 
showed number gfp+ DRGN (Figure  3.8A). Animals treated with the DC+PEI-
nt3/gfp plasmid showed some gfp+ DRGN (Figure  3.9A) whilst DRGN treated with 
DC+PEI-shAMIGO3/gfp showed wide spread of gfp+ localisation in DRGN 
(Figure  3.10A). Intact control DRGN had no gfp+ DRGNFigure 3.7B, whilst DRG 
injected with DC+PEI-gfp plasmids, approximately ≤2% of gfp+ DRGN were 
classified as small, ≤3% as medium and ≤5% as large (Figure  3.8B). In DRG 
injected with DC+PEI-nt3/gfp plasmid, gfp+ DRGN were decreased. A small 
number of DRGN were transfected compared to medium (≤1%) and large 
diameter DRGN (≥3%) (Figure  3.9B). Interestingly the transection rate was 
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significantly increased following DC+PEI-shAMIGO3-nt3/gfp injected plasmids 
such that ≤ 4% were small gfp+ DRGN, ≤12% were medium and and ≤ 22% were 
large diameter DRGN (Figure  3.10B). The total gfp+ DRGN after DC+PEI-gfp 
plasmid injection was ≤4% compared to DC+PEI-nt3/gfp plasmid where ≤2% 
DRGN were transfected. Interestingly the total number of gfp+ DRGN in the 
DC+PEI-shAMIGO3/gfp group was significantly higher (≤12%) demonstrating the 
highest proportion of transfection compared to other groups. 
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Figure  3.6: Knockdown of AMIGO3 and overexpression of NT3 by in vivo 
jetPEI-delivered plasmid DNA disinhibited DRGN neurite outgrowth.  
(A) Representative images to show in presence of CME, plasmid DNA encoding 
gfp or shAMIGO3/gfp were unable to disinhibit DRGN neurite outgrowth, but 
plasmids encoding shAMIGO3 and NT3 promote disinhibited DRGN neurite 
outgrowth. (B) Quantification of the mean DRGN neurite length and (C) the 
proportion of DRGN with neurites showing that AMIGO3 suppression combined 
with nt3 overexpression promotes significant disinhibited DRGN neurite outgrowth. 
Scale bar = 50µm. (n=3). 
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Figure  3.7: GFP expression in DRGN section of intact control (IC) group.  
 (A(i), (ii), (iii)) DRGN section represent GFP+ DRGN and (B) the proportion of 
GFP+ and size distribution; small (0-29μm), medium (30-59μm) and large (> 
60μm) diameter DRGN (green bar); % total GFP+/GFP- small, medium and large 
DRGN (black bar). Scale bar in (i)=500μm, in (ii) and (iii)=50μm. (n=6). 
(i) 
(ii) (iii) 
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Figure  3.8: GFP expression in DRGN section of DC+PEI/gfp group.  
 (A(i), (ii), (iii)) DRGN section represent GFP+ DRGN and (B) the proportion of 
GFP+ and size distribution; small (0-29μm), medium (30-59μm) and large (> 
60μm) diameter DRGN (green bar); % total GFP+/GFP- small, medium and large 
DRGN (black bar). Scale bar in (i)=500μm, in (ii) and (iii)=50μm. (n=6). 
 
(iii) (ii) 
(i) 
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Figure  3.9: GFP expression in DRGN section of  DC+PEI-nt3-gfp group.  
 (A(i), (ii), (iii)) DRGN section represent GFP+ DRGN and (B) the proportion of 
GFP+ and size distribution; small (0-29μm), medium (30-59μm) and large (> 
60μm) diameter DRGN (green bar); % total GFP+/GFP- small, medium and large 
DRGN (black bar). Scale bar in (i)=500μm, in (ii) and (iii)=50μm. (n=6). 
(iii) (ii) 
(i) 
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 Figure  3.10: GFP expression in DRGN section of  DC+PEI-shAMIGO3/gfp 
group.  
 (A(i), (ii), (iii)) DRGN section represent GFP+ DRGN and (B) the proportion of 
GFP+ and size distribution; small (0-29μm), medium (30-59μm) and large (> 
60μm) diameter DRGN (green bar); % total GFP+/GFP- small, medium and large 
DRGN (black bar). Scale bar in (i)=500μm, in (ii) and (iii)=50μm. (n=6). 
(iii) (ii) 
(i) 
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3.3.6 In vivo-jetPEI/shAMIGO3 down regulated AMIGO3 in DRGN 
By using semi-quantitative RTPCR the levels of AMIGO3 mRNA increased 
significantly after injury and by 7.54 ± 0.33  and 7.42 ± 0.33-fold in both DCC and 
DC+PEI-gfp-treated DRG compared to those observed in intact controls 
(Figure  3.11A). However, AMIGO3 mRNA levels were suppressed by nearly 11-
fold in DRG treated with PEI-shAMIGO3/nt3 compared to DC+PEI-shgfp; 
(Figure  3.11A). Immunohistochemistry detected high levels of AMIGO3 in DCC 
and DC+PEI-gfp-treated DRG in all DRGN, however in the DC-PEI-gfp group 
(Figure  3.11B(iv)-(vi)) almost 30% of GFP+/AMIGO3+ DRGN were observed in 
DRG although the remaining AMIGO3+ DRGN were GFP-. In the DC+PEI-
shAMIGO3/gfp group, similar numbers of DRGN as in the DC+PEI-gfp group were 
GFP+ but little or no AMIGO3+ DRGN were observed (Figure  3.11B(i)-(iii) and 
(iv)-(vi)),. 
 
These results demonstrate that: (1), in vivo-jetPEI delivered plasmids encoding 
shAMIGO3 efficiently knocked down AMIGO3 protein in DRGN and that: (2), 
knockdown of AMIGO3 occurs in both transfected and un-transfected DRGN.  
. 
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 Figure  3.11: AMIGO3 levels are suppressed in DRGN after injection of in 
vivo-jetPEI transduced plasmids encoding shAMIGO3.  
(A) Low levels of AMIGO3 mRNA in intact controls increased significantly after 
DCC injury and remained unaffected in DC+PEI-gfp. AMIGO3 mRNA levels 
reduced significantly in both DC+PEI/shAMIGO3/gfp and DC+PEI-shAMIGO3/nt3 
groups. (B) Immunohistochemistry for AMIGO3 showed high levels of AMIGO3 in 
DRGN after DCC (B(i)), which were gfp- (B(ii)). AMIGO3 levels remained high in 
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DC+PEI-gfp groups (B(iv)), with gfp expression in some DRGN (B(v)). AMIGO3 
levels were suppressed in DRGN from DC+PEI-shAMIGO3/gfp groups (B(vii)), 
with gfp expression in some DRGN (B(viii)). B(iii), B(vi) and B(ix) are merged 
images from the red and green channels. Scale bar = 500μm. *** = P<0.0001, 
Analysis of Variance. (n=3). 
. 
3.3.7 NT3 levels in DRGN after in vivo-jetPEI-shAMIGO3/nt3 transfection 
The levels of NT3 mRNA remained low and unchanged in intact control, DCC and 
DC+PEI-gfp-treated DRG. However, in DRGN treated with DC+PEI-
shAMIGO3/nt3, nt3 mRNA levels increased significantly and by 33 ± 1.35-fold, 
compared to DC+PEI-gfp-treated DRGN (Figure  3.12A). Little or no NT3 
immunoreactivity was present in DRGN in DCC and DC+PEI-gfp groups 
(Figure  3.12B(i)-(iii) and (iv)-(vi), respectively). However, in the DC+PEI-nt3/gfp 
groups, high levels of NT3 immunoreactivity were observed in both GFP+ and 
GFP- DRGN (Figure  3.12B(vii)-(ix)).  
 
These results demonstrate that: (1), in vivo-jetPEI successfully transfected DRGN 
with plasmids encoding NT3 resulting in NT3 protein expression and that; (2), NT3 
immunoreactivity was present in both transfected and un-transfected DRGN 
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 Figure  3.12: NT3 levels are overexpressed in DRGN after injection of in vivo-
jetPEI transduced plasmids encoding shAMIGO3.  
(A) Low levels of NT3 mRNA were detected in DCC and DC+PEI-gfp groups, 
whilst significantly higher levels were detected in DC+PEI-nt3/gfp and DC+PEI-
shAMIGO3/nt3 groups. (B) Immunohistochemistry for NT3 showed low levels of 
NT3 in DRGN after DCC (B(i)), which were gfp- (B(ii)) and in DC+PEI-gfp groups 
(B(iv)), with gfp expression in some DRGN (B(v)). NT3 levels (B(vii)) were high in 
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both gfp+ and gfp- DRGN (B(viii)). Scale bar = 500μm. *** = P<0.0001, Analysis of 
Variance. (n=3). 
 
3.3.8 PEI-shAMIGO3/nt3 transfected DRGN regenerate axons in the DC 
After DC injury, a large cavity was present at the lesion site in the cords of 
DC+PEI-shAMIGO3/gfp groups, with little or no immunoreactivity for regenerating 
GAP43+ axons (Figure  3.13A). By contrast, in the injured cords of the DC+PEI-
shAMIGO3/nt3 groups, no cavities developed and many regenerating GAP43+ 
axons were seen in the caudal segment and some traversed the lesion site, 
growing for long distances into the rostral segment of the spinal cord 
(Figure  3.13B).  
 
Many axons could be seen traversing through the lesion site, following an arduous 
path and exiting the lesion site in the distal cord (Figure  3.13C); high power 
magnification). Quantification of the number of GAP43+ DC axons regenerating 
through the lesion site shows that 24.5 ± 4.2, 18.0 ± 2.1, 12.7 ± 3.3 and 9.3 ± 
3.1% of axons regenerated 0, 2, 4 and 6mm beyond the lesion site, respectively, 
in DC+PEI-shAMIGO3/nt3 whilst no axons were present in DC+PEI-
shAMIGO3/gfp (Figure  3.14). These results demonstrate that PEI-shAMIGO3/nt3 
plasmids promote significant DC axon regeneration after DC injury. 
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Figure  3.13: Suppression of AMIGO3 in DRGN promotes DC axon 
regeneration.   
(A) There were no GAP43+ regenerating axons in the DC of the 
PEI+shAMIGO3/gfp group with a large cavity present at the lesion site. (B), 
However, knockdown of AMIGO3 and co-incident up-regulation of NT3 in the 
DC+shAMIGO3/nt3 group promoted GAP43+ DRGN axon (arrowheads) 
regeneration through the DC lesion site (B and C (high power view of axons 
emanating from the lesion site)), with the absence of a cavity in the lesion site. 
Scale bar in A and B=500μm; in C = 50μm. (n=6) 
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Figure  3.14: Quantification of GAP43+ axon fibre counts. 
The quantification was done at various distance from the lesion site showed a 
significant proportion of axons present at 2, 4 and 6mm caudal to the lesion site. 
(n=6).
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3.4 Discussion 
 
Viral vectors are commonly used to transfect CNS cells with shRNA to inhibit 
target mRNA translation (Davidson and Breakefield, 2003, Raoul et al., 2006, 
Reynolds et al., 2004).  One drawback of viral vectors, such as adeno-associated 
virus (AAV), is limited multiple gene transfection engendered by a restricted insert 
capacity and shRNA delivery delays suppression of translation of targeted mRNA 
by 14-28d, retarding the therapeutic effect and reducing their translational 
potential (Miyagoe-Suzuki and Takeda, 2010, Mason et al., 2010, McCarty et al., 
2001). Another significant barrier to their use in vivo is that transgene expression 
requires 7-14 days to reach a maximum and hence are limited in acute conditions. 
 
Non-viral gene delivery vectors include cationic lipid agents and a more recently 
formulated non-lipid polymer, polyethylenimine (in vivo-jetPEI) which transfects 
cells both in vitro and in vivo (Wiseman et al., 2003, Boussif et al., 1995).  In vivo 
jetPEI has high transfection efficiency and results in up to 4X higher transfection 
rates than naked DNA (Wiseman et al., 2003).  Moreover, jetPEI is easy to 
prepare, stable, and safe, and jetPEI/shRNA transfection induces faster 
suppression of mRNA translation than viral vectors giving immediate therapeutic 
benefit (Lungwitz et al., 2005). In the CNS, Liao and Yau reported that Melanopsin 
expression is rapidly abolished in RGC after intravitreal injection of in vivo-jetPEI-
shMelanopsin (Liao and Yau, 2007). 
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 In this study, AMIGO3 levels were elevated in non-regenerating (DC) compare to 
intact and regenerating (SN and pSN+DC) injury models by 
immunohistochemistry, also AMIGO3 was localised in DRGN cultured and used 
siRNA specific to AMIGO3 in presence of CME and stimulated by FGF-2 to 
promotes neurite outgrowth, these findings were repeated from results published 
in  (Ahmed et al., 2013). 
  
In addition, the use of a non-viral vector to deliver several genes to DRGN was 
investigated and showed that large diameter DRGN were preferentially transduced 
and that an shRNA knocked down AMIGO3 levels and at the same time up-
regulated NT3 in DRGN, inducing DC axon regeneration. in vivo-jetPEI delivered 
shAMIGO3/nt3 plasmid DNA: (1), efficiently knocks down AMIGO3 while at the 
same time increases nt3 mRNA, both in vitro and in vivo; (2), transduces a 
significant proportion of large diameter DRGN; (3) ehances disnhibited DRGN 
neurite outgrowth and axon regeneration.. 
 
3.4.1 In vitro findings 
 
In this report, the efficiency of in vivo-jetPEI-delivered plasmids has been tested to 
suppress AMIGO3 and at the same time upregulate NT3 in DRGN cultures. It has 
been recognised by us and others that a combinatorial strategy will be required to 
promote optimal CNS axon regeneration due to the complexity of the injury. For 
example, we have shown that suppression of axon growth inhibitory molecules 
combined with neurotrophic factor stimulation promotes significant disinhibited 
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DRGN neurite outgrowth in the presence of CME (Ahmed et al., 2005, Ahmed et 
al., 2006, Ahmed et al., 2009, Ahmed et al., 2011b). Here that 2µg of plasmid DNA 
encoding shAMIGO3 was sufficient to significantly knock down AMIGO3, to similar 
levels that we observed with siAMIGO3 (Ahmed et al., 2013). The same amount of 
DNA was also able to promote overexpression of NT3 in DRGN such that DRGN 
produced significant titres of NT3 in culture.   
 
Similar to our previous observations with siAMIGO3, knockdown of AMIGO3 using 
an shAMIGO3 alone however, was insufficient in overcoming CME-mediated 
neurite inhibition, requiring simultaneous stimulation with NT3 to promote DRGN 
neurite outgrowth. Our results confirm that disinhibition alone in insufficient to 
promote DRGN neurite outgrowth in the presence of CME but that concomitant 
stimulation of growth is required.  
 
3.4.2 In vivo findings   
 
In vivo-jetPEI is increasingly being used as safer alternative to viral vectors that 
pose safety question, including induction of immune responses and virus-
associated pathogenicity (Nayak and Herzog, 2010, Mingozzi and High, 2013, 
Daya and Berns, 2008). In vivo-jetPEI is a cationic polymer and has a high 
cationic charge density potential allowing it to condense DNA to form stable 
complexes, promoting gene transfer into cells (Demeneix et al., 1998, Wightman 
et al., 2001). In vivo-jetPEI has been used to deliver a variety of genes including 
siRNA to tissues such as (Acosta et al., 2014, Bivas-Benita et al., 2013, Ellermeier 
et al., 2013, Wahlquist et al., 2014, Zuckermann et al., 2015). Additionally, in vivo-
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jetPEI is also being tested in human applications, including the treatment of cancer 
and for genetic vaccination treatments (Lisziewicz et al., 2001, Ziller et al., 2004). 
On the other hand, short hairpin RNA (shRNA) has been used in this study to 
supress AMIGO3 and it is know that foreign RNA induced endogenous immune 
response such as interferon and PKR. For example, lentiviral encoding shLINGO-
1 was used to enhance CNS axon regeneration but however the vector increase 
neurons death even at low transfection doses (Hutson et al., 2012, Hutson et al., 
2014). Here the endogenous immune response include interferon have not 
determined due to lack of time but however, it has been suggested that in vivo 
jetPEI vector does not induced inflammatory cytokines (Bonnet et al., 2008) 
 
Several studies have referred to the analysis of DRGN sizes as small, medium 
and large due to the high heterogeneity of DRGN in size distribution 
(Schmalbruch, 1987, Jacques et al., 2012b). The implication here is that our 
plasmids mainly targeted large diameter DRGN. Surprisingly, however, these 
results are entirely consistent with previously reported levels of viral vector-
mediated transfection rates and DRGN diameters, where used AAV8 to deliver gfp 
(Jacques et al., 2012b). It is possible that, as was concluded for AAV8-mediated 
transfection of large diameter DRGN that the large surface area exposed to the 
plasmid resulted in a higher chance of these DRGN being transfected (Jacques et 
al., 2012b). In addition, it is also well established that the majority of the DRGN 
that project their axons in the ascending tract of the DC are the large diameter 
DRGN and hence high transfection rate by our plasmids is actually beneficial, 
since our DC injury transects these particular axons, and any beneficial effects of 
axon regeneration may be derived from these DRGN. Another possible advantage 
of targeting of the large diameter DRGN is that growth of small diameter DRGN in 
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response to, for example NGF, has been linked to nociception and hence this may 
be avoided by this preferential targeting of our plasmids (Lewin et al., 1993, 
Eskander et al., 2015). Having said this, all DRGN may be affected by preferential 
transfection of large diameter DRGN through the local production of NT3 and 
paracrine effects on neighbouring DRGN.  
 
Not only did the in vivo-jetPEI-delivered shAMIGO3 suppress AMIGO3 levels by 
greater than 80% in DRGN, immunoreactivity for AMIGO3 were reduced in both 
gfp+ (both low and high gfp expressing DRGN) and gfp- DRGN. This suggests that 
the plasmid efficiently suppressed AMIGO3 levels in both transduced and non-
transduced DRGN. At present it is difficult to explain why non-transduced DRGN 
showed reduced AMIGO3 levels but to our knowledge this is the first report to 
show such an effect. It may suggest that suppression of AMIGO3 in DRGN has 
paracrine effects on neighbouring DRGN, representing an intriguing observation 
that suggest that not all DRGN in the DRG need to be targeted to promote 
therapeutically effective outcomes. Similarly, overexpression of NT3 was also 
apparent in both gfp+ and gfp- DRGN suggesting that both transfected and non-
transfected DRGN produced high titres of NT3. Our results therefore demonstrate 
that in vivo-jetPEI efficiently knocked down AMIGO3 and up-regulated NT-3 in 
DRGN. 
 
Knockdown of AMIGO3 and simultaneous stimulation with NT3 promoted 
significant DRGN axon regeneration after DC injury. This is the first demonstration 
that knockdown of AMIGO3 promotes DRGN axon regeneration in vivo and 
demonstrates that AMIGO3 is an additional molecule that might require targeting 
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to promote CNS axon regeneration. We previously showed that AMIGO3 could 
substitute for LINGO-1 in binding to p75NTR and NgR1 to induce RhoA activation in 
response to CME. Our current results are consistent with these findings. Axons 
regenerated for up to 6mm caudal to the lesion site but unfortunately behavioural 
analysis could not be performed since the T8 DCC model does not lead to 
measurable functional deficits, including mechanical and thermal hyperplasia 
(Kanagal and Muir, 2008, Surey et al., 2014). 
 
As it’s been observed previously in DRGN cultures grown in the presence of CNS 
myelin extracts, that knockdown of AMIGO3 promoted signifcant DRGN neurite 
outgrowth, our current study demonstrates in vivo proof-of-principal. Namely, that 
knockdown of AMIGO3 together with co-incident growth stimulation (here by NT-3) 
promotes signficant DC axon regeneration. In addition, spinal cord cavitation was 
reduced as a result of AMIGO3 knockdown and NT-3 overexpression and instead 
the lesion site was filled with invading cells. However we do not know why this 
happen but suggesting a further therapeutic use of
AMIGO3/NT-3 in spinal cord injury. 
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 CHAPTER 4: Inflammatory-induced responses 
after non-viral mediated suppression of AMIGO3 
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4.1 Introduction  
4.1.1 Inflammation  
Inflammation is one of the human body’s natural responses against injury, 
infection and is involved in pathogeneses of neurodegenerative disease, stroke 
and cancer among others.  Inflammation aims to initiate the healing response and 
restore the damaged tissues back to normal through removal of harmful stimuli. 
The acute phase inflammation requires rapid influx of blood granulocytes, typically 
neutrophils, followed promptly by monocytes that mature into inflammatory 
macrophages.  
The acute phase of inflammation results in signs such as heat, pain, swelling and 
redness, symptoms typically associated with inflammation and surrounding the 
injury /infection area (Ricciotti and FitzGerald, 2011, Surey, 2015). After removing 
the harmful stimuli by phagocytosis, the inflammation process starts to resolve 
which allows lymphocytes and macrophages to return to normal phenotypes and 
pre-inflammatory numbers.  
The rapid resolution of tissue damage results from a successful acute 
inflammation, but dysfunction and persistent inflammation leads to scarring and 
loss of organ function and therefore leads to chronic inflammation (Nathan, 2002). 
Long lasting chronic inflammation can cause not only autoimmune diseases e.g. 
rheumatoid arthritis but also could lead to cancer (Surey, 2015). 
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4.1.2 Inflammation markers 
The inflammatory mediators after SCI can be localised using inflammatory 
markers including CD68, GFAP, CD4 and CD8. Cluster of differentiation 68 
(CD68) also named ED-1 was identified originally as a marker for macrophages, 
which can be used to mark the recruitment and activation after infection/injury, 
especially after inflammation of neurodegenerative disease (Perego et al., 2011, 
Holness and Simmons, 1993). CD68 is also expressed in active endothelial cells 
and human fibroblasts (Kunz-Schughart et al., 2002, Beranek, 2005) and can be 
used as a marker of active phagocytosis after infection/injury (Perego et al., 2011).  
 
GFAP is expressed in different glial cell sub-types in the CNS including astrocytes 
and ependymal cells. GFAP is an intermediate filament protein and generally high 
levels of GFAP represent activation of glial cells and astrocytes in 
neurodegenerative disease (Roessmann et al., 1980, Jacque et al., 1978, 
Brahmachari et al., 2006). A study investigated neuropathic pain, observed that 
GFAP was expressed mainly by astrocytes in dorsal horn of the rat spinal cord 
following SC injury models (Silva et al., 2015).  GFAP also expressed DRGN 
satellite cells following injection of relevant doses of Paclitaxel (known to induce 
neuropathic pain) for ten days (Peters et al., 2007). 
Between 1-3 days after SCI, there are fewer macrophages/monocytes found 
where a significant number of CD68+ microglia are present in the injury site and 
these last in the cord from weeks to months. The accumulation of activated 
macrophages and microglia is thought to be implicated in the progression of 
secondary injury after SCI (Fleming et al., 2006, Blight, 1992, Blight et al., 1995). 
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Cluster of differentiation 4 and 8 (CD4 and CD8) are used as markers of T cells 
after injury. Both CD4 and CD8 are transmembrane glycoprotein where CD4 is 
known as a marker for T ‘helper’ cells that activate B cells, whereas CD8 are T 
‘cytotoxic’ cells and kill other target cells (Okoye and Wilson, 2011, Alberts et al., 
2002). T-cell infiltration in rats was elevated between 3-7 days after SCI but then 
dropped by 50% after 3 weeks (Surey, 2015). 
 
4.1.3 Hypothesis  
In vivo-jetPEI is increasingly being used in vitro/vivo studies and used as a safer 
alternative to viral vectors in terms of the non-specific immune responses that 
some viruses elicit. This leads to hypothesis that in vivo suppression of AMIGO3 in 
DRGN using in vivo-jetPEI vector seen in Chapter 3 will not induce an overt 
inflammatory response.   
 
 
 
4.1.4 Aims 
• To assess inflammatory responses in glia, macrophages and T cells in L4/5 
DRGN after intra-DRG injection with PEI-shAMIGO3-nt3/gfp seen in 
Chapter 3 using immunohistochemistry. 
• To compare the inflammatory response with intact animals and those 
injected with PBS using immunohistochemistry. 
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4.2 Results 
4.2.1 Characterisation of the inflammatory response after suppression of 
AMIGO3 
Macrophages (CD68): Intact animals showed infiltration of CD68+ macrophages in 
DRGN sections (Figure  4.1A) whereas animals receiving PBS through intra-DRG 
route, higher numbers of CD68+ macrophages could be seen compared to intact 
animals (Figure  4.3B). A slight increase in CD68+ immunoreactivity was observed 
in DRG sections of the animals injected with DC+PEI-gfp, DC+PEI-nt3/gfp and 
DC+PEI-shAMIGO3/gfp plasmids via intra-DRG injection route compared to 
animals receiving PBS (Figure  4.5A, Figure  4.7A and Figure  4.9A).  
  
Glial fibrillary acidic protein (GFAP): The immunoreactivity of GFAP+ glial cells was 
virtually absence in intact animals (Figure  4.1B) compared to animals that 
received PBS. In PBS injected animals GFAP+ was slightly increased 
(Figure  4.3B). Interestingly, GFAP+ immunoreactivity was confined in DRGN 
sections of those that received PBS with no apparent differences between PBS 
and animals injected with DC+PEI-gfp, DC+PEI-nt3/gfp and DC+PEI-
shAMIGO3/gfp plasmids (Figure  4.5B, Figure  4.7B and Figure  4.9B).  
 
Resident T-cells: CD8+ a marker for T ‘cytotoxic’ cells were absent in DRGN 
sections of intact animals (Figure  4.2A) whilst, no significant increase was 
observed in CD8 immunoreactivity in animals receiving PBS after 29 days 
(Figure  4.4A). Interestingly, CD8 immunoreactivity in DRGN sections of animals 
treated with DC+PEI-gfp, DC+PEI-nt3/gfp and DC+PEI-shAMIGO3/gfp plasmids 
121 
 
was identical to that of intact animals (Figure  4.6A, Figure  4.8A and 
Figure  4.10A). These results suggested that in vivo-jetPEI did not induce T cell 
immunoreactivity in DRGN after intra-DRG injection over the time-course of the 
experiment. 
Furthermore, CD4+ resident T ‘helper’ cells showed a similar pattern as that 
observed with CD8+ T ‘cytotoxic’ cells; no significant differences were observed in 
treated animals compared to intact (Figure  4.2B), PBS (Figure  4.4B) or in 
animals injected with DC+PEI-gfp, DC+PEI-nt3/gfp and DC+PEI-shAMIGO3/gfp 
plasmids (Figure  4.6B, Figure  4.8B and Figure  4.10B). 
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Figure  4.1. Localisation of CD68+ and GFAP+ inflammation responses in 
DRGN sections.  
(A) Immunohistochemistry of CD68 macrophages (RED) for intact animals. (B) 
immunoreactivity of GFAP glial cells (RED)  for intact animals. Scale bar in (i) 
=500μm and in (ii) =50μm. (n=6) 
A 
B 
(i) 
(ii) 
(i) 
(ii) 
(i) 
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Figure  4.2: Localisation of CD8+ and CD4+ inflammation responses in DRGN 
sections.  
(A) Immunohistochemistry of CD8 T cells ‘cytotoxic’ (RED)  for intact animals. (B) 
immunoreactivity of CD4 T cells ‘helper’ (RED)  for intact animals. Scale bar in 
(i)=500μm and in (ii)=50μm. (n=6) 
A 
B 
(ii) 
(ii) 
(i) 
(i) 
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Figure  4.3: Localisation of CD68+ and GFAP+ inflammation responses in 
DRGN sections for animals received PBS for 29 days.  
(A) Immunohistochemistry for CD68 macrophages (RED). (B) immunoreactivity of 
GFAP glial cells (RED). Scale bar in (i)=500μm and in (ii)=50μm. (n=6) 
A 
B 
(i) 
(ii) 
(i) 
(ii) 
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Figure  4.4: Localisation of CD8+ and CD4+ inflammation responses in DRGN 
sections for animals received PBS for 29 days.  
(A) Immunohistochemistry of CD8 T cells ‘cytotoxic’ (RED). (B) immunoreactivity 
of CD4 T cells ‘helper’ (RED). Scale bar in (i)=500μm and in (ii)=50μm. (n=6) 
A 
B 
(i) 
(ii) 
(ii) 
(i) 
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Figure  4.5: Localisation of CD68+ and GFAP+ inflammation responses in 
DRGN sections for animals injected with DC+PEI-gfp for 29 days.  
(A) Immunohistochemistry for CD68 macrophages. (B) immunoreactivity of GFAP 
glial cells. Scale bar in (i) =500μm and in (ii) =50μm. (n=6) 
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Figure  4.6 Localisation of CD8+ and CD4+ inflammation responses in DRGN 
sections for animals injected with DC+PEI-gfp for 29 days.  
(A) Immunohistochemistry of CD8 T cells ‘cytotoxic’ (RED). (B) immunoreactivity 
of CD4 T cells ‘helper’ (RED). Scale bar in (i)=500μm and in (ii)=50μm. (n=6) 
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(ii) 
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Figure  4.7 Localisation of CD68+ and GFAP+ inflammation responses in 
DRGN sections for animals injected with DC+PEI-nt3/gfp for 29 days.  
(A) Immunohistochemistry for CD68 macrophages (RED). (B) immunoreactivity of 
GFAP glial cells (RED). Scale bar in (i) =500μm and in (ii) =50μm. (n=6) 
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Figure  4.8: Localisation of CD8+ and CD4+ inflammation responses in DRGN 
sections for animals injected with DC+PEI-nt3/gfp for 29 days.  
(A) Immunohistochemistry of CD8 T cells ‘cytotoxic’ (RED). (B) immunoreactivity 
of CD4 T cells ‘helper’ (RED). Scale bar in (i)=500μm and in (ii)=50μm. (n=6) 
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Figure  4.9: Localisation of CD68+ and GFAP+ inflammation responses in 
DRGN sections for animals injected with DC+PEI-shAMIGO3/gfp for 29 days.  
(A) Immunohistochemistry for CD68 macrophages (RED). (B) immunoreactivity of 
GFAP glial cells (RED). Scale bar in (i) =500μm and in (ii) =50μm. (n=6) 
A 
B 
(i) 
(ii) 
(i) 
(ii) (ii) 
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Figure  4.10 Localisation of CD8+ and CD4+ inflammation responses in DRGN 
sections for animals injected with DC+PEI-shAMIGO3/gfp for 29 days.  
(A) Immunohistochemistry of CD8 T cells ‘cytotoxic’ (RED). (B) immunoreactivity 
of CD4 T cells ‘helper’ (RED). Scale bar in (i)=500μm and in (ii)=50μm. (n=6) 
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4.3 Discussion  
In this report, I investigated the differences in the inflammatory response including 
glial cells, macrophages and T-cells in groups of animals after intra-DRG injection 
of several treatments including PBS, PEI-gfp, PEI-nt3/gfp  and  PEI-shAMIGO3-
nt3/gfp which performed in chapter 3. Red colour staining was used to avoid gfp 
(green) expression which encode with the plasmids that been injected previously. 
Non-viral vector was used (in vivo-jetPEI) in this study to minimize immune 
responses after injection of plasmids, since in vivo-jetPEI is increasingly being 
used as safer alternative to viral vectors that pose safety questions, including 
induction of immune responses and virus-associated pathogenicity (Nayak and 
Herzog, 2010, Mingozzi and High, 2013, Daya and Berns, 2008). Moreover, PEI is 
safe and does not induce off-target immune-mediated cytokines such as TNF-α, 
IFN-γ, IL-6, IL-12/IL-23, IL-1β, and IFN-β (Bonnet et al., 2008). Therefore, the lack 
of immunogenic responses after PEI injection is to be expected and represents a 
further advantage over viral vectors. On the other hand, other delivery methods 
such as viral vectors such as (AAV) induce non-specific inflammatory responses. 
For example, AAV particles access the lymph nodes draining the DRG or the CSF, 
and lead to both local and systemic inflammatory responses (Kuhlmann et al., 
2001, Weller et al., 2010).  
  
In this study, I used anti-CD68 (ED1) antibody to detect macrophages in DRGN 
sections which is known to detect up to 98% of rat macrophages (Dijkstra et al., 
1985). DRGN contain occasional CD68+ macrophages (Hu and McLachlan, 2003, 
Hu et al., 2007a, Kim and Moalem-Taylor, 2011), which was evident in our studies 
(Figure  4.1A). Macrophages are found in many tissues but the function of those 
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seen in intact DRG is to act as part of the initial, innate immune response to 
immediate infection or tissue damage. Furthermore, resident macrophages in 
DRG are implicated in phagocytosis of neuronal debris within the DRG (Hu and 
McLachlan, 2003).  
Animals that received PBS showed slightly higher CD68+ macrophages than that 
observed in intact animals, this increase of CD68+ macrophages may due to direct 
trauma following intra-DRG injection with PBS. Since normally the insertion of 
glass micropipette directly to the DRG ganglia parenchyma, it is likely to result in 
some tissue disruption and hence may lead to CD68+ macrophage activation. 
Interestingly, a slight increase of CD68+ immunoreactivity could also be observed 
in DRG sections of animals injected with DC+PEI-gfp, DC+PEI-nt3/gfp and 
DC+PEI-shAMIGO3/gfp plasmids compared to animals which received PBS, 
probably as consequences of the use of in vivo-jetPEI vector. This suggests that in 
vivo-jetPEI may cause minimal activation of immune responses but these remains 
to be confirmed in further studies. 
 
 GFAP+ immunoreactivity in glial cells was virtually absence in intact compared to 
animals receiving PBS, where GFAP+ immunoreactivity was slightly increased. In 
addition, no apparent differences between PBS and animals injected with 
DC+PEI-gfp, DC+PEI-nt3/gfp and DC+PEI-shAMIGO3/gfp plasmids were 
observed, suggesting that the slight activation of glia could be due to the trauma to 
the DRG by the injection and not from the in vivo-jetPEI containing DNA.  
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Both cytotoxic and helper T cells were absent in DRGN injected with PBS and 
animals treated with DC+PEI-gfp, DC+PEI-nt3/gfp and DC+PEI-shAMIGO3/gfp 
plasmids. This was possibly due to the fact that samples were harvested at 29 
days after SCI, whilst in a separate study by Surey et al. (2014) (Surey, 2014), T-
cell infiltration after the same rat SCI was elevated between 3-7 days after injury 
and then dropped by 50% after 3 weeks (Surey, 2015).  
In conclusion, the results of this chapter suggest that in vivo-jetPEI is safe to use 
as it invokes only little or no inflammatory responses after delivery of plasmid 
DNA. This is in contrast to viral vectors that may invoke a strong non-specific 
immune response.  
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 CHAPTER 5: Overexpression of RTN3 enhances 
dorsal column axon regeneration after spinal cord 
injury 
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5.1 Introduction 
5.1.1 A basic background of Reticulons (RTNs) 
Reticulons (RTNs) are membrane-bound proteins of which four genes have been 
identified in mammals and termed RTN1, 2, 3 and 4/Nogo, they are called 
endoplasmic reticulum (ER) proteins because of their subcellular localisation 
where they exhibit a reticular distribution (Oertle and Schwab, 2003, Yang and 
Strittmatter, 2007, Senden et al., 1994). In addition, RTNs are also called 
neuroendocrine-specific proteins (NSP) when they were first discovered and found 
enriched in neuronal and neuroendocrine tissues (Roebroek et al., 1993, Hens et 
al., 1998). Moreover, RTNs are characterized by highly conserved reticulon 
homology domains (RHD), about 150-200 amino acid that are located in RTNs C-
terminal which are involved in improvement of localization and function of these 
proteins.  
RTNs are found in a variety of tissues for example, in brain, kidney, spleen and 
liver. Also, they play different roles such as (1) ER shaping and morphology, (2) 
membrane trafficking; for example, they were described to interact with Golgi and 
plasma membrane suggesting that they are involved in this site (3) apoptosis; as a 
number of evidences that overexpression of RTNs involved in ER-stress induced 
cell death by Ca2+ depletion from endoplasmic reticulum stores.   
Moreover, RTNs are found to be involved in many neurodegenerative diseases 
such as Alzheimer’s, amyotrophic lateral sclerosis and multiple sclerosis 
(Chiurchiu et al., 2014). However, RTN1, 2 and 4 have three splice isoforms A, B 
and C whilst RTN3 only has two spliced isoforms RTN3A and B Figure  5.1. The 
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human RTN1 is expressed in neurons and neuroendocrine tissues as well as in 
neuroblastoma cell lines where type C is the most studied and is considered being 
a neuronal differentiation marker (Roebroek et al., 1993, Hens et al., 1998, 
Chiurchiu et al., 2014). 
RTN2 is found to be enriched in muscles and brain respectively, Liu et al indicates 
that RTN2B interact with excitatory amino acid transporter (EAAT1) which is 
important in learning and memory, where RTN2B has a positive regulation and 
enhances EAAT1 delivery from ER to cell surface (Liu et al., 2008). The fourth 
member of the family is known as Nogo and has been widely investigated in 
recent years because of it is involvement in CNS growth cone collapse after injury.  
RTN4/Nogo is expressed in oligodendrocytes and interacts with NgR1 receptor in 
neuronal membranes after spinal cord injury and inhibits axon regeneration and 
neurite outgrowth (Schwab, 2010, O'Neill et al., 2004).  
In the pages below, I will focus on the third member of the RTN family as it is our 
gene of interest amongst others. However, due to lack of resources about our 
novel findings that up-regulation of RTN3 promotes axon regeneration after SCI, 
here we will indicate the other role of RTN3 to give a brief background about this 
gene. The background will indicate the most important findings about the role of 
RTN3 in neuronal tissues. 
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Figure  5.1: Schematic representation of mammalian reticulon family. 
 Topology and classification of splice isoforms of RTNs; the top scale bar is amino 
acid describe the length of each RTN. Light blue and black boxes represent 
reticulon homology proteins (RDH) that interact with C-terminal of RTNs (Adapted 
from (Chiurchiu et al., 2014)). 
 
 
 
139 
 
5.1.2 Reticulon 3 may play role in developing axons during embryo 
 RTN3 is expressed in many types of tissues but first isolated was from human 
retina and later shown to have the highest expression in the brain (Cai et al., 
2005). The human RTN3 gene is localized in 11q13 and mutations of this gene 
cause dysfunction of the retina and is therefore speculated that this gene may play 
a role in retinal function (Kumamaru et al., 2004). Expression of RTN3 in the 
olfactory and optic nerve during development and adult stages was found to be 
important in axonal development. Kumamaru et al, (2004) showed that RTN3 is 
expressed highly in Muller cells in the rat retina and is also highly expressed in the 
optic nerve in embryo but less so in the adult. However, in the olfactory system 
RTN3 is found to be highly expressed in both embryo and adult stages and may 
therefore permit regeneration of these neurons since olfactory neurons are 
replaced regularly. Furthermore, RTN3 is also localised in cultured cortical 
neurons and concentrated in axon growth cones in the early days after culture 
(Kumamaru et al., 2004). RTN3 was also co-localized with synaptophysin in the 
developing axons of cultured cortical neurons (Figure  5.2). However, all these 
finding suggest that RTN3 may have some function in glial cells and formation of 
synapses as it is co-localized with synaptophysin. Moreover, RTN3 may play 
important role in the developing axon by the transportation of proteins and lipids 
through the synapses (Kumamaru et al., 2004). 
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 Figure  5.2: Distribution of RTN3 in cortical neurons culture and synapses.  
(A) RTN3 immunostaining distribution where detected in the all over the cortical 
neurons. (B) RTN3, (C) synaptophysin expression in axon using confocal 
microscopy. (D) Merged image shows colocalization of RTN3 and synaptophysin. 
(adapted from (Kumamaru et al., 2004)).  
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5.1.3 Overexpression of RTN3 causes neurite dystrophy in 
neurodegenerative diseases 
Neurite dystrophy refers to swollen dendrites or swollen axons found mainly in 
patient brains suffering from neurodegenerative diseases (NDD) such as 
Alzheimer’s, Parkinson’s and Lewy body diseases. For example, in patients with 
Alzheimer’s disease (AD), neurites dystrophy is often found in the areas around 
neuritic amyloid plaques (Irizarry et al., 1998, Hu et al., 2007b). RTN3 
immunoreactive dystrophic neurites (RIDNs) are present and extensively 
accumulate in neurite dystrophy of AD’s brains and amyloid precursor protein of 
transgenic mice expressing RTN3 (Tg-RTN3). The formation of RIDNs is also 
accompanied by expression of high molecular weight of RTN3 in NDD patients 
(Hu et al., 2007b, Shi et al., 2009a). The levels RTN3 in transgenic mice Tg-RTN3 
appear to govern the formation RIDNs, where the more expression of RTN3 the 
more RIDNs will form initially in cortical regions and hippocampal CA1 region, a 
critical area of memory and learning (Shi et al., 2009a).  
Interestingly, the levels of RIDNs were not detectable in mice younger than 6 
months, whereas a few intermittent RIDNs were detectable in mice at age of 1 
year. Moreover, RIDNs are abundantly present in mouse brains at aged 2 years. 
However, the amount of RIDNs found in Tg-RTN3 mice at early age of 3 months 
resembles that in 2 years old non-transgenic mice, these finding suggested that 
aggregation of RTN3 is involved in dystrophic neuritis and results in Alzheimer’s 
disease pathogenesis (Shi et al., 2009a). 
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5.1.4 RTN3 expression is reduced during axonal transport of BACE1 thus 
causing reduction of amyloid deposits 
The pathological features of Alzheimer’s disease are complex: one of the 
pathological hallmarks is the presence of neuritic amyloid plaques surrounded by 
dystrophic neurites, reactive astrocytes and activated microglia (Deng et al., 
2013). The aggregation of β-amyloid peptides (Aβ) in the brain mostly results in 
accumulation of amyloid deposits and that are excised from amyloid precursor 
protein (APP). However, β-amyloid cleaving enzyme 1 (BACE1) is initiated as 
cleavage of APP at β-secretase site occurs, and this enhances the generation of 
Aβ (Deng et al., 2013, Shi et al., 2014). Increasing BACE1 activity was found to 
generate amyloid deposition and Aβ accumulation in Alzheimer’s disease patients, 
thus reduced BACE1 activity and prevented pathological damage. 
BACE1 not only resides in neuronal soma but is also found in synapses where 
BACE1 was shown in presynaptic terminals (Kandalepas et al., 2013). Formation 
of amyloid deposits is correlated with the release of Aβ from synaptic terminals 
and thus, BACE1, APP and Aβ release from neuronal presynaptic terminals need 
to be transport through the axons to allow the cleavage to occur at synaptic site. 
However, APP has been shown to be axonally transported (Koo et al., 1990, Lee 
et al., 2005a, Wang et al., 2012b). 
RTN3 is among the RTNs that were expressed richly in neurons and present 
enriched in axons and dendrites (Deng et al., 2013). However, RTN3 negatively 
regulates BACE1 activity thus, overexpression of RTN3 reduces the transport of 
BACE1 through the axons as well as increasing the retention of BACE1 in the ER 
(Shi et al., 2009b). The retention of BACE1 in the ER could decrease the levels of 
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BACE1 exiting from late Golgi, preventing axonal transport (Deng et al., 2013). 
However, increased expression of RTN3 impacts the transportation of BACE1 
through the axons and demonstrated reduction of amyloid deposits and reduced 
pathological damage in Alzheimer’s disease patients. 
 
5.1.5 Hypothesis 
In the microarray data that has been collected from rat DRGN in regenerating and 
non-regenerating injury models, RTN3 found significantly increased in 
regenerating injury paradigms compared to intact and non-regenerating models. 
Therefore I hypothesised that up-regulation of RTN3 promotes axon regeneration 
after SCI.  
 
5.1.6 Aims 
• To validate our microarray data by RT-PCR and localization of RTN3 in 
DRG sections using immunohistochemistry. 
• Determine the levels of RTN3 protein in DRG lysates in regenerating and 
non-regenerating injury models by western blot. 
•  Knock down/up-regulate RTN3 in primary DRGN cultures using siRNA to 
test its effects on disinhibited DRGN neurite outgrowth. 
• Supress or overexpress the gene in vivo depending on how it regulates 
disinhibited DRGN neurite outgrowth and determine its effects on DC axon 
regeneration. 
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5.2 Materials and methods  
Please refer to the main methods and materials chapter for standard and detailed 
protocols. 
5.2.1 Experimental design 
Preconditioned sciatic nerve injury was performed to 2 group of animals (n = 3) 7 
days prior to DC crush, followed the DC crush. First group of animal received a 
PEI/CMV-GFP plasmid and used as a control, whereas the second group injected 
with CMV-RTN3/gfp plasmid include in vivo-jetPEI vector via intra-DRG rout 
(Figure  5.3). Animals were allowed to survive for 21 days and killed by overdose 
of CO2 and intracardially perfused, and L5 DRG ganglia and DC lesion site were 
collected for further analysis. 
 
5.2.2 Preparation of plasmid and in vivo-jetPEI vector 
Since the used of in vivo-jetPEI as a delivery vector displayed efficient transfection 
rates and reduced immune response seen in DRGN following injection (see 
chapter 3 and 4), therefore I used the same non-viral delivery vector here to 
overexpress RTN3 after DC injury. 0.24µl of in vivo-jetPEI was mixed with 5% 
glucose solution and then added to 2µg/µl of CMV-RTN3/gfp plasmid ( 
Figure  5.3) (as explained in section 3.2.2). Due to lack of time, optimal 
concentration of plasmid was not preformed; however I used the concentration as 
shown in (chapter 3). Finally, 2µl of the complex was loaded into glass 
micropipettes and injected directly into L5 DRG ganglia using intra-DRG route 
immediately after the DC crush at T8.   
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A                                                               B 
   
 
 
Figure  5.3: plasmids map used in this study. (A) is CMV-RTN3/gfp to 
enhance the expression of RTN3, and (B) is CMV-GFP used as a control. 
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5.3 Results 
5.3.1 mRNA levels of RTN3 were increased in regeneration injury model. 
By microarray, there was no change in RTN3 mRNA levels after DC injury 
compared to intact controls. However, in regenerating SN and pSN+DC models, 
RTN3 mRNA levels were significantly elevated by 4.11 ± 0.03 and 6.22 ± 0.04-fold 
(P<0.0001), respectively, compared to intact controls (Table  5.1). 
These results suggested that elevated levels of RTN3 are required to promote 
DRGN axon regeneration. 
 
 
 
 
------------------------------------------------------------------------------------------------------------- 
Gene                      Description                 DC                 SN                 pSN+DC 
------------------------------------------------------------------------------------------------------------- 
RTN3                     Reticulon3             1.01±0.01       4.11±0.03          6.22±0.04        
------------------------------------------------------------------------------------------------------------- 
Mean ± SEM values were shown from four different samples. 
Table  5.1: Microarray data analysis of fold-change in mRNA levels of RTN3.  
The fold-differences compared to control intact DRGNs 7 days in DC, SN and 
pSN+DC crush models. (n=6) 
 
147 
 
5.3.2 Immunohistochemistry and western blot of RNT3 levels correlated 
with mRNA levels 
RTN3 immunostaining was absent in intact control DRG sections whereas in DRG 
sections taken after 7 days following DC injury, RTN3 was barley detected and 
slight immunoreactivity could be seen in the nucleus of DRGN (Figure  5.4).  
However, in regeneration SN injury higher levels of RTN3 immunoreactivity were 
localised in DRG nucleus, whereas in pSN+DC, RTN3 was widely observed in the 
nucleus and the cytoplasm of DRGN (Figure  5.4). Moreover, RT-PCR was used 
for further confirmation and results displayed mRNA of RTN3 was elevated in 
regeneration injury models (SN and pSN+DC) (Figure 5.6). 
Western blot was also used to determine RTN3 levels from extracted total protein 
from DRG in regenerating and non-regenerating model. Our results showed low 
expression of RTN3 protein levels in intact and DC treated DRGNs (Figure 5.6A). 
Interestingly, RTN3 protein levels were significantly increased in regenerating SN 
and pSN+DC treated DRG (Figure 5.6A) suggesting that up regulation of RTN3 
plays role in axon regeneration. Densitometry of detected bands confirmed that 
RTN3 levels were 50% higher in regenerating SN and pSN+DC models compared 
to DC or intact controls (Figure 5.6B). 
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Figure  5.4: immunohistochemistry to show level of RTN3 in intact and 
injured rat DRG section.  
RTN3 protein levels were absent in intact DRG and barley detected in non-
regenerating DC models. RTN3 was localised in the nucleus in regeneration SN 
models, and present in the nucleus and cytoplasm in pSN+DC. All sections were 
double stained with Neurofilament 200. Scale bar = 500µm. (n=3) 
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Figure  5.5: Protein levels of RTN3 at 7 days in intact, non- regeneration and 
regeneration models.  
(A) western blot of protein lysates of DRG in different injury models showing RTN3 
protein increased in regenerating models compared to intact or DC injury models. 
(B) densitometry was used to quantify the levels of RTN3 protein. (n=3) 
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Figure  5.6: mRNA levels of RTN3 after 7days of intact, non- regeneration and 
regeneration injury models.  
(A) RT-PCR for cDNA reversed from mRNA that extracted from DRG bundle 
showed RTN3 remained low in intact and DC model compared to SN and 
pSN+DC models where high expression of RTN3 was observed. (B) Densitometry 
was used to quantify the mRNA level of RTN3. (n=3) 
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5.3.3 Knockdown of RTN3 using siRNA supresses neurite outgrowth 
According to the previous finding that RTN3 found unregulated in regeneration 
models, here i tested whether the gene is involved in axon regeneration. Firstly I 
used dissociated adult rat DRGN to investigate the consequence of RTN3 
knockdown on disinhibited DRGN neurite outgrowth. Our prediction was that 
knockdown of RTN3 will reduce DRGN neurite outgrowth as upregulation of the 
gene correlates with axon regeneration. DRGN were treated with Lipofectamine 
alone, siEGFP (non-specific transfection control), FGF2, FGF2+siRTN3 and 
siRTN3. DRGN were grown for 3 days and then knockdown of RTN3 was 
analysed by western blot.  We found that in (Figure 5.7, Figure 5.9) there were no 
changes in RTN3 protein level in Lipofectamine/untreated, siEGFP treated control 
DRGN. However, DRGN treated with siRTN3 caused a reduction of RTN3 levels 
by >70% to barely detectable levels. Knockdown of RTN3 correlated with 
significant reduction in DRGN neurite outgrowth (Figure 5.7, Figure 5.9).  
In addition, immunocytochemistry showed 92% reduction in the number of RTN3+ 
DRGN after siRTN3 treatment in DRGN, demonstrating successful RTN3 
knockdown (Figure 5.9).  After siRTN3 treatment, DRGN neurites were 
significantly reduced after RTN3 knockdown in terms of the mean neurite length to 
24.96 ± 2.1µm after siRTN3 treatment (Figure  5.) whilst the number of DRGN with 
neurites reduced to 37 ± 4 (Figure  5.). DRGN survival however, was unaffected in 
all treatment conditions (Figure  5.) showing that knockdown of RTN3 gene has no 
negative impacts in DRGN survival. These results suggested that RTN3 regulates 
neurite outgrowth and reduction of RTN3 supresses the growth of DRGN neurites 
and thus, RTN3 plays a role in neurite outgrowth. 
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Figure  5.7: Protein level of RTN3 in DRGNs primary cultured treated with 
siRTN3 for 3 days.  
(A) Western blot for RTN3 in untreated, siGFP, siRTN3 and FGF2+siRTN3 treated 
DRGNs for 3 days showed knockdown of RTN3. (B) Densitometry used to 
quantify the suppression of RTN3 after mediated by siRNA.  (n=3) 
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Figure  5.8: Immunocytochemistry for RTN3 in primary DRGN.  
(A) Representative immunolocalization for RTN3 in untreated DRGN showing he 
percentage of RTN3 protein in ß-III tubulin+ DRGN. (B) DRGN transfected with 
siRTN3 showed reduced RTN3 protein level by 92%. Scale bar = 100µm. (n=3) 
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Figure  5.9: siRNA mediated RTN3 in rat primery DRGNs cultured.  
Representitive  photomicrographs of βlll-tubulin of DRGNs neutite outgrowth in 8 
wells chamber slide transfected with siRNA and untransfected DRGNs. 
Photomicrographs showed inhibition of neurite outgrowth corrolated with 
supression of RTN3 even with growth factor. Scale bar = 100µm. (n=3) 
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Figure  5.10: DRGN survival and neurite outgrowth after knockdown of RTN3.  
(A) Mean neurite length, (B) mean number of survival DRGN and (C) mean 
number of DGRN with neurites. ± SEM means values shown from three different 
animals. ***P<0.001, Analysis of Variance. (n=3) 
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5.3.4 RTN3 may interact with CRELD1 after DC injury models 
Since immunocytochemistry of RTN3 was localised in DRGN nucleus after SN 
injury and in pSN+DC, I speculated that there is an unknown gene that is up-
regulated after DC injury and interacts/recruits RTN3 in DRGN membranes thus 
allowing the DRGN to produce RTN3 protein widely as seen in (Figure  5.4). 
After further research I found cell adhesion molecules named cysteine rich with 
EGF like domains 1 (CRELD1) to interact with RTN3 and which reduced HeLa cell 
apoptosis (Xiang and Zhao, 2009). CRELD1 changed RTN3 localization from 
nucleus to cell membrane possibly via ER, where I speculated that this 
observation correlated with our predictions since RTN3 resides in ER after SN 
injury then is localized in DRGN membranes after DC injury models (Figure  5.4). I 
speculate that CRELD1 is co-expressed with RTN3 protein in non-regeneration 
DC injury models, however immunohistochemistry for CRELD1 showed that 
CRELD1 was present DRGN in all injury models including intact controls 
(Figure  5.7). Western blot and RT-PCR confirmed that CRELD1 is expressed in 
DRGN in both intact and injured DRGN (Figure  5.8). 
These primary findings suggested that CRELD1 may interact with RTN3 after DC 
injury, therefore further investigation and experimental work are required to 
confirm whether CRELD1 has a role in modulating and distributing RTN3 in DRGN 
as shown in pSN+DC. 
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Figure  5.7: immunohistochemistry showed level of CRELD1 in intact and 
injured rat DRG sections.  
CRELD1 protein level was expressed in all DRG sections includes intact, non-
regeneration and regeneration models. All sections were double stained with 
Neurofilament 200. Scale bar = 500µm. (n=3) 
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Figure  5.8: protein and mRNA levels form DRGN ganglia for CRELD1.  
(A) Western blot and (B) RT-PCR showed CRELD1 protein and mRNA levels in 
intact, non-regeneration and regeneration models. Densitometry was used to 
quantify CRELD1 protein and mRNA. (n=3) 
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5.3.5 In vivo delivery of RTN by in vivo-jetPEI-RTN3/gfp promotes dorsal 
column axon regeneration 
Since raised RTN3 levels correlate with DRGN axon regeneration and 
suppression of RTN3 reduced DRGN neurite outgrowth, I speculated that 
overexpression of RTN3 might promote DC axon regeneration in vivo. Here I 
tested whether overexpression of RTN3 promotes DC axon regeneration by 
delivery of a plasmid containing RTN3/gfp using in vivo-jetPEI to the injured 
DRGN. Regeneration was simultaneously stimulated with preconditioning SN 
lesions. 
Seven days after preconditioning lesions, animals received DC injury followed by 
immediate injection of PEI-RTN3/gfp plasmid to the left L5 DRG bundle and 
animals were allowed to survive for 3 weeks.  Double immunohistochemistry for 
RTN3 and GFP showed that in control pSN+DC treated rats which were injected 
with a control gfp containing plasmid, GFP expression was present in most DRGN 
but RTN3 immunoreactivity was present at low levels (Figure  5.9A). However, 
DRGN treated with RT3/gfp plasmid demonstrated GFP expression in a similar 
proportion of DRGN to pSN+DC-gfp treated controls but that RTN3 
immunoreactivity was over-expressed to much higher levels than the control 
DRGN. These results suggested successful overexpression of RTN3 in 
transfected DRGN (Figure  5.9B). 
Furthermore, Immunohistochemistry for GAP43 to detect regenerating axons at 
the T8 DC lesion site showed that a few axons had regenerated into the lesion site 
(Figure 5.14A) but in animals where RTN3 was overexpressed, many GAP43+ 
axons had regenerated and reached to caudal segment and some axons 
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traversed and passed through the cavity compare to the control treated group 
(Figure  5.10B). I conclude that over expression of RTN3 in DRGN ganglia 
promotes axon regeneration (Figure  5.10). Nonetheless, the mechanism of how 
RTN3 promotes the axons to regenerate is still unknown but all these finding 
suggested that up-regulation of RTN3 after SCI leads to the regeneration of 
axons. 
 
 
 
 
 
 
 
 
Figure  5.9: RTN3 levels are overexpression after intra-DRG injection of 
pSN+DC-PEI-RTN3/gfp plasmid in L4/5 DRGN.  
(A) Immunohistochemistry showed low levels of RTN3 were detected in DRGN 
ganglia of a control pSN+DC animal whilst (B) significantly higher levels of RTN3 
and GFP were detected in DRGN ganglia of animal injected with PEI-RTN3/gfp 
plasmid. Scale bar = 100µm. (n=3) 
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Figure  5.10: Overexpression of RTN3 in DRGN promotes DC axon 
regeneration.  
(A) There were no GAP43+ axons regeneration following pSN+DC. (B) 
Overexpression of RTN3 promotes GAP43+ axons (arrowheads) regeneration 
through the DC lesion site. (C) High power view of axons emanating from the 
lesion site. Scale bar in A and B=500μm; in C = 50μm. (n=3) 
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5.4 Discussion 
In this report, I investigated the role of RTN3 in terms of axonal regeneration. I 
found mRNA and protein levels of RTN3 were significantly increased in 
regenerating models compared to intact and non-regenerating models. I also, 
knocked down RTN3 using siRNA and showed that this suppressed DRGN neurite 
outgrowth. These results prompted us to overexpresses RTN3 in vivo by using 
non-viral vectors and I found that overexpression of RTN3 promotes the axons in 
the DC to regenerate.  
 
5.4.1 RTN3 levels increase in regenerating injury models  
I found that mRNA levels of RTN3 were increased in in microarrays in 
regenerating DRGN models.  I therefore predicted that RTN3 might be positively 
involved in the dynamics of the axon growth cone, leading to axon regeneration. 
Immunohistochemistry in DRGN showed that RTN3 was localised in DRGN nuclei 
after SN injury and was absent in both intact and non-regenerating DC injury 
models, correlating with our microarray data. By western blot, I found that RTN3 
protein levels were also absent in intact and non-regenerating DRGN models and 
significantly in regenerating models, corroborating with our other findings. The 
localisation of RTN3 in DRGN nuclei, however, after SN injury may be involved in 
different regulatory mechanisms such as shaping the ER (Wakana et al., 2005, 
Zurek et al., 2011) and remains to be investigated. Immunohistochemistry of 
RTN3 in pSN+DC injury models were present both in the nucleus but also in the 
cytoplasm and shows a slightly different distribution of the RTN in these models. 
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I’m currently unsure why this is so but this remains to be investigated. I also, 
confirmed that the mRNA and protein levels of RTN3 were elevated in pSN+DC by 
western blot and RT-PCR therefore suggest that RTN3 is required to promote 
CNS axon regeneration. 
 
5.4.2 Knockdown of RTN3 using siRNA negatively affected neurite 
outgrowth  
To confirm the role of RTN3, I used dissociated adult rat DRGN cultures to 
investigate the consequence of RTN3 knockdown on DRGN neurite outgrowth 
(Ahmed et al., 2010, Ahmed et al., 2013, Ahmed et al., 2011a). Since RTN3 was 
raised 6-fold in pSN+DC models I predicted that knockdown of RTN3 will suppress 
DRGN neurite outgrowth. I used different concentrations of siRNA to RTN3 and 
observed that there was a significant reduction of neurite outgrowth in DRGN 
treated with siRTN3 compared to control samples, even when stimulated to grow 
with FGF2. Knock down of RTN3 however, did not induce DRGN death and hence 
our results show that knocking down RTN3 has a direct effect on DRGN neurite 
outgrowth, confirming a role of RTN3 in DRGN neuritogensis. The mechanism by 
which RTN3 promotes DRGN neurite outgrowth is currently not known. However, 
it is likely that RTN3 modulates intracellular signaling pathways that promote 
DRGN neurite outgrowth. The elucidation of the mechanisms leading to enhanced 
DRGN neurite outgrowth will be investigated in future experiments. 
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5.4.3 CRELD1 is expressed after DC injury and may interact with RTN3 
I have also tried to investigate the signalling mechanisms of RTN3, but without 
much success. However, one of the signalling molecules, CRELD1, was equally 
expressed in DRGN of all models and did not show any modulation and therefore 
our immunohistochemical findings only suggest that CRELD1 is available to 
interact with RTN3 but how this interaction occurs and what signalling molecules 
are invoked remains to be elucidated.  CRELD1 does change the localisation of 
RTN3 from the ER to the cell membrane (Xiang and Zhao, 2009) and this is 
probably what happened in our pSN+DC models. Other proteins are also known to 
interact with RTN3 but not recruiting RTN3 from ER to the cell membrane, for 
example FADD, the endogenous FADD protein was found to recruited by RTN3 to 
the ER membrane and caused cell death (Xiang et al., 2006). CRELD1 is also a 
cell adhesion molecule and considered as one of the gene candidates in 
atrioventricular septal defects (Rupp et al., 2002, Robinson et al., 2003).  
 
5.4.4  pSN+DC-PEI-RTN3/gfp promotes dorsal column axon regeneration 
after DC injury 
After successful intra-DRG injection using in vivo-jetPEI vector in previous 
chapters (Chapter 3), I used the same experimental setup in this report to up-
regulate the expression of RTN3 and determine its consequences on DC axon 
regeneration. Immunohistochemistry in DRGN showed abundant expression of gfp 
suggesting efficient transduction of DRGN after intra-DRG injection of the plasmid 
via the non-viral vector. Also, RTN3 was significantly overexpressed in DRGN 
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receiving the RTN3 vector and hence confirming the utility of in vivo-jetPEI for use 
in CNS gene delivery. 
After overexpression of RTN3, many GAP43+ axons regenerated through the 
crush site, with some traversing the cavity and reaching the distal segment of 
spinal cord. These results showed that RTN3 overexpression promotes DC axon 
regeneration.  
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 Chapter 6: A novel role of AEG-1/MTDH/LYRIC in CNS 
axon regeneration 
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6.1 Introduction 
6.1.1 Astrocyte Elevated Gene-1  
Human immunodeficiency virus-1 (HIV-1) has a negative impact in the CNS and 
results in HIV-1 associated dementia (HAD) and neurodegeneration, where HAD 
is developed in about 20% of HIV-1 infected patients (Lipton and Gendelman, 
1995, Lee et al., 2013). HIV-1 mainly infects resident macrophages (microglia) and 
rarely targets astrocyte but not neurons (Minagar et al., 2002). It is said that HIV-1 
infects <1% of astrocyte despite their abundance in the brain, but believed that 
HIV-1-infected astrocytes are participants in neurodegeneration and HAD (Brack-
Werner, 1999) 
However, astrocyte elevated gene-1 (AEG-1) was among the 15 AEGs that was 
initially discovered in primary human fetal astrocytes (PHFAs) after infection by 
HIV-1 using rapid subtraction hypridization approaches (RaSH). In the HIV-1 
infected PHFAs method, a series of HIV-1 induced genes termed (astrocyte 
supressed genes, ASGs) and (astrocyte elevated genes, AEGs) were identified 
(Su et al., 2002).  
AEG-1 is sometimes loosely referred to as metadherin (MTDH) and lysine-rich 
CEACAM1 co-isolated (LYRIC1). AEG-1 is found highly expressed during the 
development period of mouse embryos and suggested to have a role in 
neurogenesis. Subsequent research has shown that AEG-1 is involved in many 
forms of cancers such as lung, prostate and renal cancer among others and 
implicated in HAD and glioma-associated neurdegeneration (Lee et al., 2011, Lee 
et al., 2013, Jeon et al., 2010). Later on, mRNA expression of AEG-1 was 
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detected in a various types of normal human tissues with elevated levels in the 
liver, heart, skeletal muscle, thyroid and adrenal glands (Su et al., 2002, Su et al., 
2003, Lee et al., 2013). In CNS, AEG-1 found relatively lower levels in normal 
brain samples compared with glioma tissues, as detected by 
immunohistochemistry (He et al., 2014). In line with these results latter findings 
from found that AEG-1 is expressed in motor neurons of C57BL/6 mice (Yin et al., 
2015). 
 
6.1.2 Metadherin (MTDH) 
MTDH (METastasis ADHEsion protein) is an AEG-1 murine ortholog and was 
cloned in 4T1 mouse mammary tumour cells in an attempt to identify cell surface 
receptors that mediate metastasis of lung cancer (Brown and Ruoslahti, 2004). A 
lung-homing-domain (LHD) which mediates lung metastasis was identified in 
‘’MTDH’’ using in vivo phage screening and subsequently called metadherin (Liu 
et al., 2011). Brown and Ruoslahti used phage expression libraries from breast 
carcinoma cDNA to identify protein domains that bind to the vasculature of the 
lung and showed that LHD of MTDH was localised to the extracellular surface 
(Brown and Ruoslahti, 2004).  
The authors also showed high levels of MTDH/AEG-1 in human breast cancer 
whilst lower levels were present in healthy breast tissue. Moreover, an LDH 
antibody antagonist inhibited breast cancer lung metastasis and suggested that 
MTDH/AEG-1 plays a significant role in this process (Brown and Ruoslahti, 2004, 
Lee et al., 2013). MTDH or metastasis adhesion protein was found overexpressed 
in human breast cancer that had predominantly metastasized to the lung, brain, 
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liver and bone (Hu et al., 2009). MTDH became an official nomenclature of LYRIC 
and AEG-1 based on the functional data of MTDH as promoting lung metastasis.  
 
6.1.3 LYsine RIch CEACAM1 (LYRIC1) 
 
In 2004, two researcher groups discovered a novel protein which they named 
LYRIC1 and 3D3/LYRIC1 derived from LYsine RIch CEACAM1 
(Carcinoembryonic antigen-related cell adhesion molecule-1) co-isolated (Britt et 
al., 2004, Sutherland et al., 2004). LYRIC1 and 3D3/LYRIC1 were discovered in 
an attempt to identify the proteins that localized at nuclear sub-compartments and 
tight junction. Rat LYRIC1 interacted with CEACAM1 and co-localized with tight 
junctions in epithelial cells. LYRIC1 was expressed and localized in cytoplasm, cell 
perimeter and involved in perinuclear disruption (Britt et al., 2004).  
 
On the other hand, Sutherland et al, 2004 cloned mouse 3D3/LYRIC 
independently from AEG-1/MTDH using gene-trap approaches in an attempt to 
find proteins that located at the nucleus sub-compartment. They used mouse 
F9/3D3 cell line for cloning and found 3D3/LYRIC1 expressed not only in ER but 
also in the nuclear envelop, suggesting that 3D3/LYRIC1 has a possible 
connection between tissue compartments and ER (Sutherland et al., 2004). Rat 
LYRIC1 is found expressed in different cells from the mouse 3D3/LYRIC 
suggesting different role in nucleus, cytoplasm and cell membrane that contribute 
to different cell signalling pathways (Lee et al., 2013).  
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6.1.4  The relative expression of AEG-1 
 
The initial characterization of AEG-1 indicates a similar physicochemical property 
including molecular weight, amino acid composition and transmembrane domain. 
Despite the differences in their tissue disruption and number and size of 
transcripts, a 3.5 kb mRNA band was reported for AEG-1 in different studies (Britt 
et al., 2004, Brown and Ruoslahti, 2004, Kang et al., 2005, Sutherland et al., 
2004). AEG-1 localization and membrane topology are important factors for their 
function. However, two types of membrane topology of AEG-1 were predicted in 
the beginning, type Ib and II. The role of type II was predicted to mediate 
metastases whereas, type Ib localized in nucleus/ER and supports tumour 
promoting activity of AEG-1 (Britt et al., 2004, Brown and Ruoslahti, 2004, Kang et 
al., 2005, Sutherland et al., 2004).  
AEG-1 expressed in healthy human tissues with higher expression in liver, heart, 
skeletal muscle, thyroid and adrenal glands (Su et al., 2002, Su et al., 2003, Lee 
et al., 2013). AEG-1 gene is now considered a pivotal oncogene implicated in 
many oncogenic signalling pathways including NF-κB, MAPK, Wnt and PI3K-Akt. 
Moreover, AEG-1 is found highly expressed in different cancer types such as 
breast, brain, colorectal cancers as well as neuroblastoma, hepatocellular 
carcinoma and non-small cell lung cancer among others (Yoo et al., 2011, Lee et 
al., 2011, Lee et al., 2008). In addition to being an important oncogene, 
overexpression of AEG-1 promotes tumour growth, chemo-resistance, invasion 
and metastasis, as well as enhancing malignant aggressiveness (Figure  6.1) (Yoo 
et al., 2011, Emdad et al., 2013). 
 
171 
 
  
 
 
 
Figure  6.1 Possible effectors molecules and biological function of AEG-1 
leads to cancer aggressiveness.  
(adapted from (Emdad et al., 2013). 
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6.1.5 The role of AEG-1 in reactive astrocyte after CNS injury 
 
Astrocytes are the most abundant cells in the brain and they provide support 
functions to the neurons including maintenance of extracellular ion balance, 
provision of nutrients to nervous tissue, and repair process after injury among 
others (Vartak-Sharma and Ghorpade, 2012, Bouzier-Sore et al., 2002). Since 
astrocytes are involved in tissue scarring and in response to CNS injury in a 
process called reactive astrogliosis (discussed in more details in section 1.4.4.1), 
induction of cancer may not be the only role of AEG-1.  
Neha et al investigated the expression of AEG-1 in astrocytes undergoing 
astrogliosis in a mouse brain injury model and found that trauma to the brain 
induces expression of AEG-1 during astrogliosis. The movement of astrocytes to 
the injured site was also investigated and results showed that by knocking down 
AEG-1 genes, there was less movement of astrocytes to the injured site and the 
wound took longer to heal compared to models where the AEG-1 was present 
(Figure  6.2).  
This suggested that AEG-1 regulates migration and proliferation of astrocytes to 
the injury site (Vartak-Sharma and Ghorpade, 2012). Injury to the CNS will 
inevitably elicit astrogliosis since AEG-1 has been implicated in modulation of 
astrocyte response to injury. 
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 Figure  6.2: The role of AEG-1 in reactive astrogliosis.  
Injury to the CNS mediates activation of many molecules such as inflammatory 
cytokines (e.g. interliuken-1β (IL-1β)), reactive oxygen species (ROS) and tumour 
necrosis factor-α (TNF-α). These molecules activate nearby healthy astrocytes 
and change the intracellular signalling pathways and microenvironments resulting 
in reactive astrogliosis. Increased expression of AEG-1 and reactive astrogliosis is 
a plausible mechanism for AEG-1-mediated regulation of astrocyte migration and 
proliferation during astrogliosis. Adapted from (Vartak-Sharma and Ghorpade, 
2012).   
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6.1.6 AEG-1 increase glutamate excitotoxicity in glioma-induced 
neurodegeneration 
Among CNS tumors, glioma has been identified as one of the commonest types of 
brain cancer in adult CNS, which originate from neuroepithelial tissues. And 
morphologically glioma is classified as astrocytic, oligodendroglial, choroid plexus 
and ependymal tumors (Nakada et al., 2007, Lee et al., 2011). Glutamate 
excitotoxicity plays a key role in glioma-induced neurodegeneration but the 
mechanisms of this phenomenon are still not fully understood. Since glutamate is 
an important neurotransmitter that is involved in normal brain function, high 
concentrations of glutamate must be removed constantly to avoid neurotoxin and 
neuron death. (Headley and Grillner, 1990, Sontheimer, 2008). 
 
Astrocytes predominantly expressed excitatory amino acid transporter 1 and 2 
(EAAT1, 2) that are responsible for clearing excitotoxic glutamate levels from 
neuronal synapses. Glioma is shown to release high levels of glutamate and a 
failure of astrocytes to produced EAAT2 leads to impaired glutamate regulation 
and widespread neuronal death (Kim et al., 2011, Ye and Sontheimer, 1999, 
Marcus et al., 2010).  
 
Increased expression of AEG-1 in astrocytes after neurodegenerative diseases 
include glioma and HIV-1 infection which causes reduced levels of EAAT2, 
meaning that AEG-1 negatively affected EAAT2 to uptake the high levels of 
glutamate, which leads to neuronal death. In normal astrocytes, a cyclic AMP-
responsive element binding protein (CREB), interacted with EAAT2 promoter and 
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positively regulated EAAT2 expression, whilst in glioma, AEG-1 plays a key role 
by inhibiting EAAT2 levels.  
 
AEG-1 was found to work as a bridge between CBP and a transcription factor 
called Ying Yang-1 (YY1) interaction in EAAT2 promoter in reactive astrocyte. This 
interaction caused YY1 to function negatively on EAAT2 by supressing CBP, 
which leads to disable abolishing glutamate from neurons synapses (Figure  6.3) 
(Lee et al., 2011). 
 
 
 
Figure  6.3: A schematic mechanism of AEG-1 supressed EAAT2 expression 
in human glioma. (A) Normal expression of EAAT2 in intact astrocyte. (B) In 
glioma, expression of AEG-1 negatively affects EAAT2 regulation leads to 
neuronal death. (Adapted from (Lee et al., 2011). 
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6.1.7 Hypothesis  
 
We showed by microarrays that AEG-1 is extremely elevated in regenerating 
DRGN injury models compared to non-regenerating injury models.  I therefore 
speculated whether high levels of AEG-1 are required to promote axon 
regeneration after SCI. 
 
6.1.8 Aims  
 
• Validate our microarray data by extracting mRNA from regenerating and 
non-regenerating DRGN injury models using RT-PCR.   
• To determine AEG-1 protein levels using western blot from DRGN protein 
lysates. 
• Localize AEG-1 protein in DRGN injury models by immunohistochemistry. 
• Knock down AEG-1 using specific siRNA in primary DRGN to determine a 
role for AEG-1 in DRGN neurite outgrowth. 
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6.2 Results 
6.2.1 AEG-1 mRNA levels increase in SN and pSN+DC injury models by 
microarray analysis. 
As it is been described in the previous chapter, microarray data was scanned in 
non-regenerating DC and regenerating SN and pSN+DC models to identify genes 
that correlated with DC axon regeneration. One of these identified was AEG-1, 
whose mRNA levels were increased by 65- and 116-fold in SN and pSN+DC 
models, respectively (Figure  6.4). These results suggested that AEG-1 levels 
correlated with axon regeneration.  
 
 
 
Figure  6.4: Levels of AEG-1 expression in regenerating and non-
regenerating SCI models at 10 days after injury. Microarray data shows fold-
change of AEG-1 mRNA in different models compared with intact controls. (n=6) 
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6.2.2 Confirmation of AEG-1 expression in pSN+DC  
 
For further confirmation that the levels of AEG-1 were elevated in regenerating 
DRGN models, semi-quantitative RT-PCR in different injury models was used 
(Figure  6.5A). The results showed that high levels of AEG-1 mRNA expression 
was present in regenerating SN and pSN+DC compared with non-regenerating 
DC or intact controls, with pSN+DC model showing the greatest levels of AEG-1 
mRNA.  
Western blot of protein lysates also confirmed high levels of AEG-1 in 
regenerating SN and pSN+DC models (Figure  6.5C), with the greatest levels of 
AEG-1 protein being detected in pSN+DC models. Immunohistochemistry also 
corroborated these observations, showing that high levels of AEG-1 
immunoreactivity was present in DRGN in SN and pSN+DC models, whilst low 
levels were detected in both intact and non-regenerating DC models (Figure  6.6). 
Taken together, these results suggested significant upregulation of AEG-1 in 
regenerating SN and pSN+DC, with the highest levels localised in DRGN after 
pSN+DC.   
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Figure  6.5: Levels of AEG-1 expression in regenerating and non-
regenerating DRGN models at 7 days after injury.  
(A) Semi-quantitative of RT-PCR from DRGN ganglia after SCI injury models 
showed increase expression of AEG-1 mRNA after pSN+DC. (B) Densitometry 
used to quantify the expression. (C) Western blotting from DRGN ganglia protein 
lysate corroborated RT-PCR results where (D) is densitometry of protein 
expression used in western blot. ***P<0.0001, Analysis of Variance. (n=3) 
65 kDa - 
41 kDa - 
GAPDH 
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Figure  6.6: Levels of AEG-1 expression in regenerating and non-
regenerating SCI models at 7 days after injury.  
Immunohistochemistry shows low levels of AEG-1 protein in sections of intact 
control and after DC injury whilst increased AEG-1 immunohistochemistry levels 
were detected in sections of DRG from regenerating SN and pSN+DC models. 
Scale bar A= 500µm; B, C and D=50 µm. (n=3). 
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6.2.3 Knockdown of AEG-1 suppresses DRGN neurite outgrowth 
 
Dissociated adult rat DRGN were used to investigate the consequence of AEG-1 
knockdown on DRGN neurite outgrowth. Since high levels of AEG-1 correlate with 
DRGN axon regeneration, I predicted that knockdown of AEG-1 will reduce DRGN 
neurite outgrowth. DRGN were treated with Lipofectamine 2000 alone, siEGFP 
(non-specific transfection control), Scr-siAEG-11 (scrambled siRNA to AEG-1) and 
siAEG-1. DRGN were grown for 3 days and then knock down of AEG-1 was 
analysed by western blot, and found that (Figure  6.7A) there were no changes in 
AEG-1 protein level in Lipofectamine/untreated, siEGFP or Scr-siAEG-1-treated 
DRGN. However, DRGN treated with siAEG-1 showed reduced AEG-1 protein to 
barely detectable levels (Figure  6.7B). Densitometry to quantify the levels of AEG-
1 protein showed 95% AEG-1 knockdown efficiency with siAEG-1 in DRGN 
cultures. 
 
Immunohistochemistry for βIII-tubulin to measure DRGN survival and neurite 
outgrowth in FGF2, FGF2+siEGFP, FGF2+Scr-siAEG-1 and FGF2+siAEG-1 
treated DRGN, showed that DRGN neurite outgrowth was significantly reduced 
after AEG-1 knockdown (Figure  6.8A), and in terms of the mean neurite length 
(Figure  6.8B) as well as, the number of DRGN with neurites (Figure  6.8C). DRGN 
survival however, was unaffected in all treated conditions (Figure  6.8D) showing 
that knockdown of AEG-1 gene has no toxicity in DRGN. These results 
demonstrate that AEG-1 knockdown suppresses DRGN neurite outgrowth, 
therefore it can be argued that AEG-1 is required for DRGN axon regeneration. 
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  Figure  6.7: siRNA mediated knockdown of AEG-1.  
(A) In Lipofectamine, siEGFP and Scr-siAEG-1-treated cultures, no changes in 
AEG-1 protein levels were observed. However, treatment siAEG-1 reduced AEG-1 
protein to barely detectable levels. (B) Densitometry to quantify the levels of AEG-
1 protein showed 95% AEG-1 knockdown efficiency with siAEG-1 in DRGN 
cultures. ***P<0.0001, Analysis of Variance. (n=3) 
65 kDa - 
41 kDa - 
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 Figure  6.8: Knockdown of AEG-1 suppresses DRGN neurite outgrowth. 
 (A) photomicrographs of bIII-tubulin+ DRGN neurite outgrowth in untreated, 
FGF+siEGFP, FGF2+Scr-siAEG-1 and FGF2+siAEG-1 transfected DRGN for 3 
days, (B) Mean neurite length (µm), (C) Mean number of DRGN with neurites and 
(D) Mean number of surviving DRGN. ***P<0.0001, Analysis of Variance. (n=3) 
184 
 
6.2.4 Knockdown of AEG-1 in DRGN cultures at 7 days after pre 
conditioning  dorsal colum (pSN+DC) lesions 
 
Since pre-conditioning SN lesions increase the levels of AEG-1 protein, I 
investigated if AEG-1 knockdown will also reduce DRGN neurite outgrowth in 
dissociated DRGN after pre-conditioning lesions. Firstly, knockdown of AEG-1 in 
pre-conditioning DRGN cultures were analysed by western blot and we found in 
(Figure  6.A) that DRGN treated with siAEG-1 showed reduction of protein levels 
compare to Lipofectamine/untreated, siEGFP and Scr-siAEG-1-treated DRGN. 
Densitometry to quantify the levels of AEG-1 protein showed 90% AEG-1 
knockdown efficiency with siAEG-1 in DRGN cultures (Figure  6.B).   
 
After 7 days pre-conditioning, dissociated DRGN displayed greater than 4-fold 
more neurite lengths than dissociated DRGN that had not received pre-
conditioning lesions (Compare Figure  6.8B to Figure  6.B). Treatment of 
dissociated pre-conditioned DRGN with siGFP or Scr-siAEG-1 did not reduce the 
number of DRGN with neurites (Figure  6.B) nor the mean neurite length 
(Figure  6.C). However, knockdown of AEG-1 in pre-conditioned DRGN 
significantly reduced the number of DRGN with neurites (Figure  6.C) and the 
mean neurite length (Figure  6.B). These results suggest that AEG-1 regulates 
DRGN neurite outgrowth even in pre-conditioned DRGN. 
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Figure  6.9: siAEG-1 also knocks down AEG-1 protein in pre-conditioned 
DRGN   
(A) no change of AEG-1 protein levels was obsereved in untreated and treated 
pre-conditoned DRGN with no treatment, siEGFP and Scr-siAEG-1. DRGN treated 
with siAEG-1 showed significatnt reduction of AEG-1 protein levels. (B) 
Densitometry to quantify the suppression of AEG-1 protein levels. ***P<0.0001, 
Analysis of Variance. (n=3) 
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 Figure  6.10: Knockdown of AEG-1 in DRGN cultures at 7 days after pSN+DC 
lesions.  
(A) photomicrographs of βIII-tubulin+ DRGN neurite outgrowth in pSN+DC, 
pSN+DC+siEGFP, pSN+DC+Scr-siAEG-1 and pSN+DC+siAEG-1 transfected 
cells showing that AEG-1 significantly suppressed the growth of DRGN provided 
by pre-conditioning SN lesions. Quantification of the data showed that AEG-1 
knockdown suppressed the (B) Mean number of DRGN with neurites and (C) 
Mean neurite length (um). ***P<0.0001, Analysis of Variance. (n=3) 
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6.3 Discussion 
 
In this study I have investigated the role of AEG-1 in axonal regeneration. This 
was done by evaluating expression of AEG-1 in regenerating and non-
regenerating DC injury models. I found that AEG-1 was highly elevated in 
regenerating injury models compared to intact and non-regenerating models. I 
also showed by siRNA-mediated knockdown in DRGN cultures that knockdown of 
AEG-1 suppressed DRGN neurite outgrowth. These results suggest that AEG-1 is 
required for axonal regeneration after CNS injury. 
 
6.3.1 AEG-1 is may require for CNS axon regeneration 
 
AEG-1 is said to modulate the response of astrocytes to injury and help in the 
formation of scar tissue or repair. The mechanism by which AEG-1 does this may 
not be known but there is evidence of increased levels of AEG-1 during 
astrogliosis and this expression helps migration and proliferation of astrocytes 
during CNS injury (Vartak-Sharma and Ghorpade, 2012). Besides its role in 
astrocyte, AEG-1 detected in highly in mouse brain embryos, demonstrating that 
AEG-1 may play an important role in development of the mouse brain (Jeon et al., 
2010). Moreover, a recent study invstgated the role of AEG-1 after peripheral 
nerve injury and found that AEG-1 regulated migration and proliferation of 
Schwann cells after SN injury (Wang et al., 2016). 
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In fact, the role of AEG-1 in cancer was widely investigated as a crucial factor of 
proliferation and tumour progression. On the other hand, AEG-1 has been shown 
to have positive regulatory effects after nervous system injuries orchestrating 
migration and proliferation of glial cells and implicated in CNS scar healing 
(Vartak-Sharma and Ghorpade, 2012, Wang et al., 2016).  
Our microarray data suggested that AEG-1 has a potential role in CNS axon 
regeneration. I found that AEG-1 was significantly up-regulated in regenerating SN 
and pSN+DC lesions compared with intact control and non-regenerating DC lesion 
models and thus correlated positively with axon regeneration. 
   
6.3.2 Knockdown of AEG-1 supresses DRGN neurite outgrowth  
Knockdown of AEG-1 in dissociated adult rat DRGN cultures showed that neurite 
outgrowth was significantly attenuated, without affecting DRGN survival. Even in 
pre-conditioned DRGN, knockdown of AEG-1 had the same effect of suppressing 
DRGN neurite outgrowth. These results confirm our predictions that knocking 
down AEG-1 negatively affects axon regeneration but has no significant effects on 
DRGN survival. The mechanisms by which AEG-1 promotes DRGN neurite 
outgrowth is not known, however, it is likely that AEG-1 modulates intracellular 
signaling pathways that promote DRGN neurite outgrowth. The elucidation of the 
mechanisms leading to enhanced DRGN neurite outgrowth will be investigated in 
future experiments.   
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 CHAPTER 7: General Discussion 
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7.1 Summary findings  
The main objective of this work is to promote CNS axon regeneration following 
CNS injury by manipulating some of the most highly regulated genes (i.e. 
AMIGO3, RTN3 and AEG-1) that obtained after microarrays screening of L4/5 
DRGN that received regenerating and non-regenerating injury models. Since the 
main hypothesis of the thesis was to whether up/down-regulation of these genes 
would primary promote spinal cord axon regeneration. 
I found in chapter 3 that AMIGO3 raised in DRGN after non-regenerating (DC) 
injury models compare to intact and regenerating models, as well as suppression 
of AMIGO3 combined with NT3 in presence of CME led to promote dissected 
DRGN neurite outgrowth, which suggested knockdown AMIGO3 enhance CNS 
axon growth after injury. However, based on in vitro outcomes; non-viral vector 
mediated shAMIGO3/NT3 plasmid was injected in vivo for 29 days after DC injury 
model aiming to disinhibit dorsal column axons from L4/5 DRGN. The results 
showed the plasmid encoding shAMIGO3/nt3-gfp targeted large DRGNs diameter 
compare to medium and small diameter and promotes axon regeneration since 
number of GAP43+ (up to 4-6 mm) were observed passing through the lesion site 
and entering into the distal segment of the spinal cord. These results suggested 
that suppression of AMIGO3 combined with expression of NT3 simultaneous 
stimulation of DC axon regeneration and promotes functional recovery 
Furthermore, inflammatory responses include macrophages, glial cells and T cells 
were also observed in animals groups injected with in vivo-jetPEI vector mediating 
DC+PEI-gfp, DC+PEI-nt3/gfp and DC+PEI-shAMIGO3/gfp plasmids. A slight 
increase of macrophages was seen in animals received in vivo-jetPEI/plasmids 
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compared to intact and PBS groups. However, GFAP+ levels were virtually 
absence in intact animals and slightly increased in animals injected with PBS and 
in vivo-jetPEI/plasmids, the similar pattern between PBS and in vivo-
jetPEI/plasmids groups may due to the mechanical breakthrough of the injection in 
DRGN bundle. On the other hand, no significant increase was observed in DRGN 
section of either CD8 or CD4 inflammatory markers following PBS or in vivo-
jetPEI/plasmids. These outcomes conclude that in vivo-jetPEI is safe and does not 
induce inflammatory responses. 
In chapter 5 and 6, mRNA levels of RTN3 and AEG-1 were elevated after pre-
conditional lesions by 6 and 116-fold, respectively compared to intact and non-
regenerating injury models. Immunohistochemistry and western blot results of both 
genes were correlated with microarrays data, suggested overexpression of both 
genes enhance CNS axon growth. By knocking down RTN3 and AEG-1 in primary 
DRGN culture using siRNA, results were showed the suppression of neurite 
outgrowth was correlated with knockdown of both genes, demonstrated that RTN3 
and AEG-1 are required for CNS axon regeneration. However, overexpress of 
RTN3 in vivo using in vivo-jetPEI vector delivering plasmid encoding RTN3 
resulted a number of GAP43+ axons reached the lesion site and passed into the 
distal segment of the spinal cord.  
The data presented in this thesis demonstrated that these genes identified by 
microarray screening play a part in the axon regeneration after SCI, and could be 
used to establish possible mechanisms to promote CNS axon growth in the 
human. 
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7.2 Combinatorial therapeutic strategies for SCI treatment hold much 
promise for the future 
The majority of SCI experimental was to investigate the consequences of single 
treatment, but however recently combining treatments have a growing interest 
since they are likely to have much better outcomes than single treatment (Tsai et 
al., 2005, Wang et al., 2012a, Tom et al., 2013, Olson, 2013). A combinatorial 
strategy is required to promote optimal CNS axon regeneration due to the 
complexity of the injury. For example, Ahmed and others have shown that 
suppression of axon growth inhibitory molecules combined with neurotrophic 
factor stimulation promotes significant disinhibited DRGN neurite outgrowth in the 
presence of CME (Ahmed et al., 2005, Ahmed et al., 2006, Ahmed et al., 2009, 
Ahmed et al., 2011b).  
However, shAMIGO3 combined with NT-3 (showed in Chapter 3) and 
overexpression of RTN3 (showed in Chapter 5) enhanced disinhibited DC axon 
regeneration after DC injury as well as up-regulation of AEG-1 (showed in Chapter 
6). All of these treatments required an axon growth stimulus such as Nt3 or pre-
conditioning lesions to effect better regeneration. Disappointingly due to lack of 
time, a combinatorial treatment of all of these genes could not be preform. Whilst, 
individual treatment for above genes showed a number of promising featured of 
DC axon regeneration combining these genes seems highly likely to prove to be 
more useful.  
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7.3 Advantages / disadvantages of in vivo-jetPEI 
A polycation such as Polyethylenimine (PEI) is one of most highly used non-viral 
vectors to transfect DNA/RNA both in vitro and in vivo (Wu et al., 2004). One of 
the features of PEI is that it carries high concentration of positive charged nitrogen 
atoms allowing it to condense negative charges molecules such as DNA and form 
PEI/DNA complex that capable to enter the cell via endocytosis (Benjaminsen et 
al., 2013). In the in vivo study, PEI gives immediate therapeutic benefit once 
transfected compared to viral vectors that requires 7-14 days to reach maximum 
transgene expression (Lungwitz et al., 2005). PEI is therefore beneficial for acute 
condition such as SCI that requires immediate therapy. PEI tends to have a higher 
transfection efficiencies, up to 4X higher, than naked DNA, a higher biosafety, 
easy to prepare and highly stable in nature (Wiseman et al., 2003). PEI mediated 
nerve growth factor (NGF) has been used to protect axotomized septal cholinergic 
neurons (which is important for memory and learning) in the brain. Results showed 
72% of these neurons survived in injured animals after PEI/pNGF injection (Wu et 
al., 2004). Moreover, PEI is safe and does not induce off-target immune-mediated 
cytokines such as TNF-α, IFN-γ, IL-6, IL-12/IL-23, IL-1β, and IFN-β (Bonnet et al., 
2008). Therefore, the lack of immunogenic responses after PEI injection is to be 
expected and represents a further advantage over viral vectors. The disadvantage 
of non-viral carriers including PEI is that they have a lower transection efficiency 
compared to delivery efficiency of viral vectors (Yang, 2015), however, in DRGN 
this was not evident as we were able to transduce as many DRGN as viral vectors 
previously tested (Jacques et al., 2012).  
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7.4 Clinical trials in SCI 
Whilst many SCI experimental therapeutics displayed promising results in 
laboratories and pre-clinical settings; only a few of these treatments have 
undergone testing in human clinical trials. There are three main categories of 
treatments that have reached clinical trials; regeneration promoting therapies, 
neuroprotective therapies and cell transplant strategies (Gensel et al., 2011, 
Varma et al., 2013). In regeneration promoting therapies, there are a few 
experimental treatments that have reached human testing. One of these is the 
humanised anti Nogo-A antibody, which thus far has completed the first phase of 
safety trials. Fifty two patients were recruited in this trial with different levels of 
spinal cord injuries and different severities, the anti-Nogo-A antibodies displayed 
no adverse effects after intrathecal administration, but disappointingly no positive 
findings were observed in terms of neurological changes (Zorner and Schwab, 
2010). Moreover, Cethrin (a bacterial enzyme derived from C3 transferase lead to 
disrupt Rho-A signalling pathway by blocking Rho-A activity) has undergone 
phase I/IIa clinical trials, following completion of both phases the outcomes 
indicated no serious adverse effects upon extradural administration, but the 
treatments do result in enhanced motor recovery (Fehlings and Baptiste, 2005, 
Fehlings et al., 2011).  
In addition, Ganglioside GM-1 is another therapeutic targeting regeneration, which 
is one of the largest SCI clinical trials in terms of the number of patients involved 
to assess the efficacy of this drug. GM-1 is derived from Gangliosides (complex 
glycolipids reside in cell membrane at high concentration found in CNS) and 
shown to promote axonal sprouting in vitro and enhanced regeneration in several 
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CNS injury models in vivo (Ferrari et al., 1983, Sabel et al., 1987). After safety 
trials in humans, intravenous dosing of GM-1 underwent phase 2 clinical trials but 
disappointingly no significant improvements in the primary outcomes were 
observed in SCI patients, except enhancement of bowel/bladder and sensory 
function (Geisler et al., 2001). Finally, oral administration of lithium was 
undertaken in clinical trials as potential treatment for SCI, in which lithium was 
found to block the actions of glycogen synthase kinase 3β (GSK-3β). This kinase 
was shown to inhibit axonal growth, however following intake of lithium no 
significant adverse effects or neurological outcomes were reported in either phase 
I or II trials (Dill et al., 2008, Yang et al., 2012).  
In terms of neuroprotective therapies, the only treatment that has undergone 
numerous clinical tests and have been recommended to use in number of 
countries for clinical treatment of acute SCI is methylprednisolone (Bracken et al., 
1997). Methylprednisolone is steroidal anti-inflammatory treatment that is 
recommended for patients that helps to attenuate secondary damage after SCI 
and shown to improve functional recovery if taken within eight hours of the injury 
(Bracken et al., 1990, Bracken et al., 1997). However, high doses of this drug 
have led to increased infection and respiratory complications therefore, as a 
standard of care it is no longer a treatment in the majority of the countries for 
acute SCI (Felleiter et al., 2012, Breslin and Agrawal, 2012). In contrast, other 
neuroprotective therapies that completed clinical trials have shown no significant 
benefit; one of these is Nimidopine (enhances cerebral blood flow to the cord by 
blocking calcium channels and decrease apoptosis in pre-clinical models) which 
increases risk of infection and has failed to display any significant neurobiological 
benefits in a 106 random control trials (Fehlings and Baptiste, 2005). Gacyclidine-
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GK 11 (an N-methyl-D-aspartate (NMDA) receptor antagonist reduces glutamate 
excitotoxicity levels) is other neuroprotective agent demonstrated to have 
remarkable results in animal models after CNS trauma with fewer adverse effects 
compared to other NMDA receptor blockers. However, GK-11 showed no 
improvements in either sensory or motor function in clinical trials during one year 
of follow up (Fehlings and Baptiste, 2005, Tator, 2006).  
Whilst, there has not been much success in various clinical trials of regenerative-
promoting therapies and neuroprotective treatments, cell transplant strategies for 
SCI have also met with limited success. In cell-based strategies, stem cells among 
the number of cell types have been the most common cells used in clinical studies 
(Gensel et al., 2011, Varma et al., 2013). For example, mesenchymal stem cells 
(MSC) showed no adverse effects after intrathecal infusion, although in one trial 
neuropathic pain with spasticity was reported in some patients, however, modest 
improvements were reported in motor and/or sensory functions in many of these 
trials (Sykova et al., 2006) (Kumar et al., 2009, Kishk et al., 2010). Olfactory 
ensheathing cells (OECs) are another cell type that have been used in SCI clinical 
trials, based on promising results seen after OEC transplantation in experimental 
SCI models (Ramón-Cueto et al., 2000, Li et al., 2003). Following transplantation 
of OEC into human patients, one group have reported improvements in both motor 
and sensory functions (Lima et al., 2006, Lima et al., 2010) whilst no 
improvements have been noticed in other groups (Feron et al., 2005) with no 
serious remarkable adverse effects reported in both groups.  
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Finally, epidural stimulation enabled a twenty three years old man who had 
paraplegia from a C7–T1 subluxation as a result of a motor vehicle accident to 
achieve full weight-bearing standing with assistance provided only for balance for 
about 4 minutes as well as 7 months after implantation, the patient recovered 
supraspinal control of some leg movements, but only during epidural stimulation 
(Harkema et al., 2011). 
All in all, there is yet to be a major success in SCI therapeutics from pre-clinical 
experimental to clinical efficacy in human patients. Whilst the failure of many trails 
is continuing, perhaps more caution should be taken into consideration before 
translating the treatment forward to the clinical test stage. Before any clinical trials 
of an experimental treatment, the therapeutics should be assessed in pre-clinical 
settings such as using the most common injury models (contusion or compression 
models) and assessed in small common animals e.g. rodents, and then progress 
to large clinically relevant animals such as porcine and non-human primates 
before being applied human patients.   
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7.5 Conclusions 
In conclusion, this study was based on genes that were induced and modified after 
DC injury detected using microarray screening in non-regenerating and 
regenerating DRGN injury models. Over 300 genes were identified and speculated 
that regulation of these genes may play important roles in CNS axon regeneration. 
In this thesis, three genes (AMIGO3, RTN3 and AEG-1) were studied along with 
their manipulation in SCI models both in vitro and in vivo.  
AMIGO3: In vivo-jetPEI vector mediated suppression of AMIGO3 combined with 
NT-3 in vivo enhanced DC axon regeneration. PEI/shAMIGO3-nt-gfp plasmid 
injected via intra-DRG route in L5 DRGN for 29 days was able to disinhibit axon 
regeneration, GAP43+ fibres were observed crossing the DC lesion site and 
entering the distal segment of the spinal cord.  
RTN3: since mRNA levels were up-regulated in regenerating injury models, we 
confirmed in vitro that overexpression of RTN3 promotes axon regeneration. Using 
in vivo-jetPEI transduced plasmids encoding RTN3 along with pre-conditioning 
lesions, we were subsequently able to enhance the number of GAP43+ axon fibres 
crossing the lesion site and reaching into the distal cord. 
AEG-1: mRNA levels of AEG-1 were found highly elevated (by 116-fold) in 
regenerating pSN+DC injury models after 7 days of injury. Our results showed 
AEG-1 protein levels were also enhanced in regenerating DRGN models and 
siRNA-mediated knockdown of AEG-1 in DRGN cultures suppressed DRGN 
neurite outgrowth, suggesting that AEG-1 is required for DRGN axon 
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regeneration. Disappointingly due to lack of time, I was unable to overexpress 
AEG-1 in vivo to confirm its role SCI.  
 
7.6 Future work 
There is much more further experimental work required and all work stated below 
for each chapter of the results was not completed due to lack of time within the 
project period.  The author would be extremely interested in perform the following 
additional work with at least three experimental replicates for results assurance. 
The evidences resulting from the additional work would strongly support this study 
and hoping to participate in the future of SCI treatments. 
 
Chapter 3: in-vivo suppression of AMIGO3 combined with overexpression of 
NT-3 disinhibited DC axon regeneration.  
Suppression of AMIGO3 combined with overexpression of NT-3 using non-viral 
vector displayed promising results where axons regenerated from lumber region of 
rat spinal cord along to injury site at T8 after 29 days. It would be worth using 
further time point such as 6, 8 and 12 weeks to assess the efficacy of suppression 
of AMIGO3. Since my supervisor and I used partial laminectomy in this study, 
complete transection model of the spin could be used to assess knockdown of 
AMIGO3, and the complete cut area of the spinal cord could be supported by 
peripheral nerve graft  (Cote et al., 2011) or collagen based gels loaded with 
Decorin and anti-scarring proteoglycans (Ahmed et al., 2014). Functional recovery 
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tests such as horizontal ladder or thermal stimuli following the above work should 
be used as further assessment of this study.   
 
Chapter 4: Inflammatory-induced responses after non-viral mediated 
suppression of AMIGO3. 
It would be better to determine the inflammatory response by fluorescence activity 
and looking at the DRGN for invasion of other cells of the immune system such as 
B cells and dendritic cells. As well as, identify the presence of other immune 
molecules such as chemokines and cytokines and quantify their levels following 
injection with in vivo-jetPEI/plasmids. However, it would be also worth to 
investigate endogenous immune response following shRNA/plasmids injection 
such as interferon/PKR. On the other hand, the use of naïve animals would be 
much more useful to determine the estimate levels of inflammation response cells 
that contributed to the procedure, this done by undergo the animals with the entire 
injection procedure without injection e.g. inserting the needle without releasing any 
fluids. This would clearly and facilitate the inflammation response involved in this 
procedure.  
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Chapter 5: overexpression of RTN3 enhances DC axon regeneration 
following SCI. 
In this chapter, more in vitro and in vivo experimental works are required since a 
few preliminary in vivo data was done due to time constraint. The further works 
can fall into the following points: 
• Scramble version of siRTN3 into primary DRGN culture. In vivo transection 
of Scr-siRTN3 will increase the fact that siRTN3 was specific to RTN3 and 
suppression of neurite outgrowth was due to knockdown of RTN3 not from 
siRNA.       
• Examine the effect of overexpression of RTN3 on rat RohA levels. This can 
be done by transfecting COS-1 cell with full length of NgR1, p75 and 
AMIGO3 in presence of myelin substrate. Full length of RTN3 can be 
transfected upon transfection of these molecules and RohA level could be 
determine by western blot. 
• Preform optimal concentration of RTN3/gfp plasmid that used in this study. 
It would be better to investigate the optimal concentration of RTN3 plasmid 
by transecting primary cultured DRGN with different concentrations starting 
from 0.5-4 µg of DNA plasmid likewise seen in chapter 3.  
 
• Further in vivo experimental groups should be involved in future work. A 
number of additional groups should be added that include sham and PBS 
injection. This will ascertain the results showed after up-regulation of RTN3 
was from the therapeutic plasmid not from other factors. 
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• More number of animals in each group should be added. I have used 3 
animals in this study due the reason state above but it would be much 
better to employ at least 6 animals in each group for future work. 
• Primarily using further time points starting from 3, 6, 8 and 12 weeks to 
determine the effect of RTN3 following DC injury, if the results are 
promising further time points could be used lasts up months.    
• Preform quantification of axon fibres in DC lesion site as shown in section 
3.3.8. Since the study was done on only 3 animals, the other strongly 
suggested to increase the number of animals that received PEI-RTN3/gfp 
and all animals will be subjected to count the GAP43+ fibres from 4mm 
caudal and restoral of epicentre lesion. 
• Up-regulation of RTN3 following complete transection of the spinal cord as 
described above, and support the lesion with peripheral graft or collagen 
based gel. 
 
 
Chapter 6: novel role of AEG-1/MTDH/LYRIC in CNS axon regeneration. 
Since up-regulation of AEG-1 has primarily shown to enhance CNS axon 
regeneration, it is necessary to assess the gene in vivo by plasmid injection as 
stated above. Most likely the further work of this chapter would be similar to 
chapter 5 future works since over expression of both genes would show similar 
results.   
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